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ABSTRACT 
 
Pancreatic islets of Langerhans play an essential role in controlling whole body glucose 
metabolism by releasing key regulating hormones, such as insulin and glucagon. Defective 
insulin or glucagon secretion has been implicated in several metabolic diseases, such as 
obesity and diabetes. Therefore, intrinsically well-regulated insulin and glucagon release 
from the islets is key to maintaining glucose homeostasis. 
AMP-activated protein kinase (AMPK), an ancient energy (AMP/ATP) sensor and its 
principal upstream kinase, STK11 (liver kinase B1, LKB1), a tumour suppressor, have been 
found to regulate glucose metabolism in several peripheral tissues such as the liver, muscle, 
hypothalamus, and adipose tissue, and are found to be expressed in both pancreatic β and α 
cells. However, the role of AMPK and LKB1 in pancreatic islets in controlling hormone 
secretion and thus the whole body glucose metabolism has never been investigated in vivo. 
In this study, I sought to understand how AMPK and LKB1 modulate insulin and glucagon 
secretion from pancreatic β and α cells respectively, by deleting AMPK or LKB1 in β cells or 
α cells in the mouse using the LoxP/Cre system.  
Deletion of both AMPK α1 and α2 catalytic subunits in islet β cells and certain populations of 
neuronal cells in the hypothalamus achieved by crossing AMPK α1 whole body knockout and 
α2 flox‟d mice with rat Ins2 promoter  (RIP2)-Cre deleter mice, led to severely elevated 
circulating glucose and diminished insulin secretion in vivo. By contrast, deletion of LKB1, 
made possible by crossing LKB1 flox‟d mice with the same deleter mice, led to an opposite 
metabolic phenotype. Hind-limb paralysis was also observed, due possibly to an effect on 
neuronal cell differentiation in the sensory part of the brain. The findings argue against a 
simple and linear LKB1-AMPK signalling pathway in pancreatic islet β cells.  
On the other hand, mice lacking LKB1 or AMPK in pancreatic α cells, generated using a 
preproglucagon promoter (PPG)-Cre deleter strain, showed reduced glucagon secretion both 
in vivo and in vitro. 
Therefore, LKB1 and AMPK represent two distinct regulators in controlling insulin and 
glucagon secretion, thus the whole body glucose metabolism. Drugs targeting LKB1 or 
AMPK, or their respective downstream targets might serve as a promising approach for the 
treatment of diabetes. 
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Chapter 1 
Introduction 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Part of this work has been published in: Sun G and Rutter GA. Diabetes Management. 2011 May; 
1(3): 333-347. 
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1.1. Pancreatic islet β cells and glucose metabolism 
1.1.1. Pancreas 
The pancreas, which develops from a region of foregut endoderm, is a glandular organ 
belonging to the digestive and endocrine system of vertebrates (1-3). It serves as both an 
exocrine and endocrine gland. The exocrine compartment, which contains acinar cells, 
produces and secretes digestive enzymes through the pancreatic duct, such as 
carboxypeptidase-A, amylase and trypsin, into the intestine to help break down nutrient 
chymes (4;5). The endocrine compartment, on the other hand, contains cells clustering into 
spherical micro-organs, the so called islets of Langerhans that secrete hormones such as 
insulin, glucagon, somatostatin and pancreatic polypeptide into the blood stream through a 
fine capillary network (Figure 1.1a); (6;7).  
1.1.2. Islets of Langerhans 
The islets of Langerhans occupy only 1-2% of the total pancreatic mass (around 5,000 per 
pancreas in rodents and 1 million per pancreas in humans). However, each islet consists of a 
group of a few thousand cells secreting specific hormones which are crucial for maintaining 
whole body glucose metabolism (3;8). These are the glucagon-producing α cells, insulin-
producing β cells, somatostatin-producing δ cells and pancreatic polypeptide-producing PP 
cells (6;9). A distinctive population of cells also expresses ghrelin, a peptide secreted largely 
by stomach to regulate feeding behaviour has also been discovered within the islets (10). 
Analysis of whole mouse pancreata using optical projection tomography (OPT) showed a 
typical mouse pancreas containing islets ranging from 20,000 to 3,600,000 μm3 in size, with 
majority of the cells at size of 32,000 to 64,000 μm3 (Figure 1.1a); (11). With the majority of 
the endocrine cells being β cells, there are nontheless proportional and distributional changes 
of endocrine cells between rodents and humans. Thus, in mouse islets, there is a higher 
proportion of β cells (60-80%) clustering in the center of the islets, with α (15-20%), δ cells 
(<10%) and PP cells (<1%) scattered mainly at the mantle (Figure 1.1b). In human islets, 
around 55% of β cells intermingle with 35% of α cells, 5-10% of δ cells and 3-5% of PP cells 
with no clear segregation of cell types to specific regions, suggesting that stronger paracrine 
effects may occur in human islets (9;12;13).  
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Figure 1.1 Morphology of a mouse pancreas, islets of Langerhans, and β cells. 
(a) Representative image of a mouse pancreas acquired by optical projection tomography (OPT). The 
yellow staining and white dots show the pancreas and the islets of Langerhans respectively. (b) 
Representative immunofluorescence staining of a mouse islet. The pancreatic β (green) and α (red) 
cells are shown. (c) Representative transmission electron microscopy (EM) image of a mouse 
pancreatic β cell. Scale bar, 500 μm (a), 12 μm (b) and 1 μm (c). 
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Islets are richly vascularized micro-organs with about a 10 fold higher density of highly 
permeabilized capillaries than those in exocrine tissues (14;15). In islets, 8-10 cells form a 
tubular structure around a capillary in such a way that no cell is more than one cell distance 
away from the capillary, suggesting a high dependency of  islet cells on the capillary network 
to deliver or receive hormones (16). The pattern of blood flow within the islets is still a 
matter of debate. The best acknowledged theory favours the view that β cells are perfused 
prior to non-β cells (14;15;17). Therefore, it is unsurprising that insulin secreted by β cells 
has effects on neighbouring β cells and other cell types. Indeed, in vitro studies (18) showed 
that insulin had an inhibitory effects on both insulin and glucagon secretion (see “glucagon” 
section below). 
1.1.3. Islet β cells and insulin granules 
Pancreatic β cells are highly specialized cells which are characterized by their ability to 
secrete insulin into the blood stream in response to elevated extracellular glucose 
concentration. The binding of insulin to its receptor on peripheral tissues such as muscle and 
liver reduces blood glucose levels by triggering glucose uptake and glycogen synthesis in 
these organs (19-22). Loss of an insulin response due to the failure of β cells to secrete 
insulin, or loss of β cells themselves thus leads to disease such as diabetes (23;24). 
Transmission electron microscopy (EM) analysis revealed that islet β cells are abundant in 
insulin-containing granules which are characterized by their appearance as a central dense 
core and a surrounding halo (Figure 1.1c); (25;26). There are around 9000 insulin granules 
with a diameter of ~0.3 μm residing in the cytosol, among which 7% are docked beneath the 
plasma membrane and are ready to release insulin, the so called readily releasable pool 
(RRP); (25;26). Whether these are the first to be released in response to glucose has recently 
been questioned. Using total internal reflection fluorescence microscopy (TIRFM), Shibasaki 
and colleagues (27) demonstrated that a group of insulin granules, which are newly recruited 
into the RRP, might release insulin without docking to the plasma membrane. Such event 
might contribute to both of the first and second-phase of glucose-stimulated insulin release 
events. 
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1.1.4. Insulin structure, transcription and expression 
1.1.4.1. Insulin processing 
Mature insulin is a 6 kDa protein consisting of two peptide chains, namely, the chain A and 
the chain B linked by two disulfide bonds (28). It is derived from proinsulin which contains a 
C-peptide intervening between the chain A and the chain B (29). Preproinsulin, which is 
initially translated from insulin mRNA, is processed into proinsulin in the endoplasmic 
reticulum with removal of the N-terminal signal peptide. Fully folded and oxidized proinsulin 
is transported to the Golgi apparatus where it is packaged into storage granules. During the 
formation and maturation of the secretory granules, proinsulin is cleaved by converting 
proteases such as prohormone convertase (PC) 1, PC2 and carboxypeptidase H (CPH) into C-
peptide and mature insulin which forms a crystal hexamer with zinc (30-32). Upon 
stimulation, insulin is released from the granules with C-peptide at equimolar concentrations 
(Figure 1.2); (31;32).  
1.1.4.2. Insulin gene structure and expression  
Unlike most of the species, which only contain one copy of the insulin gene, the rodent 
insulin gene has two isoforms (Ins1 and Ins2) with Ins2 being the homologue of human 
insulin gene (33;34). The human insulin gene contains three exons intervened by two introns 
(32). The promoter region (~1.6 kb) contains a number of cis-acting regulatory elements 
serving as the binding sites for transcription factors which regulate transcription (32). Among 
them, three major binding sites have been found to be important for conferring β cell-specific 
expression of insulin gene and the regulation of expression in response to various stimuli 
including, an A box region for pancreatic and duodenal homeobox-1 (Pdx1) binding, an E 
box region for neurogenic differentiator 1 (NeuroD1) binding and a C1 element for V-maf 
musculoaponeurotic fibrosarcoma oncogene homologue A (MafA) binding (35-37). 
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Figure 1.2 Preproinsulin processing in pancreatic β cells. 
Preproinsulin is first processed into proinsulin with removal of N-terminal signal peptide in the 
endoplasmic reticulum. After being folded and oxidized in the endoplasmic reticulum, the proinsulin 
is transported to Golgi apparatus via transport vesicle to be packaged into insulin storage granules. In 
the presence of prohormone convertase 1/2 (PC1/2) and carboxypeptidase H (CPH), the proinsulin is 
cleaved into mature insulin and C-peptide which are ready to be released upon stimulations. The 
figure is generated using images from “Servier Medical Art” (http://www.servier.com/servier-
medical-art). 
 
 
 
 
 
 
 
 28 
1.1.4.3. Regulation of insulin gene expression by glucose 
Insulin gene expression is regulated by various nutrients and hormones such as: glucose (38-
42), leptin (43;44), glucagon-like peptide (GLP)-1 (45;46) and insulin itself (41;42;47;48). 
Among them, glucose is probably the most physiologically relevant, as it is the major fuel in 
mammalian cells. Glucose stimulates insulin gene expression both transcriptionally and post-
transcriptionally (39). An increase of glucose concentration within physiological range (2 to 
17 mmol/l) up-regulates insulin gene transcription in islets within 45 min (39). This is 
mediated by transcription factors in the promoter region including Pdx1 (49;50), NeuroD1 
(51) and MafA (52;53) which work in a co-ordinated and synergistic manner (54;55).    
1.1.5. Glucose-stimulated insulin secretion (GSIS) 
Glucose-stimulated insulin secretion from pancreatic islets is biphasic with a rapid first phase 
followed by a sustained second phase. Stimulation involves a series of tightly controlled 
signalling events, which contribute differently to the phases (Figure 1.3); (56;57). Rise of 
blood glucose levels above threshold (4-5 mmol/l for mouse, 7 mmol/l for human and rat) 
triggers uptake of glucose into islet β cells. The intracellular glucose is then glycolyzed by a 
number of enzymes to generate adenosine triphosphate (ATP). Accumulation of ATP and 
hence an increase in ATP/ADP ratio closes ATP-dependent K
+
 (KATP) channels, prompts 
Ca
2+
 influx and triggers “first phase” insulin release (56;57). However, glucose has also been 
found to stimulate insulin release in a KATP channel-independent manner, which probably 
underlies the “second phase” insulin release (57).  
1.1.5.1. Glucose transport 
The uptake of glucose into human islet β cells relies on the prevalence of the glucose 
transporter 1 (GLUT) on the cell membrane, whilst the same action is mediated by GLUT2 in 
rodents (58). When extracellular glucose rises, glucose diffuses across the plasma membrane 
through GLUT1 or GLUT2 (59). The movement of glucose into the β cells is rapid and is 
unlikely to be rate-limiting for glucose metabolism (60). However, the presence of glucose 
transporter appears to be important to maintain normal glucose metabolism, as loss of 
GLUT2 in rodent β cells has been associated with diabetic phenotypes (61). For example, 
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Figure 1.3 KATP channel-dependent glucose-stimulated insulin secretion. 
Extracellular glucose, which diffuses across the cell membrane via glucose transporter 2 (GLUT2) in 
rodents and GLUT1 in humans is phosphorylated into glucose 6-phosphate (G6-P) by glucokinase 
(GK). After glycolysis, G6-P is converted into pyruvate which later enters the mitochondria to 
generate metabolic fuel, adenosine triphosphate (ATP) via tricarboxylic acid cycle (TCA cycle). 
Increase of ATP to ADP level closes ATP sensitive K
+
 channels (KATP channels) and thus depolarizes 
the cell membrane. Plasma membrane depolarization opens voltage-gated L-type Ca
2+
 channels which 
effectively facilitate influx of extracellular Ca
2+
. The increase of intracellular Ca
2+ 
level triggers 
insulin exocytosis. The figure is generated using images from “Servier Medical Art” 
(http://www.servier.com/servier-medical-art). 
 
 
 30 
GLUT2 protein levels on the surface of β cells in male Zucker diabetic fatty rat (62) and 
streptozotocin (STZ) (a β cell toxin)-injected neonatal rat (63) were profoundly decreased. 
Moreover, GLUT2-null mouse islets displayed impaired first phase glucose-stimulated 
insulin secretion and insulin biosynthesis (64;65). 
1.1.5.2. Glucose phosphorylation and ATP synthesis 
Glucose taken up by β cells through the membrane is phosphorylated to generate glucose 6-
phosphate (G6-P) by a low affinity glucokinase (GK) which belongs to the hexokinase family 
(HK IV); (66). The level of expression and cooperative kinetics of this enzyme enable 
glucose phosphorylation by GK to be the rate-limiting step of glucose metabolism in β cells 
(67). Therefore, GK has been widely accepted as a glucose sensor (66-69). Ablation or 
reduction of glucokinase activity in pancreatic β cells led to phenotypes resembling type 2 
diabetes (T2D) in mice, with impaired glucose-stimulated insulin secretion (70). Indeed, 
mutations in the glucokinase gene are associated with maturity onset diabetes of the young 
(MODY), a non-insulin-dependent form of diabetes which occurs at an early age (71). In 
patients carrying such mutations, the threshold of glucose to stimulate insulin secretion is 
elevated (72). Moreover, glucokinase has also been indicated to regulate β cell mass, as half 
deletion of glucokinase in islets from GK heterozygous mice reduced high fat diet induced 
islet β cell hyperplasia (73) and treating β cells with a pharmacological GK activator 
stimulates cell proliferation by increasing the number of β cells re-entering mitosis (74). 
1.1.5.3. KATP channel-dependent insulin secretion 
As discussed above, pancreatic islet β cells are equipped with ATP sensitive K+ channels 
(KATP channels). They comprise four channel-forming subunits (Kir6.2) surrounded by four 
transmembrane proteins, (SUR1); (75;76). Kir6.2 which is an inwardly rectifying K
+
 channel 
(75) carries a cytosolic binding site for ATP (77). SUR1 which belongs to the “ATP-binding 
cassette family” is able to bind pharmacological compound like sulfonylureas which inhibits 
KATP channel activity (76). Therefore, glucose closes KATP channels principally by elevating 
intracellular ATP levels (see above). Such closure of KATP channels prevents efflux of K
+
 
ions, leading to depolarization of plasma membrane from a resting potential of -70 mV to the 
range (-30 to -40 mV) where high voltage-gated Ca
2+
 channels are activated (78). The 
opening of Ca
2+
 channels allows influx of Ca
2+
 into the cells. The resulting increase of 
intracellular Ca
2+
 is thought to be the major factor contributing to the release event of docked 
insulin granules (79), probably by interacting with a soluble N-ethylmaleimide sensitive 
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fusion attachment protein receptor (SNARE) protein complex (80). There are several types of 
high voltage-gated Ca
2+
 channels present on the surface of islet β cells including L-, N-, P/Q- 
and R-type Ca
2+
 channels (81), among which L-type Ca
2+
 channels are most abundant and are 
believed to be mainly responsible for KATP channel-regulated Ca
2+
 influx (79;82).  
1.1.5.4. KATP channel-independent insulin secretion 
Further stimulation of insulin secretion by glucose in islet β cells already under exposure of 
50 mmol/l K
+
 (maximally stimulate electrical activity induced by closure of KATP channel) 
led to the idea that other signalling pathways independent of KATP channel-related insulin 
secretion exist in islet β cells (83;84). It has been postulated that the second phase insulin 
secretion might be partly regulated by this pathway (85). However, the mechanism 
controlling this process is much less defined. Several possible candidates such as, pyridine 
nucleotide, citrate, malonyl-CoA, proteinase A and C , cAMP phosphodiesterases (PDE) and 
AMP-activated protein kinase (AMPK) are suggested to be involved in this branch of 
glucose-stimulated insulin secretion (56;57). 
1.1.5.5. Insulin granule movement and exocytosis  
Fusion of insulin secretary granules to the cell membrane and release of insulin are the final 
steps of glucose-stimulated insulin secretion (56;57;86;87). As mentioned above, there are at 
least two distinct pools of insulin secretory granules: a small percentage (7%) of insulin-
containing granules docking beneath the cell membrane (≤ 0.3 μm away from cell 
membrane), the so called readily releasable pool (RRP) and a large reserve pool (RP) some 
distance from the cell membrane (>0.3 μm); (25). The insulin in the granules of RRP bursts 
within 10 minutes after glucose-stimulated cytosolic Ca
2+
 increase. This corresponds with the 
rapid first phase insulin secretion after glucose stimulation (86). Recent studies by Shibasaki 
and colleagues suggest that certain amount of insulin granules in the RRP might release 
insulin without docking onto the cell membrane and might contribute to the first phase of 
glucose-stimulated insulin release (27;88). On the other hand, the recruitment of granules in 
RP to RRP is slow and is ATP and Ca
2+
-dependent, probably accounting for the sustained 
second phase insulin secretion (89). The observations of blocked insulin granule movement 
after treatment with a microtubule disruption agent, nocodazole (90) or over-expression a 
dominant-negative mutant of kinesin heavy chain (microtubule-associated motor protein); 
(91) suggest the idea that insulin granules might travel from RP to RRP along microtubule 
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network by binding to kinesin heavy chain (56). Whether this process is regulated by glucose 
is unclear (88).     
1.1.6 Control of insulin secretion and β cell mass by central nervous system 
The pancreatic islets are innervated by both parasympathetic and sympathetic nerves (92). It 
is well established that a central regulation of insulin secretion from pancreatic β cells exists. 
Indeed, the parasympathetic neurotransmitter, acethylcholine can bind to muscarinic receptor 
3 expressed on the surface of pancreatic β cells and increases insulin secretion from isolated 
pancreas (93), whilst the sympathetic neurotransmitter, norepinephrine binds to α2-
adrenoreceptor and inhibits insulin secretion from pancreas (94;95). Most recently, by 
intracerebroventricularly (i.c.v.) injecting anorexgenic peptides, leptin and resistin into the 
medial basal hypothalamus of the mice, Park and colleagues (96) demonstrated that these 
satiety-controlling peptides can also regulate insulin secretion via central nervous system, and 
neurons within the medial basal hypothalamus might be responsible for mediating these 
effects. However, it is not clear which neuron(s) might be involved in the hypothalamus to 
regulate insulin secretion from pancreas. Moreover, these mice displayed an increase in β cell 
mass. Although the mechanism underlying these effects is still largely elusive, Park‟s results 
imply a possible central regulation of adipose tissue-derived peptides on β cell growth and 
function (96).  
1.1.7. Effects of insulin on peripheral tissues 
Pancreatic islets monitor plasma glucose levels and secrete insulin in response to elevated 
blood glucose concentration. Insulin restores blood glucose levels by three approaches: 1) 
promoting glucose uptake in muscle and adipose tissue, 2) facilitating glycogen synthesis in 
liver and muscle, and 3) inhibiting hepatic glucose production (Figure 1.4); (19-22). The 
action of insulin on peripheral tissues is mediated primarily by the binding of insulin to its 
receptor (insulin receptor) expressed on the cell membranes of these tissues (22;97). The 
insulin receptor is a receptor tyrosine kinase capable of autophosphorylation and 
phosphorylation of downstream substrates, which in turn activates several signalling 
pathways involved in glucose metabolism.     
First of all, to promote glucose uptake, insulin increases glucose transporter 4 (GLUT4) 
localization at the plasma membrane of muscle and adipose tissue via two signalling 
pathways. Firstly, phosphorylation of insulin receptor substrate 1 (IRS1) by the insulin  
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Figure 1.4 Glucose-reducing effects of insulin on the muscle and adipose tissue. 
Insulin reduces glucose levels by (1) facilitating glucose uptake into the muscle and adipose tissue by 
increasing GLUT4 translocation to the plasma membrane, (2) increasing glycogen synthesis directly 
by activating the glycogen synthase or indirectly by activating the glycolytic pathways, and (3) 
reducing gluconeogenesis by inhibiting transcription of the gluconeogenic genes such as G6Pase, 
PEPCK etc. The figure is generated using images from “Servier Medical Art” (http://www.servier. 
com/servier-medical-art). 
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receptor acts as a docking site for the binding of the p85 regulatory subunit of 
phosphatidylinositol-3‟ kinase (PI3K); (98). The recruitment of PI3K to the IRS1 in turn 
phosphorylates phosphoinositide on the 3-position to produce phosphatidylinositol-3-
phosphate. The phosphorylation of the latter phosphorylates protein kinase B (PKB)/Akt and 
PKC (99;100) possibly via regulation of phosphoinositide-dependent kinase 1 (PDK1), which 
are required for GLUT4 translocation (101-104). In addition, a second mechanism by which 
insulin receptor phosphorylates Cbl and hence promotes Cbl-associated protein (CAP) 
mediated TC10 (a member of Rho GTPase family) translocation to the plasma membrane has 
been suggested to regulate GLUT4 localization to the plasma membrane of adipose tissue 
(Figure 1.4); (105-107).  
Secondly, to increase glycogen synthesis, insulin leads to the dephosphorylation and 
activation of glycogen synthase via inhibition of glycogen synthase kinase 3 (GSK3), a 
downstream target of PI3K- signalling pathway (108). Insulin may also increase glycogen 
stores indirectly by promoting the glycolytic pathway through modulations of glucokinase 
(GK), phosphofructokinase (PFK) and pyruvate kinase (PK) gene expression, hence 
increasing the availability of substrate (glucose-6-phosphate) to convert into glycogen by 
glycogen synthase (Figure 1.4); (109;110).  
Finally, insulin suppresses hepatic glucose output by inhibiting both glycogenolysis (from 
glycogen stores) and gluconeogenesis (from lactate/pyruvate or amino acids) via inhibiting 
gene expression such as, phosphoenolpyruvate carboxykinase (PEPCK) (111), glucose-6-
phosphatase (G6Pase); (112), fructose-1,6-biphosphatase (F-1,6-Pase); (113) and PPARγ co-
activator 1 (PGC1-α); (114). The latter effect has been proposed to be caused by transducer 
of regulated CREB activity 2 (TORC2)-mediated dephosphorylation of cAMP response 
element binding protein (CREB) which consequently prevents its binding to promoter regions 
of these genes (115). Loss of sensitivity of peripheral tissues to insulin (insulin resistance) 
due to defects on any of these three pathways underlies the early onset of T2D (Figure 1.4); 
(116).   
1.1.8. Pancreatic islet β cells and type 2 diabetes (T2D) 
T2D is a metabolic disorder which, if left untreated, increases the risk of heart attack, stroke, 
amputation and kidney failure due to long term hyperglycemia (117;118). It is the major form 
of diabetes in humans, representing 85-90% of all cases (http://www.who.int/). Unlike type 1 
diabetes (T1D) which is characterized by the destruction of islet β cells by the immune 
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system (119), T2D is characterized by insulin resistance of peripheral tissues such as muscle, 
liver and adipose tissue, and islet β cell failure or loss (23;24). Pancreatic islet β cells play a 
central role in determining the severity of the disease. At early stage of T2D at which patients 
are still glucose tolerant, pancreatic islets are able to increase their β cell mass and hyper-
secrete insulin to compensate for the insulin resistance. However, with progression of the 
disease when β cells fail to produce enough insulin to meet the demands from peripheral 
tissues, glucose intolerance occurs (23;24;120-122). Disappearance of first phase insulin 
secretion and progressive reduction of β cell mass underlie β cell failure in T2D (123-126). 
Therefore, understanding the mechanism of β cell failure and finding proteins that might 
restore β cell function in T2D will be beneficial for developing drugs to treat this disease. 
1.1.8.1. β cell mass, apoptosis and autophagy in T2D 
In type 2 diabetic human patients, β cell mass was found to be reduced by 30-40% (126-129). 
This was accounted for by both reduced islet number and islet size due to reduced β cell 
number (125). It is generally thought that increase of apoptosis contributes to the reduction of 
β cell mass in T2D (124;127;130), as the relative rates of new islet formation and frequency 
of β cell proliferation were similar between type 2 diabetic and normal pancreata (127). 
Several factors have been found to cause apoptosis in T2D, including glucotoxicity 
(131;132), lipotoxicity (133), endoplasmic reticulum (ER) stress (134;135) as well as pro-
inflammatory cytokines etc (136;137). It is, however, difficult to determine at this stage 
which factor is the main contributor leading to β cell apoptosis in T2D.  
Autophagy is a self-protective mechanism in which cells “eat” defective or damaged 
organelles in response to toxic conditions (138;139); (See chapter 5 for detailed introduction). 
Autophagy has been associated with non-apoptotic cell death, though whether it is the cause 
or the result of cell death is still a matter of debate (139;140). An increase in the number of 
autophagic vacuoles has been discovered recently in type 2 diabetic human islet β cells by 
Masini and colleagues (141). This is accompanied by an increased number of dead β cells 
containing such vacuoles (141). It is proposed (142) that autophagy might be up-regulated in 
T2D β cells to protect them from toxins that caused β cell death. However, further 
investigation is needed to fully address this question. 
1.1.8.2. Insulin secretory deficiency in T2D 
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A loss of first phase insulin secretion in response to glucose stimulation is the hall mark of β 
cell failure in T2D (123). Islets isolated from type 2 diabetic patients secreted less insulin 
than non-diabetic islets in response to high glucose stimulation (16.7 mmol/l); (143;144). 
Moreover, the threshold for glucose-stimulated insulin secretion in diabetic islets is 
significantly higher (12 mmol/l) than non-diabetic islets (7 mmol/l); (144). Such 
observations, along with a reduction of glucose oxidation in diabetic islets, led to the 
speculation that there might be a mitochondrial defect in diabetic islets (143;145). Indeed, 
enlarged and rounded mitochondria were found in diabetic islet β cells (146). Such defective 
mitochondrial behaviour is accompanied by a decreased ATP/ADP ratio (146). In addition, 
glucokinase mRNA levels were found to be reduced in T2D islets, consistent with defective 
glucose sensing and metabolism (143). By contrast, insulin secretion after KCl treatment is 
normal in T2D islets further suggesting a defect in glucose signalling (144). Single nucleotide 
polymorphisms in the syntaxin 1A gene, whose product forms part of the SNARE complex, 
are associated with age-dependent onset of type 2 diabetes. Though functional analysis is 
required, this finding suggests that there might be a defective exocytosis machinery in type 2 
diabetic islet β cells (147). Taken together, these findings suggest that an impairment of β cell 
function in T2D might result from a combined action on glucose sensing, ATP generation 
and possibly insulin granule exocytosis.    
1.1.8.3. Treating T2D by targeting β cells 
Despite the importance of β cell mass and function in regulating glucose homeostasis in T2D, 
the availability of drugs targeting β cells are limited. There are two major groups of anti-
diabetic drugs affecting insulin secretion: sulfonylurea, which increases β cell electrical 
activity by binding to KATP channels (148;149) and glucagon like peptide-1 (GLP1) analogs, 
which facilitate KATP channel-dependent insulin exocytosis via the cAMP and protein kinase 
A (PKA) pathway (150). GLP1 has also been found to increase β cell mass and insulin 
production in rodents by up-regulating β cell proliferation (PI3K mediated mitogen-activated 
protein kinase (MAPK) and protein kinase C (PKC) activation); (151) and insulin expression 
pathways (cAMP/PKA mediated Pdx1 expression); (152;153). Although GLP1 inhibits β cell 
apoptosis from freshly isolated human islets (154;155), no effects of GLP1 on β cell mass 
have been confirmed in man. Moreover, both types of drug have certain limitations with 
respect to their use for treating T2D. For example, hypoglycemia is the major risk of using 
sulfonylureas (156) whilst the response to GLP1 is found to be decreased in long-standing 
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T2D (157). Therefore, understanding the mechanism regulating β cell mass and function are 
needed to develop new drugs or improve the effects of existing drugs to treat T2D.  
 
1.2. Pancreatic α cells and glucagon secretion 
As opposed to the effects of insulin secretion on hyperglycemia, glucagon, which is secreted 
by pancreatic α cells, counter-regulates the glucose-reducing effects of insulin. Binding of 
glucagon to its receptor on the surface of liver cells stimulates hepatic glucose output through 
glycogenolysis and gluconeogenesis (158;159). This is of paramount importance in 
maintaining normal glucose homeostasis, as elevated fasting and postprandial glucagon levels 
relative to insulin levels is a major factor leading to increased rate of glucose output and 
blood glucose levels in T2D (158;160-162). Moreover, elimination of the effects of glucagon 
on peripheral tissues in glucagon receptor knockout mice, lowers the hyperglycemia after 
treatment with STZ (163;164). This result also highlights the possibility of controlling 
hyperglycemia in diabetes by simply modulating glucagon signalling. On the other hand, 
increased episodes of hypoglycemia have frequently been reported in insulin-dependent type 
1 diabetes and advanced insulin-deficient type 2 diabetic patients treated with glucose 
lowering drugs (165-167). In normal physiological conditions, a healthy individual will 
display reduced insulin, and increased glucagon levels, in response to lower blood glucose 
concentrations (3-4.5 mmol/l); (168). However, in advanced T1D or insulin deficient T2D, 
the counter-regulatory response of glucagon to hypoglycemia is attenuated or lost 
(158;159;165-167;169). Despite the importance of glucagon in regulating blood glucose 
levels, the mechanism through which glucagon secretion is controlled are still largely elusive 
due to the relative scarcity of α cells and polluted paracrine interactions from neighbouring 
cells within islets (158;170-172). Nonetheless, elucidation of the signalling pathways 
controlling pancreatic α cells that regulate glucagon secretion will be useful to design 
approaches to treat diabetes. 
1.2.1. Glucagon structure, transcription and expression  
1.2.1.1. Glucagon structure and preproglucagon processing  
Mature glucagon expressed in pancreatic α cells as a single chain poly-peptide of 29 amino 
acids. The hormone is homologous to two other preproglucagon gene products, glucagon-like 
peptide 1 (GLP1) and 2 (GLP2) secreted from L cells of intestine and some neuronal cells in  
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Figure 1.5 Preproglucagon structure and processing. 
Schematic illustration of preproglucagon (top), proglucagon (middle) structure and other proglucagon 
products in pancreas, intestine and brain after prohormone cleavage (PC); (bottom); (not to scale). 
SP, N-terminal signal peptide; GRPP, glicentin-related polypeptide; Black box, dibasic amino acid 
residues (KR, RR, KK; K, lysine; R, arginine), which represent potential sites for cleavage by 
prohormone convertases. Image was adapted from Furuta M et al., J. Biol. Chem., 2001 (173). 
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the brain (158;174). The initial translational product of glucagon mRNA is preproglucagon. It 
consists of an N-terminal signal peptide, glicentin-related polypeptide (GRPP), unprocessed 
glucagon, and unprocessed GLP1 and GLP2 separated by two intervening peptides, IP1 and -
2 (Figure 1.5); (158;174). Due to the presence of different levels of prohormone convertase 
(PCs), with exclusive expression of PC2 in α cells, the 180-amino acid proglucagon molecule 
which derives from preproglucagon, is cleaved into bioactive glucagon in pancreatic α cells. 
By contrast, the same proglucagon molecules are processed into GLP1 and -2 in L cells due 
to the presence of PC1/3 (Figure 1.5); (158;173-175). However, traces of active GLP1 (7-36 
and 7-37 amino acid) were also found in pancreatic rat islets, indicating a possible role for 
GLP1 secreted by islets (Figure 1.5); (176;177).  
1.2.1.2. Regulation of glucagon gene expression by glucose  
Elevation of glucagon gene expression in pancreatic islets in response to starvation in vivo 
has been reported using in situ RNA hybridyzation (178). However, the effect of glucose on 
glucagon biosynthesis in vitro is still debated. Both activation and inhibition of glucagon 
gene expression by glucose were reported using two murine α cell lines, αTC1-6 (179) and 
αTC1-9 cells (180;181), whilst glucose did not significantly alter glucagon mRNA levels in 
either rat (182) or mouse islets (172). 
1.2.2. α cell morphology, α cell mass and glucagon granules 
Pancreatic α cells only occupy 20-30% of total islet population and less than 1% of total 
pancreas mass (9;12;13). However, it appears that maintenance of such proportional α to β 
cell ratio is important to keep balanced glucagon output and glucose homeostasis, as α cell 
hyperplasia along with increased glucagon secretion occurs in T2D with increased α to β cell 
ratio (6). Most recently, Lu and colleagues (183) demonstrated that mice with pancreatic α 
cell-specific deletion of a tumour suppressor, mennin (Men1), led to α cell hyperplasia and 
hyperglucagonaemia. This result suggests that manipulating α cell proliferation can alter 
glucagon secretion in vivo.   
Similar to β cells, α cells are also specialized in storing and secreting hormone-containing 
granules. Each pancreatic α cell contains around 7,500 glucagon-containing granules, with 
diameters around 0.27 μm (184). Unlike insulin granules, the glucagon-containing granules 
are dark and round shaped without surrounding halos when examined with transmission 
electron microscopy. 
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1.2.3. Regulation of glucagon secretion 
1.2.3.1. Glucose-stimulated glucagon secretion 
Unlike glucose-stimulated insulin secretion from pancreatic β cells, increases in glucose 
concentration inhibit glucagon secretion both in vivo (158;169;172) and in vitro, at least in 
intact islets (158;185-187) or perfused rat pancreas (188). In healthy humans, ingestion (189) 
or infusion (190) of glucose resulted in a decrease of plasma glucagon levels, while starvation 
led to decrease of glucose levels followed by elevated glucagon release (191). Studies using 
isolated rodent islets suggested that a glucose concentration of less than 2-3 mmol/l is 
required to trigger glucagon release and 6-10 mmol/l glucose is enough to maximally inhibit 
glucagon release in rodents (186;187;192). By contrast, the threshold for stimulation of 
insulin secretion is slightly higher (4-5 mmol/l for mouse, 7 mmol/l for human and rat); 
(186;192). This difference underlies that release of factors from the β cells such as insulin, 
Zn
2+
 and others is unlikely to be the chief mechanism through which glucose inhibits 
glucagon release. Interestingly, Vieira and colleagues recently reported that high glucose 
concentrations alleviate the inhibitory effect of glucose on glucagon secretion, with only half 
maximal inhibition of glucagon secretion achieved with 1h incubation of mouse islets with 20 
mmol/l glucose (192).   
1.2.3.2. Electrical activity in pancreatic mouse α cells 
Similar to β cells, there are both K+-selective channels (158;184;185;193;194) and voltage-
gated Ca
2+
 channels on the α cell plasma membrane (158;195-197), and involved in 
triggering glucagon exocytosis. However, the regulation of electrical activity and response to 
glucose in pancreatic α cells is different compared to that of β cells (158). In mouse α cells, 
KATP channels maintain the membrane potential at around -60mV (184;198;199), much 
higher than the resting membrane potential found in β cells (-70~-80mV) during glucose 
starvation (56;200). At this glucose concentration (less than 2-3 mmol/l), due to the presence 
of low voltage-activated T-type Ca
2+
 channels, the membrane potential is elevated to the 
range (-50 mV) where Na
+
 channels and high voltage-activated Ca
2+
 channels (mainly N-type 
Ca
2+
 channels) start to open, resulting in influx of Ca
2+
, hence the firing of action potential 
and the glucagon release event (184;186;192;196;201). Upon glucose elevation, glucose 
transporter 1 (GLUT1) facilitates uptake of glucose into α cells (202). Intracellular glucose is 
then glycolyzed and metabolized through the TCA cycle, resulting in elevated ATP 
production (203). Sequentially, KATP channels close and plasma membrane depolarizes in  
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Figure 1.6 Basal glucose-stimulated glucagon secretion from mouse pancreatic α cells.  
Left, at low glucose concentrations, KATP channels are open and maintain the membrane potential at 
around -60mV. This leads to opening of low voltage gated T-type Ca
2+
 channel. Opening of the latter 
brings the membrane potential to the range where Na
+
 channel and high voltage gated Ca
2+
 channel 
(mainly N-type Ca
2+
 channel) open. The resulting influx of Ca
2+
 leads to simultaneous glucagon 
secretion. Right, at high glucose concentrations, glucose is transported across cell membrane via 
GLUT1 and is metabolized to generate ATP which closes KATP channels. The closure of latter 
increases the membrane potential to the range where T-type Ca
2+
 channel and subsequent Na
+
 and 
high voltage gated Ca
2+
 channel do not open. Thus no increase of intracellular Ca
2+
 is rendered and 
glucagon secretion is inhibited (196;201). 
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response to increased ATP levels (199). However, unlike the β cell whose plasma membrane 
potential relies heavily on KATP channels, the firing of action potential of α cell depends on T-
type Ca
2+
 channels and Na
+
 channels, which are inactivated after membrane depolarization 
(Figure 1.6); (199;201). 
1.2.3.3. Paracrine and autocrine effects on glucagon secretion 
In rodents at least, the islet microcirculation is thought to be from β cells to α cells (14-17). It 
is, therefore, unsurprising that β cell secretory products might have impact on α cell 
physiology. Indeed, whilst glucose inhibited glucagon secretion in rat islets, it provoked 
glucagon release from purified rat pancreatic α cells (204;205).  
Insulin, the major β cell secretory product, has been found to profoundly inhibit glucagon 
secretion from α cells. Thus, exogenous addition of insulin to mouse islets (186) or isolated 
rat α cells inhibited glucagon secretion (204;205). Further evidence for this mechanism was 
provided by works from Kulkarni‟s group using knockout mice deleted for the insulin 
receptor specifically in α cells (172). In this model, circulating glucagon levels were 
increased when insulin signalling was interrupted in α cell (172).  
In addition to insulin, other secretory products within β cells, such as Zn2+ (205;206), γ-
aminobutyric acid (GABA) (207;208), and somatostatin which is secreted from somatostatin-
producing cells (198;209), have also been reported to affect glucagon secretion at a species-
dependent manner.   
Glucagon itself has also recently been found to exert an autocrine effect on glucagon 
secretion (210). A positive feed-back loop is therefore suggested that glucagon might 
stimulate its own exocytosis (210).  
1.2.3.4. Autonomic regulation of glucagon secretion 
Sudden drops of glucose concentrations are detrimental to brain function, as there are no 
glucose storing or synthesizing cells present in the brain to maintain glucose supply under 
these conditions (158;169). Therefore, in addition to direct regulation of glucagon secretion 
in response to a decrement of blood glucose, the pancreatic α cells are also subject to signals 
from the central nervous system (158;169). There are three major autonomic inputs from the 
central nervous system to α cells, including 1) sympathetic nerves which release 
norepinephrine and sympathetic neuropeptides; 2) parasympathetic nerves which release 
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parasympathetic neuropeptides; and 3) adrenal medulla which releases the sympathetic 
neurohormone, epinephrine (169). Attention has been focused on the effect of epinephrine on 
glucagon secretion, as this hormone stimulates glucagon secretion both in vivo (211) and in 
vitro (192;205;212) by acting via β2-adrenergic receptors which express dominantly in 
pancreatic α cells (213). Conversely, epinephrine reduces insulin secretion from β cells which 
are thought to express mainly α2-adrenergic receptors (213;214). Blocking β2-adrenergic 
receptors by using a specific antagonist significantly reduced glucagon but not insulin 
secretion probably by lowering cAMP levels (213), hence inhibiting voltage-gated L-type 
Ca
2+
 channels mediated Ca
2+
 influx (215).  
1.2.4. Effects of glucagon on peripheral tissues  
Glucagon increases blood glucose levels mainly by inhibiting glycogen synthesis and by 
promoting hepatic glycogenolysis and gluconeogenesis (158;216;217). In contrast to the 
effects of insulin on glycogen synthesis in the liver, binding of glucagon to its receptor (218) 
on hepatocytes stimulates glycogen break-down by phosphorylating and hence inhibiting 
glycogen synthase (219;220), or by activating glycogen phosphorylase activity via its 
phosphorylation (216). Such effects are probably mediated via elevation of intracellular 
cAMP and subsequent PKA activation (219);  (Figure 1.7). Glucagon also depletes liver 
glycogen stores indirectly by inhibiting glycolytic pathways via phosphorylation and 
inhibition of phosphofructokinase 1 (PFK1) activity. Thus, PKA activation by glucagon 
phosphorylates and inhibits phosphofructokinase 2 (PFK2), which in turn reduces F(2, 6)P2 
levels. Because PFK1 is allosterically activated by F(2, 6)P2, a decrease in the concentration 
of the latter also inhibits PFK1 activity  (221).  Moreover, the action of glucagon on 
inhibition of glycolysis in peripheral tissues also results from phosporylation and inhibition of 
pyruvate kinase (PK) by PKA (222); (Figure 1.7). In the case of long term hypoglycaemia, 
glucagon restores blood glucose levels by gluconeogenesis from lactate/pyruvate and amino 
acids (223). This is achieved in part by up-regulation of genes encoding the transcription co-
activator, PGC1-α (224), and enzymes such as phosphoenolpyruvate carboxykinase 
(PEPCK); (225;226) and glucose-6-phosphatase (G6Pase); (227); (Figure 1.7). Glucagon 
dephosphorylates and translocates TORC2 into the nucleus via an elevation of cAMP and 
subsequent activation of PKA, where it phosphorylates CREB. The consequent binding of 
phosphorylated CREB to the promoter regions of gluconeogenic genes activates their 
transcription (115). Thus, induction of hypoglycaemia in dogs infused with insulin for three 
hours led to upregulation of both glycogenolysis and glucose production.  
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Figure 1.7 Glucose-increasing effects of glucagon on the liver. 
Glucagon increases hepatic glucose output by (1) enhancing glycogenolysis and inhibiting glycogen 
synthesis via activation and inhibition of glycogen phosphorylase and glycogen synthase respectively, 
(2) inhibiting glycolysis by dephosphorylating PK and PFK, and (3) stimulating gluconeogenesis by 
increasing transcription of PEPCK and G6Pase. 
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1.2.5. Treating type 2 diabetes by targeting glucagon signalling 
Because relatively high glucagon to insulin levels are evident in T2D, it is therefore, possible 
to overcome hyperglyemia by controlling glucagon secretion or glucagon action on liver 
(158). Indeed, much attention has been focussed on the possibility of tackling T2D by using 
these two approaches (158;228;228).  
1.2.5.1. Targeting the glucagon receptor  
The effects of glucagon on blood glucose levels rely heavily on its binding to the glucagon 
receptor in the liver (159). Mice deleted for the glucagon receptor (GCR
-/-
) display lowered 
blood glucose levels (229) and are resistant to diet or streptozotocin-induced hyperglycemia 
(163;164). In light of this discovery, several attempts have been made by pharmaceutical 
companies to generate drugs to inhibit the glucagon receptor (228). These include a glucagon 
receptor antagonist (230-232), antiglucagon monoclonal antibodies (233;234) or glucagon 
receptor antisense oligonucleotides (235) and impact on liver glucose production by 
inhibiting intracellular cAMP generation (230). However, concerns have been raised recently 
that inhibition of cAMP-responsive transcription factor CREB, caused by blocking glucagon 
receptor signalling might shift liver towards lipid accumulation, due to its positive effect on 
fatty acid oxidation (236), hence raising potential complications through hepatic steatosis. 
1.2.5.2. Targeting glucagon secretion 
So far, no commercial drugs targeting pancreatic α cells selectively have been developed to 
treat T2D. The discovery of the effects of GLP1 on glucagon secretion and β cell function 
(237-240), led to the development of GLP1 as a potential drug to treat T2D. In addition to its 
stimulatory effect on insulin secretion and β cell mass (238;239;241), GLP1 suppresses 
glucagon secretion (239;242). It has recently been proposed that such an effect might be 
mediated through PKA-dependent inhibition of N-type Ca
2+
 channels via an increase of 
cAMP (212). Considering the importance of controlling glucagon levels in T2D 
(160;161;243), there may thus be considerably large potential to treat T2D by targeting 
proteins that regulate glucagon secretion.  
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1.3. Diabetes and AMPK  
AMP-activated protein kinase (AMPK), a phylogenetically conserved serine/threonine 
protein kinase (244-247) that has recently emerged as an interesting potential drug target for 
treating diabetes (248). Indeed, several front-line anti-diabetes drugs such as metformin and 
thiazolidinediones appear to act, at least in large part, through activating AMPK in liver and 
adipose tissue (249-251). As an energy sensor, AMPK and the signalling pathways upstream 
and downstream of this enzyme have been intensively studied for the past decade both in 
vitro and in vivo. These indicate that AMPK might play important roles in modulating 
glucose metabolism and insulin sensitizing organs such as skeletal muscle, liver, brain and 
adipose tissue (252-255). A substantial amount of results from Rutter lab (256-258) and 
others (259) has demonstrated a pivotal role for AMPK in the control of insulin secretion. 
Recent exciting studies, particularly those describing tissue-specific AMPK knockout mice 
developed with LoxP-Cre technology (260) have implied that AMPK activity is regulated 
differently in different organs in response to glucose or insulin, and that the activation of 
AMPK and its upstream kinases also exerts different downstream effects in different tissues. 
Therefore, it is also possible that AMPK and its upstream kinases might affect pancreatic 
islets differently.  
1.3.1. AMPK structure, isoforms, tissue distribution and subcellular localisation 
Mammalian AMPK exists as a heterotrimer consisting of a catalytic α subunit (α1 or α2) 
(261;262), a regulatory β subunit (β1 or β2) which is required for the binding of other 
subunits (263), and an AMP-binding γ subunit (γ1, γ2, or γ3); (264).  Each of the separate 
subunits and isoforms is encoded by an individual gene (262;265). The α subunit contains a 
N-terminal Ser/Thr kinase domain, an auto-inhibitory sequence (AIS) and a C-terminal β 
subunit binding domain (266;267). The kinase domain includes the critical phosphorylation 
site, Thr172, which is indispensible for the activation of AMPK by upstream kinases 
including liver kinase B1 (LKB1; STK 11), a tumour suppressor, and Ca
2+
/calmodulin-
dependent protein kinase kinase (CaMKKβ); (268-271); (Figure 1.8a). AMPK can be 
inactivated by protein phosphatases including PP2A and PP2C (272), though recent studies 
suggest that a phosphatase complex containing the catalytic subunit of protein phosphatase-1 
and regulatory subunit R6 might be involved in glucose-regulated AMPK inactivation (273). 
Single site mutation at Thr172 to Aspartic Acid (D) mimics phosphorylation of AMPK at this 
site hence creating a constitutively active form of this protein kinase (274). The 
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autoinhibitory sequence (AIS) domain appears to reduce AMPK activity, since truncated 
AMPK α subunits lacking this domain have an almost four fold higher AMPK activity than 
those with an intact AIS (267). The two isoforms of AMPK catalytic α subunit, α1 and α2 are 
encoded by two distinct genes (prkaa1 and prkaa2), and share high homology at the N-
terminals. Both are capable of being phosphorylated by upstream kinases at the Thr172 site 
(262). The distribution of α1 and α2 subunits is distinct in both the subcellular, cellular and 
whole body level, with α2 present in both the cytosol and nucleus suggesting a role in 
controlling transcription and gene expression. α2-containing complexes are predominately 
found in skeletal muscle and heart, whilst α1 complexes, present chiefly in the cytosol, are 
found in most of the other chief metabolic organs such as liver, endocrine pancreas and 
adipose tissues (256;275;276).  
The regulatory β subunit consists of a glycogen binding domain (GBD), and α and γ subunit 
binding domains (277;278); (Figure 1.8a). Recently, much attention has been focused on the 
functions of the β subunit and the observations that: 1) binding of α1→6 linked branches of 
glycogen at the GBD during glycogen depletion, e.g., caused by muscle contraction, appears 
to be necessary for dephosphorylation of glycogen synthase at site 2, promoting glycogen re-
synthesis (279); and 2) the β1 subunit is critical for AMPK activation by the thienopyridone 
drug A769662 (280;281). The γ subunit of AMPK has two Bateman domains formed by four 
tandem cystathionine β-synthase motifs (CBS 1-4), three of which are essential for 
AMP/ATP binding (282); (Figure 1.8a). Recently, the resolution of the crystal structure of the 
αβγ core complex containing the C-terminal domain of α1 and β2 with full length γ1 
confirmed that among these three motifs in the γ subunit, two of them are interchangeable 
between AMP/ADP and ATP binding and the other one tightly occupied by AMP (283); 
(Figure 1.8b).  
High AMP:ATP ratios activate AMPK either allosterically (284) or by rendering AMPK a 
better substrate for upstream kinases (285) and a poorer substrate for protein phosphatases 
(272). Owing to the action of adenylate kinase, the AMP:ATP ratio in cells varies 
approximately as the square of ADP:ATP ratio, which makes the former ratio a very sensitive 
indicator of cellular energy changes. Therefore, any activities which deplete ATP such as 
hypoxia or glucose deprivation are expected to activate AMPK (244;245;272). Recent work 
by Carling‟s and Gamblin‟s groups suggests that ADP itself can protect AMPK from 
dephosphorylation by binding into the α-hook region of one of the two interchangeable  
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Figure 1.8 Domain structures of AMPK subunits and the crystal structure of AMPK α1β2γ1 complex. 
(a) Schematic illustrations of domain structures (not to scale) of AMPK α, β and γ subunits. 
Sequences of mammalian α1/α2 and β1/β2 isoforms are very similar, whilst γ isoforms vary mainly at 
the N-terminal domains. The image was adapted from Hardie G. Nature. 2007 (245). (b) A ribbon 
representation of crystallized AMPK α1β2γ1 complex with two bound AMPs and staurosporine. The 
image was from Xiao B et al. Nature. 2011 (286).  
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binding sites in γ subunit. Such mobilizing causes an allosterical change of the complex to 
facilitate the interaction between the activation loop of the kinase domain and the regulatory 
fragment of the β subunit, hence protecting Thr172 in the kinase domain against 
dephosphorylation (286); (Figure 1.8b).  
1.3.2. Upstream kinases of AMPK 
The first identified mammalian upstream kinase of AMPK is also a serine/threonine kinase, 
liver kinase B1 (LKB1, also called STK11); (287). It is highly conserved across species with 
LKB1 being closely homologous to XEEK1 in D. melanogaster, X. laevis and PAR4 in C. 
elegans. LKB1 is a tumour suppressor and inactivation mutation of Lkb1 has been found in 
almost 80% of Peutz-Jeghers syndrome (PJS) patients. Affected individuals develop multiple 
gastro-intestinal hamartomatous polyps as well as a wide spectrum of benign and malignant 
tumours (288;289). Moreover, whilst mice systemically inactivated for LKB1 (LKB1
-/-
) die 
during embryonic stages (E8.5-11) due to defects in vasculogenesis and placental 
development (290;291), heterozygous LKB1 mice (LKB1
+/-
) display gastro-intestinal polyps 
and hepatocellular carcinomas, similar to those observed in PJS patients (290).  
LKB1 is allosterically activated by binding to the pseudokinase STE20 related adaptor 
(STRAD); (292) and mouse protein-25 (MO25) which serves to stabilize the heterotrimeric 
complex (293). Upon activation of LKB1, the enzyme forms a complex with STRAD and 
MO25, and relocates from the nucleus to cytosol, where it exerts its effects on cell 
proliferation, polarity and other processes (293). Intriguingly, several studies using stimuli 
that activate AMPK reported no changes in LKB1 activities (270;294;295). These findings 
suggested that LKB1 might be constitutively active in certain tissues and cell lines. Indeed, 
pancreas isolated from overnight starved or fed mice showed LKB1 immunoreacitivies 
exclusively in the cytosol of pancreatic endocrine cells, suggesting the constitutive activation 
of this kinase in the latter cell types (296-298). An alternative short form of LKB1 which 
varies at C-terminal has recently been identified by Carling‟s (299) and Hardie‟s group (300). 
Whilst the long form of LKB1 is expressed in a wide range of tissues, the short form has a 
relative restricted tissue distribution with predominant expression in testis, suggesting a role 
of this form in reproduction (299).  
LKB1 has been reported to play important roles in controlling various cell function and 
morphology (301). One of the most well characterized signalling pathways is probably the 
LKB1-AMPK mediated mTOR inhibition. Therefore, Dissociation of Raptor and the 
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consequent inactivation of mTOR acitivity by LKB1-mediated AMPK activation triggers a 
series of downstream events via phosphorylation of related proteins, such as cell growth 
(probably mediated by activation of ribosomal protein S6 and inactivation of 4E binding 
protein 1 (4E-BP1)); (302) and autophagy (dephosphorylation and inactivation of Unc-51-
like kinase 1(ULK1)); (303) or via regulation of transcription factors, such as mitochondrial 
metabolism (PGC1-α); (304). On the other hand, LKB1 is required to maintain the cell 
polarity and the formation of cell junctions of epithelial cells and certain neurons via several 
AMPK-related protein kinases, such as MARK2, SAD-A and NUAK1/2 (305-308). Indeed, it 
has been found that at least 12 AMPK-related protein kinases can be phosphorylated by 
LKB1 (294). Therefore, with characterizations of these kinases in different tissues, roles of 
LKB1 in these tissues will also be better understood. 
In addition to LKB1, another serine/threonine protein kinase, Ca
2+
/calmodulin dependent 
protein kinase kinase β (CaMKKβ) has been found to activate AMPK in response to a rise of 
Ca
2+ 
concentrations, suggesting an involvement of AMPK in cellular process that alter 
intracellular Ca
2+
 levels (268;269;271). CaMKKβ is a known kinase for two documented 
camodulin kinases (CaMK I and CaMK IV) implicated in regulating the transcription of 
genes such as cAMP-responsive element binding (CREB) and activating transcription factor 
1 (ATF-1) and also implicated in vesicle mobilization (309). CaMKKβ contains a CaM 
kinase domain, an autoinhibitory domain and a CaM binding domain where a 
phosphorylation site by PKA is located. In cells, CaMKK resides both in cytosol and nucleus 
(310).  
1.3.3. AMPK in the endocrine pancreas 
AMPK activity was found to be reduced in islets from type 2 diabetic patients suggesting that 
AMPK might be involved in islet dysfunction in T2D (143). Indeed, AMPK has recently 
emerged as a key regulator of insulin secretion in the minute-to-minute timescale (256-
259;311;312) and β cell mass (e.g. survival and proliferation pathways) more chronically 
(253;313-316).  
1.3.3.1. AMPK regulates β cell insulin secretion and gene expression 
The role of AMPK in controlling insulin secretion from pancreatic β cells was first addressed 
by Salt and colleagues (311) in a pharmacological study on a tumoral β cell line and rodent 
islets. These authors demonstrated that 5-aminoimidazole-4-carboxamide 1-β-D-
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ribofuranoside (AICAR, a permeant analog of adenosine and a well known AMPK activator)-
treated INS-1 rat β cells displayed increased basal (at 3 mmol/l glucose) but inhibited 
glucose- (16.7 mmol/l) stimulated insulin secretion. Similar results were also obtained by the 
group of Van de Casteel and Pipeleers (259), and by Rutter‟s group (257) using MIN6 mouse 
β cells and primary rat islets. Studies from the Rutter lab showed that AMPK activation by 
AICAR reduced glucose-stimulated insulin secretion, preproinsulin promoter activity and 
insulin gene expression (256;257;259). Metformin was later shown to activate AMPK in 
MIN6 β cells and primary human islets (258). Increases in AMPK activity, achieved by 
treatment with metformin, were also associated with reduced glucose-stimulated insulin 
secretion to near basal levels (258;317). These results were further confirmed by Wheeler‟s 
group showing almost 50% decrease of glucose-stimulated insulin secretion from isolated rat 
islets treated with AICAR and metformin overnight (318). However, recent investigations of 
the involvement of AMPK in controlling insulin secretion by Philipson‟s group found that 
AICAR treatment, instead of reducing, increased glucose-stimulated insulin secretion from 
mouse islets (317). Similarly, studies by Birnbaum and Newgard indicated that AICAR and 
phenformin (a more potent analogue of metformin), exerted no effect on glucose-stimulated 
insulin secretion in MIN6 β cells and primary mouse islets (319;320). These divergent results 
highlight the limitations of using pharmacological approaches in the study of AMPK. AICAR 
mimics the effect of AMP on AMPK activation, and metformin and phenformin have also 
been reported to activate AMPK by inhibiting complex I of the respiratory chain, leading to 
an increase in cellular AMP:ATP ratio; the impact on other, AMPK-independent processes 
and signalling pathways is likely to be significant (321). To avoid such complications, a 
constitutively-active form of AMPK (CA, α1312T172D) or a dominant-negative form of the 
enzyme (DN, α2 D157A) (322) were used in later studies. Whereas over-expression of 
AMPK-CA in MIN6 β cells and rat islets reduced glucose-stimulated insulin secretion and 
insulin gene expression, AMPK-DN-expressing viruses increased basal insulin release and 
insulin gene expression (257). The effects of AMPK activation were later shown to reflect 
reduced insulin vesicle movement in MIN6 cells infected with AMPK-CA-expressing virus 
(312). 
1.3.3.2. AMPK regulates β cell apoptosis 
Apart from insulin secretion and insulin gene expression, AMPK has also been reported by 
several groups to exert pro-apoptotic effects in β cells. Physiologically, this is expected to 
lower β cell mass and total insulin output per pancreas (259;313;323-325). Prolonged 
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activation of AMPK in MIN6 cells or purified mouse islet β cells, achieved by 24 or 48 h 
exposure to AICAR or metformin, led to an increase in the number of apoptotic cells assessed 
by DNA fragmentation (259;314;315;323;324). This change was proposed to be due to 
increased oxygen radical formation and mitochondrial dysfunction. The latter was then 
proposed to activate c-Jun-N-terminal kinase (JNK) and caspase 3-dependent death 
pathways, eventually leading to the onset of apoptosis (259;325). Using an adenovirus to 
express AMPK-CA, Rutter and colleagues confirmed that activation of AMPK in MIN6 cells 
and dissociated mouse islet β cells significantly increased levels of cleaved caspase 3, a key 
marker of apoptosis (316). Conversely, AMPK-DN virus-infected cells showed decreased 
levels of active caspase 3 after cytokine treatment (316). Correspondingly, in pancreatic β 
cells isolated from AMPK α2 deficient mice, AICAR induced apoptosis was significantly 
reduced (314). 
1.3.3.3. β cell AMPK and LKB1 regulate whole body glucose homeostasis in mice 
A first attempt to identify the role of AMPK specifically in pancreatic β cells in controlling 
whole body glucose metabolism was achieved by Rutter‟s group using STZ-induced diabetic 
mice which were transplanted with islets infected with adenovirus carrying AMPK-CA or -
DN. Mice receiving AMPK-CA-infected islets demonstrated poorer glycemic index over 20 
days post-transplantation and poorer glucose tolerance whereas those which received AMPK-
DN-infected islets had improved glycemic control and better glucose tolerance (326). Recent 
studies by Hezel and colleagues (298) demonstrated that mice deleted for LKB1 in all 
pancreatic cell types using Pdx1-Cre deleter mice displayed an improved glucose tolerance. 
Since the insulin secretion from isolated islets and relative β cell mass were not measured in 
their studies, it is not known whether such effects were caused by deletion of LKB1 in 
pancreatic β cells per se.     
1.3.3.4. AMPK regulates α cell glucagon secretion  
Little information has been obtained to date regarding the role of AMPK and its upstream 
kinases in pancreatic α cells. Interestingly, silencing of Pas-(per-arnt-sim) domain containing 
protein kinase (PASK), which is distantly related to AMPK, in mouse αTC1-9 cells led to 
increased AMPK α2 gene expression accompanied by increased glucagon secretion and pre-
proglucagon gene expression. Conversely, over-expression of PASK in αTC1-9 cells or 
human islets inhibits glucagon release, suggesting that PASK might regulate glucagon 
signalling partially through AMPK (181).  
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1.3.4. AMPK in the medial-basal hypothalamus 
1.3.4.1. The role of hypothalamic AMPK in regulating food intake 
The basomedial hypothalamic area of the brain is a key compartment for energy sensing and 
satiety regulation. Hypothalamic AMPK activity is regulated by feeding status and various 
hormones and nutrients including insulin, ghrelin, leptin, adiponectin and cannabinoids, and 
these changes have been suggested to control body weight and food intake (246;327-331). 
Increases in AMPK activity, achieved by expressing AMPK CA in the mediobasal 
hypothalamus (including arcuate (ARC) and paraventricular (PVH) nucleus) or 
intracerebroventricular (i.c.v.) injection of AICAR into these areas increased food intake and 
body weight, concomitant with increased expression of the orexigenic peptides, neuropeptide 
Y (NPY) and agouti-related protein (AgRP); (332). Conversely, introduction of adenoviral 
AMPK-DN or compound C in the same areas decreased the expression of both peptides and 
lowered food intake (332). It was proposed that two intracellular signalling pathways might 
be involved in the satiety-controlling effects of AMPK. One was through AMPK-mediated 
inhibition of acetyl-CoA carboxylase (ACC) and malonyl-CoA activation, which in turn, 
leads to enhanced carnitine palmitoyltransferase 1 (CPT-1) activity in the hypothalamus. This 
signalling pathway is largely responsible for the orexigenic effects of ghrelin in the 
hypothalamus (333). An alternative mTOR-dependent signalling pathway in the mediobasal 
hypothalamus was recently suggested to mediate AMPK-regulated increase in food intake. 
Here, AMPK was proposed to inhibit phosphorylation of its downstream target, ribosomal 
protein S6 kinase β-1 (S6K1); (334;335). To clarify exactly which areas of the hypothalamus, 
and which neuronal subtypes, were involved in these effects, Wither‟s group generated 
proopiomelanocortin (POMC) and AgRP specific AMPK α2 knockout mice (336). Mice 
lacking AMPK α2 in POMC neurons displayed increased food intake and became obese, 
while mice inactivated for AMPK α2 in AgRP neurons showed the opposite phenotype, with 
decreased food intake and body weight.  
1.3.4.2. The role of hypothalamic AMPK in regulating hepatic glucose production 
In addition to regulating satiety and body weight, the hypothalamus has also been implicated 
in integrating energy signalling to control hepatic glucose production (337-339). In light of 
the reduced glucose output in mice with decreased CPT-1 levels in hypothalamus (340), it is 
plausible that AMPK, whose phosphorylation of ACC decreases malonyl-CoA levels and 
thus, increases CPT-1 activity, might also increase hepatic glucose production through an 
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indirect mechanism. Most recently, using rats infused into the mediobasal hypothalamus with 
virus carrying AMPK DN or compound C, Yang and colleagues (341) demonstrated that 
inhibition of AMPK in this brain region reduced glucose production without changing 
peripheral glucose disposal.  
1.3.4.3. The role of hypothalamic AMPK in controlling β cell function and β cell mass 
As well as modulating hepatic glucose production, the hypothalamus may also be able to 
control β cell function and β cell mass (96). Thus, i.c.v. infusion of resistin, a hormone 
secreted by adipose tissue, into rats for four weeks led to a remarkably elevated first phase 
insulin secretion, concomitant with increased β cell mass. Decreased AMPK phosphorylation 
in response to leptin was also alleviated by resistin infusion, implying that the modulation of 
AMPK activity in the hypothalamus by resistin might regulate β cell function and β cell 
growth (96).  
1.3.4.4. Upstream kinases of AMPK in the hypothalamus 
Intriguingly, although AMPK regulates food intake and body weight in POMC neurons, mice 
lacking either CaMKKβ or LKB1 in the same neurons did not exhibit changes in any of the 
feeding behaviours (342). However, LKB1 deletion in POMC neurons increases hepatic 
glucose production with up-regulation of genes associated with gluconeogenesis, as opposed 
to the observations that AMPK α2 deletion in the same neurons does not change peripheral 
tissue sensitivity (336;342). Further studies of the role of LKB1, or possibly other AMPK-
related kinases, in hypothalamus are needed to fully understand the mechanisms of which, 
LKB1 and AMPK controls satiety in hypothalamus and hepatic glucose production. 
In summary, AMPK is likely to be a key regulator of energy signals in the hypothalamus, 
integrating signals from peripheral tissues to control satiety, glucose production and insulin 
secretion. However, caution needs to be taken when interpreting data from i.c.v. infusion 
studies which affect large areas of the mediobasal hypothalamus. Thus the identity of the 
neurons involved, and the role played by AMPK in such neurons, remains only partly 
clarified. Total ablation of AMPK using neuron specific-Cre transgenes will be a useful tool 
to answer these questions. 
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1.4. Study of gene functions in the pancreas using tissue-specific knockout or transgenic 
mice  
The knowledge of gene function at the level of whole animals has been expanded 
progressively over the past decade, largely owning to successful generations of knockout and 
transgenic mice (Figure 1.9). Moreover, tissue-specific knockout and transgenic mice allow 
studies of gene functions in particular cell types that would otherwise be unavailable or 
embyonically lethal under the condition of whole body knockout. Using pancreatic islet cell-
specific knockout and transgenic mice, many proteins that are important to regulate islet 
functions and survival in vitro have also been found to regulate whole body glucose 
homeostasis in vivo. The cell-selective expression or deletion of certain gene in vivo depends 
solely on the location where the promoter is expressed. To study pancreatic gene functions in 
regulating whole body glucose metabolism, several promoters have been used (343-347).  
1.4.1. Pdx1-driven gene over-expression or deletion in mice 
Pdx1 is expressed in a region of the foregut endoderm destined to become antral stomach, 
pancreas, and rostral duodenum (348). During early stages of embryonic development (9-10 
days post cortium), Pdx1 is highly expressed in both the exocrine and endocrine pancreas, as 
well as in a subpopulation of duodenal and gastric enteroendocrine cells (348;349). In the 
neonatal pancreas, Pdx1 expression mainly occurs in acinar cells, whilst it becomes abundant 
in endocrine cells (all cell types in pancreatic endocrine cells) at the age of three weeks with 
reduced expression levels in the exocrine cells. In adult mice, pancreatic Pdx1 expression is 
almost entirely restricted to pancreatic β cells (344).  
1.4.2. RIP2-driven gene over-expression or deletion in mice 
As pancreatic β cells play a central role in regulating glucose homeostasis in response to 
hyperglycemia, a promoter which can be used to engineer a transgenic or knockout mouse 
model where certain gene can be studied specifically in these cells can be useful. The first 
candidate appeared almost 10-15 years ago. The rat Ins2 promoter (RIP2) was initially used 
to generate β cell specific transgenic or knockout mice (343). By E11.5 days, the expression 
of RIP2 was already detectable in pancreatic β cells with no traces of expression in other 
pancreatic endocrine cells (345). Therefore, a large sum of studies have been documented 
using RIP2 promoter to generate transgenic or knockout mice and to study functions of genes 
that might regulate glucose homeostasis (350). However, several concerns of using this Cre 
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deleter strain to study gene functions in pancreatic β cells have been raised. Firstly, using 
ROSA26-Stop-LacZ (R26R) mice, which enable Cre-mediated gene recombination to be 
detected by the expression of β-galactosidase, Gannon and colleagues (345) first discovered 
that low levels of RIP2 expression can also be detected in regions other than pancreatic β 
cells. These regions include: ventral forebrain, spinal cord, neural retina and pigmented 
epithelium of the eyes (345). Recently, studies of RIP2-Cre expression in the brain were 
further analyzed by using ROSA26-Stop-Tomato and ROSA26-Stop-EYFP reporter mice 
which enable Cre-mediated gene recombination to be detected by fluorescence microscopy. 
This method allows simultaneous staining of tissue sections with fluophore-conjugated 
antibodies to identify cellular locations where Cre might be expressed. Using these mice, 
Song‟ and Wicksteed‟s group reported widespread expression of RIP2-Cre in the brain 
including arcuate nucleus of the hypothalamus where several neurons involved in nutrient 
sensing and feeding controls reside (351;352). However, it is found that RIP2-Cre positive 
neurons at least do not express POMC or neuropeptide Y (353). Therefore, the effects of gene 
ablation in the brain which might alter feeding controls and glucose metabolism need to be 
considered when RIP2-Cre deleter strain is used to generate knockout mice. In addition, mice 
expressing RIP2-Cre develop mild glucose intolerance compared to wild type non-Cre 
expressing mice due to decreased glucose stimulated insulin secretion and β cell mass in the 
former (350;354). Therefore, precautions need to be taken to always include RIP2-Cre as a 
littermate control when comparing phenotypes of pancreatic β cell-knockout mice with 
deletion of certain protein generated using this method.  
1.4.3. Inducible gene deletion in pancreatic β cells 
Due to the extrapancreatic expression of RIP2-Cre, a more pancreatic β cell specific deleter 
strain is needed. Recently, an inducible system in which, a deleter strain expressing Pdx1-
Cre-ER
TM
 was developed to specifically induce Cre-mediated gene recombination in 
pancreatic β cells (346). Thus, to construct Pdx1-Cre-ERTM, Pdx1 promoter is fused with the 
ligand binding domain (LBD) of the human estrogen receptor (346;355). The advantage of 
this system is that when such construct is expressed alone in the cells, it will be retained in 
the cytosol, whilst in the presence of a ligand, tamoxifen, the Cre-ER
TM
 translocates to the 
nucleus resulting in Cre-mediated recombination (356). Because Pdx1 is mainly expressed in 
pancreatic β cells in adult mice (344), therefore, by adjusting the timing and amount of 
tamoxifen (high doses of tamoxifen injection led to Cre expression in brain (352)) 
administrated to mice, the gene deletion can be achieved in pancreatic β cells selectively.  
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Figure 1.9 Illustration of generation of transgenic and loxP/Cre knockout mice. 
(a) Generation of tissue-specific transgenic mice using microinjection method. The gene of interest 
(transgene) is cloned into an expressing vector under a promoter which drives the gene expression in 
particular cell type or a subpopulation of cell types. This vector is later microinjected into the male 
pronucleus of a fertilised oocyte which is collected from a superovulated female mouse previously 
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mated with a male mouse. This oocyte is cultured ex vivo to the two-cell stage during embryonic 
development and are subsequently re-implanted into a pseudopregnant foster mother. The offspring is 
then screened for integration of the DNA construct in the genome by using PCR or southern blot 
techniques. (b) Generation of flox‟d mice and (c) tissue-specific knockout mice. The process starts 
with construction of a targeting vector with gene of interest (sometimes can be several exons of a 
gene) and a neomycin cassette separated by three loxP sites. This vector also contains several 
kilobases of genomic DNA where the homologous recombination would occur, further away from the 
two most distant loxP sites at both directions. After electroporation of the targeting vector into 
embryonic stem cells (SCs), the neomycin resistant SCs in which the homologous recombination 
occurs are collected. These cells are then transiently transfected with a Cre-expressing vector to 
remove the neomycin cassette and leave the cells with targeting gene flanked by two loxP sites. 
Subsequently, these SCs are microinjected into blastocysts and re-introduced into pseudopregnant 
mice. The offspring will then be screened for carrying flox‟d gene by PCR or southern blot analysis. 
The mice positive for flox‟d gene can be crossed with a transgenic mouse expressing Cre recombinase 
under a certain promoter. The Cre-expressing mice homozygous for flox‟d gene will have the targeted 
gene excised selectively in tissues where the Cre is expressed (357;358). Grey box, neomycin 
cassette; Black triangle, flox sequence; SC, embryonic stem cell. 
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Very recently, Wicksteed and colleagues generated another inducible pancreatic β cell-
specific deleter strain, MIP-Cre-ER
TM
. By fusing a 8.5kb fragment of mouse Ins1 promoter 
(MIP) with Cre-ER
TM
, the tamoxifen induced Cre expression occurred exclusively in 
pancreatic β cells. Moreover, high doses of tamoxifen administration did not cause Cre 
expression in the brain, which makes MIT-Cre-ER
TM
 mediated recombination an ideal system 
to study “loss of functions” of a gene in adult pancreatic β cells (352). 
1.4.4. PPG-driven gene over-expression or deletion in mice 
The promoter that can be used to drive gene expression in pancreatic α cells is limited. The 
preproglucagon (PPG) promoter is so far the only promoter used to study gene functions in 
pancreatic α cells. The PPG-Cre transgenic mice were first generated almost 10 years ago by 
expressing a construct in which, the rat PPG promoter (2.1kb) is fused with the Cre 
recombinase (347). By crossing PPG-Cre mice with mice in which a STOP codon is floxed 
in front of a gene fragment encoding human growth hormone (hGH), Hererra and colleagues 
(347) demonstrated that expression of such hormone due to the removal of STOP codon by 
PPG-Cre-mediated LoxP recombination is mainly in the pancreatic α cells. However, 
because preproglucagon can be processed into GLP1 which is mainly expressed in the 
intestine (158;173;174), the PPG-Cre might also be expressed in these cells. Indeed, PPG-
Cre expression in intestine was reported (172). As mentioned earlier, GLP1 is a potent insulin 
and glucagon inducer (239). Therefore, it needs to be noted that deletion of genes in L cells 
of intestine achieved by using PPG-Cre mice might affect glucagon secretion by altering 
GLP1 secretion, and thus mask the bona fide effects of such gene deletion in pancreatic α cell 
per se.    
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1.5. Aims of this thesis  
The present studies were undertaken with two major aims:  
1. To understand the effects of LKB1 and AMPK on the islet β cell morphology, survival 
and glucose-stimulated insulin secretion, and to further examine how these changes 
might affect the whole body glucose homeostasis by generating the mice with these 
kinases individually and selectively ablated in the pancreatic β cells.  
2. To understand the effects of LKB1 and AMPK on the islet α cell morphology and 
glucose-regulated glucagon secretion, and to further determine whether these changes 
might affect whole body glucose metabolism by creating the mice with these kinases 
individually and selectively deleted in the pancreatic α cells.  
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Chapter 2  
General Materials and Methods 
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2.1. In vivo Animal Work 
2.1.1. Generation of genetically-modified (GM) mouse models 
2.1.1.1. Generation of mutant mice lacking Ampkα1 globally and selectively lacking Ampkα2 
in pancreatic β cells and RIP2-Cre neurons  
Ampkα1+/−, α2 fl/fl mice (Ampkα1 heterozygous mice expressing homozygouly flox‟d 
Ampkα2);  (kindly provided by Dr. Benoit Viollet, CNRS, Paris, France); (359;360) were first 
crossed with wild type C57BL/6 mice to generate double heterozygous Ampkα1+/−, α2fl/+ 
mice. Offspring were then crossed with heterozygous RIP2-Cre transgenic mice (Jackson 
Laboratory, Bar Harbor, ME, USA). The resulting triple heterozygous AMPKα1+/−, α2fl/+, 
Cre-expressing mice were interbred with their siblings. Since RIP2-Cre transgenic mice have 
been suggested to show glucose intolerance and impaired insulin secretion (350;354), Cre-
expressing mice were always used as controls. Due to the low probability (1:64) of obtaining 
double knockout mice through heterozygote crossing, two different breeding strategies were 
used to obtain double AMPK knockout mice and their littermate controls. First, to generate 
Ampkα1 knockout mice, bearing flox‟d Ampkα2 alleles (Ampkα1−/−, α2fl/fl) and expressing 
Cre recombinase (βAMPKdKO) and their heterozygous Ampkα1+/−, α2fl/+, Cre-expressing 
mice controls, Ampkα1−/−, α2fl/+, Cre negative and Ampkα1+/−, α2fl/fl, Cre-expressing mice 
were crossed. Second, to produce heterozygous Ampkα1+/−, α2fl/+, Cre-expressing mice and 
their wild type Ampkα1+/+, α2+/+, Cre-expressing littermate controls, Ampkα1+/−, α2fl/+, Cre-
expressing mice and wild type mice were crossed. All mice were kept on a C57BL/6 
background and offspring genotypes were obtained in the expected Mendelian ratios.  
2.1.1.2. Generation of mutant mice selectively over-expressing AMPK-CA or -DN in 
pancreatic β cells and RIP2-Cre neurons  
An expression vector containing the RIP2 promoter fragment (600 bp), c-myc-tagged rat 
Ampkα1312.T172D (AMPK-CA) or Ampkα2.D157A (AMPK-DN) cDNA, and an SV40 poly 
(A) cassette was excised with BssHII and microinjected into the male pronucleus of fertilised 
C57BL/6 oocytes. The injected zygotes were re-implanted into pseudo-pregnant female 
C57BL/6 mice (GenOway, Lyon Cedex, France). We obtained three βAMPK-CA (named 
C1, C2 and C10) and two βAMPK-DN (D1 and D2) founder mice that stably transferred the 
corresponding transgenes to their offspring. Founder mice were crossed with wild type 
C57BL/6 mice to achieve F1 generation. The distributions of genotypes in the offspring 
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followed a Mendelian pattern. All AMPK transgenic mice were kept heterozygous. F3 and 
later generations, and their littermate wild type controls, were used for experiments. All lines 
were maintained on a pure C57BL/6 background.  
2.1.1.3. Generation of mutant mice selectively lacking LKB1 in pancreatic β cells and RIP2-
Cre neurons 
Mice homozygous for flox‟d alleles of the Lkb1/Stk11 gene (Mouse Models of Human Cancer 
Consortium, http://mouse.ncifcrf.gov/) were first crossed with heterozygous RIP2-Cre-
expressing transgenic mice (Jackson Laboratory, Bar Harbor, ME, USA). The resulting 
double heterozygous Lkb1
fl/+
,Cre-expressing mice were intercrossed with Lkb1
fl/+
 mice to 
generate βLKB1KO (Lkb1fl/fl, Cre positive), βLKB1het (Lkb1fl/+, Cre positive), and 
βLKB1Wt (Lkb1+/+, Cre positive). βLKB1KO, βLKB1het, and βLKB1Wt mice were born at 
the expected Mendelian ratios and kept on a mixed FVB/129S6 and C57BL/6 background.  
2.1.1.4. Generation of mutant mice selectively lacking AMPK α1 and α2 in pancreatic α cells 
Mice homozygous for Ampkα1fl/fl (kindly provided by Dr. Benoit Viollet, CNRS, Paris, 
France) were crossed with mice heterozygous for Ampkα2fl/+. The resulting double 
heterozygous mice (Ampkα1fl/+, α2fl/+) were crossed with PPG-Cre-expressing mice (kindly 
provided by professor Pedro-Luis Herrera, University of Geneva, Geneva, Switzerland); 
(347) to generate triple heterozygous mice (Ampkα1fl/+, α2fl/+, Cre positive). These mice were 
then bred with mice homozygous for both flox‟d Ampkα1 and α2 (Ampkα1fl/fl, α2fl/fl) to 
produce αAMPKdKO mice (Ampkα1fl/fl, α2fl/fl, Cre positive). αAMPKdKO mice were further 
crossed with  Ampkα1fl/fl, α2fl/fl mice to generate littermate controls (Ampkα1fl/fl, α2fl/fl). All 
mice were kept on a C57/B6 background and both αAMPKdKO and their littermate controls 
were born at the expected Mendelian ratios. 
2.1.1.5. Generation of mutant mice selectively lacking LKB1 in pancreatic α cells 
Mice heterozygous for flox‟d allels of Lkb1/Stk11 gene (mixed FVB/129S6 and C57BL/6 
background) were backcrossed with C57/B6 mice for four times, before being crossed with 
PPG-Cre expressing mice (kindly provided by professor Pedro-Luis Herrera, University of 
Geneva, Geneva, Switzerland); (347). The resulting heterozygous mice were intercrossed 
with siblings to generate αLKB1KO mice (Lkb1fl/fl, Cre positive). The αLKB1KO mice were 
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further bred with Lkb1
fl/fl
 mice to generate littermate controls (Lkb1 
fl/fl). Both αLKB1KO 
mice and their littermate controls were born at the expected Mendelian ratios. 
2.1.2. Mice maintenance and diet 
Mice were housed two to five animals per cage in a pathogen-free facility with 12 h 
light/dark cycle and had free access to standard mouse chow diet or a high-fat diet (60% 
[kcal%] containing lard (Research Diet, New Brunswick, NJ, USA). As indicated, 6-week-
old mice were transferred to a high-fat diet for a maximum of 18 weeks. All in vivo 
procedures described here were performed at the Imperial College Central Biomedical 
Service and approved by the UK Home Office Animals Scientific Procedures Act, 1986.  
2.1.3. Body weight and food intake  
Fed mouse weight was monitored weekly after 6 weeks of age. To measure daily food intake, 
mice were individually housed in cages with 5-6 chow food pellets placed on top of the cage 
grids. Food weights were measured daily for three consecutive days and average daily food 
intake was calculated.  
2.1.4. Intraperitoneal glucose tolerance test (IPGTT) 
Mice fasted for 15 h (water allowed) were intraperitoneally injected with 1 g glucose/kg 
mouse weight. Blood (2-4 μl) from the tail vein was obtained at 0, 15, 30, 60, 90 and 
120 min. after injection (326;360;361). Blood glucose levels were measured with an 
automatic glucometer (Accuchek; Roche, Burgess Hill, UK). To study the effect of α-
adrenergic antagonist on glucose tolerance, mice were intraperitoneally injected with 
10 mg/kg mouse weight phentolamine 30 min. before glucose challenge (362).  
2.1.5. Insulin tolerance test (ITT) 
Bovine insulin (0.75 U/kg; Sigma, Dorset, UK) was intraperitoneally injected into fed mice 
between 13:00 and 14:00 hours. Blood glucose levels were measured at 0, 15, 30 and 60 min. 
after injection (363;364).  
2.1.6. AICAR tolerance test 
To induce hypoglycaemia without using insulin which is known to inhibit glucagon secretion 
from pancreatic α cells in vitro (186), we performed intraperitoneal AICAR tolerance test. 
Mice fasted for 15 h (water allowed) were intraperitoneally injected with 1.75 g AICAR/kg 
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mouse weight (Toronto Research Chemicals, North York, Canada). Blood (2-4 μl) from the 
tail vein was obtained at 0, 20, 40, 60, 90 and 120 min. after injection (362;365). Blood 
glucose levels were measured with an automatic glucometer (Accuchek; Roche, Burgess Hill, 
UK).  
2.1.7. Arginine tolerance test 
Arginine is a positively charged amino acid. Treating α cells with arginine depolarizes the 
plasma membrane and induces glucagon secretion. To examine whether the secretion 
machinery of pancreatic α cell is abnormal, mice fasted for 15 h (water allowed) were 
intraperitoneally injected with 3g/kg mouse weight of L-arginine (pH 7.4); (Arginine 
hydrochloride was obtained from Sigma); (172). Blood (50 μl) from the tail vein was 
collected at 0, 10 and 30 min. after injection into EDTA coated tubes containing 1 μl DPP IV 
inhibitor (final concentration: 100 μmol/l); (Millipore, Watford, UK). Blood glucose, insulin 
and glucagon levels were measured as described below.  
2.1.8. Plasma insulin and glucagon measurement  
For plasma insulin measurement after acute glucose injection, mice fasted for 15 h were 
intraperitoneally injected with 3 g glucose/kg mouse weight. 15-20 μl blood from mice tail 
veins was collected into a heparin coated tubes (Sarstedt, Beaumont Leys, UK) at 0, 15 and 
30 min. after injection. Plasma was separated by centrifuging the blood at 2,000 g for 5 min. 
For blood collected into EDTA coated tubes, plasma was separated by centrifuging the blood 
at 13,200 r.p.m. for 20 min. Blood plasma (5 μl) was used to measure plasma insulin levels 
with an ultrasensitive mouse insulin ELISA kit (Mercodia, Uppsala, Sweden); (91;366) 
according to the manufacturer‟s instructions.  
For plasma glucagon measurement, plasma was separated by centrifuging the blood at 4
o
C, 
13,200 r.p.m. for 20 min. Blood serum (10 μl) was used to measure plasma glucagon levels 
by radioimmunoassay with a competitive 
125
I labeled glucagon (Millipore, Watford, UK); 
(186;192).  
Normal fed plasma insulin and glucagon levels were measured in blood collected from mice 
tail veins between 10:00 and 11:00 hours. 
2.1.9. Urine collection and catecholamine measurement 
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Daily urine collection from single mouse for a period of three days was performed using 
metabolic cages (362). Catecholamine levels in urine were determined by reverse-phase 
HPLC (performed in collaboration with Dr. Oonagh Prendiville, Charing Cross hospital, 
London, UK).  
 
2.2. In vitro cell work 
2.2.1. Mammalian cell culture 
TC1-9 cells (a murine  clonal α cell line, passages number 35–45; American Type Culture 
Collection)
 were grown in Dulbecco‟s modified Eagle‟s medium (DMEM); (Invitrogen, 
Paisley, UK)
 
supplemented with 18 mmol/l NaHCO3, 16 mmol/l glucose, 0.1 mmol/l 
nonessential
 
amino acids, 10% [vol./vol.] heat-inactivated fetal bovine serum (FBS), 100 
U/ml penicillin,
 
and 100 U/ml streptomycin in a humidified atmosphere containing 5% CO2 
(186).  
2.2.2. Islet isolation and dissociation 
Mice were sacrificed by neck dislocation and collagenase NB8 from Clostridium histolyticum 
(SERVA Electrophoresis); (1 mg/ml in RPMI-1640) was injected into the pancreatic duct (5 
ml/mouse); (258;316;367). The distended pancreata were then incubated at 37°C for 10 min. 
Digested pancreata were washed 2-3 times with RPMI-1640 and were separated from 
exocrine tissues by centrifugation through a Histopaque gradient (Sigma Aldrich, Dorset, 
UK) at densities of 1.119, 1.083 and 1.077 g/ml at 2,500 r.p.m. for 20 min. After washing in 
RPMI-1640 once, single islets were handpicked and further incubated in RPMI-1640 medium 
supplemented with 100 U/ml penicillin and 100 U/ml streptomycin and 10% [vol./vol.] heat-
inactivated fetal bovine serum (FBS) for 24 h before further analysis. 
To obtain clusters or single cells, islets were dissociated immediately after isolation by 
incubation for 5 min. in Ca
2+
 free-cell dissociation buffer (Invitrogen, Paisley, UK). After 
brief centrifugation, this solution was replaced by islets culture medium, and the islets were 
disrupted by gentle pipetting. Clusters and single cells were then cultured for one day on 
circular glass coverslips pre-treated with 0.01% [wt./vol.] poly-Lysine (Sigma, Dorset, UK); 
(367). 
2.2.3. Treatment of islets or clonal cells for insulin or glucagon measurement 
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To measure insulin secretion from pancreatic mouse islets, six size-matched mouse islets 
were pre-incubated for 1 h at 37°C in Krebs-Ringer bicarbonate buffer (KRB) solution (in 
mmol/l: 130 NaCl, 3.6 KCl, 1.5 CaCl2, 0.5 MgSO4, 0.5 KH2PO4, 2 NaHCO3, 10 HEPES and 
0.1% [wt/vol.] BSA, pH 7.4) containing 3 mmol/l glucose, with gentle shaking (120 rev/min). 
Islets were further incubated for 30 min. at 37°C in 500 μl KRB solution in the presence of 3 
or 16.7 mmol/l glucose and supernatant fractions containing secreted insulin were collected. 
For total insulin extraction, islets were lysed in 500 μl acid-ethanol-Triton solution (1.5% 
[vol./vol.] HCl, 75% [vol./vol.] ethanol, 0.1% [vol./vol.] Triton X-100); (257;258).  
To measure glucagon secretion from mouse αTC1-9 cells or mouse islets, 80-90% confluent 
cells plated in 12 well plate or 12 size-matched islets were pre-incubated for 30 min. at 37°C 
in KRB solution containing 10 mmol/l glucose, with gentle shaking (120 rev/min). Pre-
incubation buffer was later replaced with 500 μl KRB solution containing 0.1, 3 or 17 mmol/l 
glucose for 1 h at 37°C (186;192). Supernatant franctions and total glucagon extracts were 
collected as per islets treated for insulin secretion.  
2.2.4. Insulin and glucagon radioimmuno-assay 
Radioimmunoassay kit (Millipore, Watford, UK) with competitive 
125
I-labelled insulin or 
glucagon was used to measure insulin or glucagon levels according to manufacturer‟s 
instructions (181;186;257;258;316).  
To measure secreted and total insulin levels, 100 μl of supernatants from islets treated with 
KRB solution at the glucose concentrations stated above or 100 μl of total islet lysates (1:500 
diluted in assay buffer (provided by the kit)) were incubated with insulin antibody and 
125
I 
labelled insulin at 4
o
C overnight. After 20 min. incubation with precipitation buffer at 4
o
C, 
125
I labelled insulin bound to the antibody was precipitated by centrifuging at 2,000 r.p.m. for 
20 min. and were measured using a gamma counter. The absolute insulin levels were 
calculated against the insulin standards (0.1 ng/ml-10 ng/ml) provided.  
To measure secreted and total glucagon levels, 50 μl of supernatants from islets or αTC cells 
(1:50 diluted in assay buffer)  treated with KRB solution containing glucose levels stated 
above or 50 μl of total islets or cell lysates (1:500 diluted in assay buffer) were incubated 
with glucagon antibody at 4
o
C overnight. After further incubation with 
125
I labelled glucagon 
at 4
o
C overnight, precipitation buffer was added. After 20 min. incubation, the 
125
I labelled 
glucagon bound to the antibody was precipitated by centrifuging at 2,000 r.p.m. for 20 min. 
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and was measured using a gamma counter. The absolute glucagon levels were calculated 
against the glucagon standards (20 pg/ml-400 pg/ml) provided. 
2.2.5. Cytosolic free Ca
2+
 measurement 
For Ca
2+
 imaging, 30-50% confluent αTC1-9 cells plated on glass coverslips pre-treated with 
0.01% [wt./vol.] poly L-lysine were incubated for 30 min. in KRB (125
 
mmol/l NaCl, 
3.5 mmol/l KCl, 1.5 mmol/l CaCl2, 0.5 mmol/l NaH2PO4,
 
0.5 mmol/l MgSO4, 3 mmol/l 
glucose, 10 mmol/l HEPES and 2 mmol/l
 
NaHCO3, pH 7.4) that was equilibrated with 
O2/CO2 (95:5) and supplemented
 
with 0.1% [wt./vol.] BSA, and containing 3 or 17 mmol/l 
glucose and 200 nmol/l FURA-RED AM (Invitrogen, Paisley, UK). Cells were excited at 
480/440 nm using an Olympus IX-81 microscope coupled to an F-view camera and captured 
using Cell^R software (Olympus, Southend-on-Sea, UK) on a 40× oil objective. Data were 
expressed as the ratio of the fluorescence emission at 440:480 nm (186).  
2.2.6. Electron microscopy  
The experiments were performed in collaboration with Prof. Piero Machetti (University of 
Pisa, Italy) and Dr. Raffa Carzaniga (Imperial College London, London, UK) Pancreatic 
islets (~30 islets) were fixed in 2.5% [wt./vol.] glutaraldehyde in 0.1 mol/l phosphate 
buffered saline, pH 7.3 (PBS) at 4°C. After being washed in PBS, islets were post-fixed in 
0.1% [wt./vol.] osmium tetroxide in PBS and dehydrated in a graded series of ethanol. The 
islets were rapidly transferred to propylene oxide and embedded in PolyBed 812 
(Polysciences Inc.).  
Ultrathin sections were cut with a diamond knife, stained with uranyl acetate and lead citrate 
and observed under a Zeiss 902 transmission electron microscope. β cells were identified 
under EM by their distinct morphology including dense core granules (368). β cells were 
considered dead based on the following criteria: loss of plasma membrane integrity, 
fragmentation into discrete bodies, engulfment of cell corpse or its fragments by an adjacent 
cell (369). The presence of marked chromatin condensation and/or that of blebs were 
considered signs of apoptosis, whereas massive vacuoles accumulation and absence of 
chromatin condensation were considered signs of autophagy (370).  
For morphometric studies, volume density values were derived from the evaluation of 3-5 
different islets for each pancreas. Twelve microphotographs were taken of each islet, at a 
magnification of x10000. A graticule (11x11 cm) composed of 169 points was placed on the 
 69 
micrographs and the number of points intersecting the autophagic vacuoles and mitochondria 
was counted. Volume density of intracellular organelles was calculated according to the 
formula: VD = Pi/Pt, where Pi is the number of points within the subcellular component and 
Pt is the total number of points within the cells, and expressed in ml/100ml of tissue (ml%) 
(371). 
To quantify docked insulin granules within a pancreatic β cell (25), EM images were taken at 
a magnification of x10000. A line was drawn at 0.3 μm beneath cell membrane by using 
TEM imaging and analysis software V3.1 (FEI company). The insulin granules per cell in the 
area between the line and the cell membrane were counted. The relative number of 
morphologically docked granules was calculated by dividing that of docked granules by that 
of total cytosolic granules. 
 
2.3. Protein studies 
2.3.1. Antibodies 
See Appendix 3 for antibodies used in this study. 
2.3.2. Immunoprecipitation 
To determine AMPK α1 and α2 activities in the hypothalamus, dissected tissues were placed 
in liquid nitrogen immediately after extraction and lyzed in 800 l ice-cold lysis buffer [mM: 
50 Tris-HCl (pH 7.4, 4°C), 250 sucrose, 50 NaF, 1 Na pyrophosphate, 1 EDTA, 1 EGTA, 1 
dithiothreitol (DTT), 0.1 benzamidine, and 0.1 phenylmethane sulfonyl fluoride (PMSF), 5 
µg/ml soybean trypsin inhibitor (SBTI), and 1% [vol./vol.] Triton X-100] (with 10% 
[wt./vol.] sucrose in lysis buffer for hypothalamus). Total extracts (100 μg proteins) were 
used for immunoprecipitating with 2.5 μg/sample anti-AMPK α1/α2 antibodies (Upstate, 
Dundee, UK) conjugated to protein G sepharose. After mixing samples with antibodies 
coated protein G sepharose for 2 h at 4
o
C, mixture was washed once with 3 ml of ice-cold IP-
NaCl buffer [mM: 50 Tris-HCl (pH 7.4, 4
o
C), 1 NaCl, 50 NaF, 5 Na pyrophosphate, 1 
EDTA, 1 EGTA, 1 DTT, 0.1 benzamidine and 0.1 PMSF, 5 μg/ml SBTI]. After being washed 
with 3ml of ice cold Hepes-Brij Buffer [mM: 50 Na-Hepes (pH 7.4) and 1 DTT, 0.02% 
[wt./vol.] Brij] once, samples with antibodies and protein G sepharose mixture was re-
suspended in 30 μl Hepes-Brij buffer for AMPK activity assay. 
 70 
2.3.3. Western (immuno-) blotting analysis 
Eighty to ninety percent confluent αTC1-9 cells plated in 6-well plates or 200-300 pancreatic 
mouse islets were lyzed into ice-cold lysis buffer (Tris-HCl pH 7.4 50 mmol/l, sucrose 250 
mmol/l, NaF 50 mmol/l, pyrophosphate sodium 1 mmol/l, EDTA 1 mmol/l, DTT 1 mmol/l, 
benzamidine 0.1 mmol/l, PMSF 0.1 mmol/l, soybean trypsine inhibitor 5 μg/ml, Triton X-100 
1% [vol./vol.]), vortex-mixed and centrifuged at 4°C, 13,000 r.p.m. for 5 min. Protein content 
was assayed using a BCA protein assay kit (Pierce, Rockford, IL, U.S.A.), against BSA Type 
V (Sigma, Dorset, UK) standards. Total protein extracts (50 to 80 μg) were subjected to 
SDS/PAGE on 7% to 12% polyacrylamide gels and transferred to PVDF membranes. After 
transferring, the filters were blocked with 5% non-fat dry milk in Tris-buffered-saline with 
0.1% [vol./vol.] Tween (TBS-T) for 1 h at room temperature, followed by incubation with 
primary antibodies overnight at 4°C (Appendix 3). The PVDF filters were then washed three 
times for 10 min. each time with TBS-T, followed by 1h incubation with secondary antibody 
conjugated to horseradish peroxidase (GE healthcare, Little Chalfont, UK). The PVDF filters 
were then washed as indicated above and subsequently exposed to an enhanced 
chemiluminiscence reagent (GE healthcare, Little Chalfont, UK). 
2.3.4. AMPK activity assay 
To determine total AMPK activity, 20 μg or 10 μg of total protein extract from αTC1-9 cells 
or pancreatic mouse islets lyzed in 100 µl ice-cold lysis buffer as for western blot, or 30 μl 
precipitated hypothalamic protein extracts were mixed with 30 Ci/mmol P
32
-γATP, 0.4 
mmol/l ATP and 1 mmol/l synthetic SAMS peptide (HMRSAMSGLHLVKRR) as substrate. 
Mixtures (10 μl) were added onto chromatography filter paper (P81 cation exchanger) at 5, 
10 and 15 min. after incubation at 37
o
C. After washing with 1% phosphoric acid for three 
times, the radio-activities remained on the filter paper were measured using a scintillation 
counter. The count per min (CPM) from 5, 10 and 15 min. after incubation were averaged 
(256;258;311).  
2.3.5. Whole pancreas and spinal cord immunohistochemistry and analysis of islet 
architecture, single cell size and cell proliferation 
Isolated pancreata or spinal cords were fixed in 10% [vol./vol.] formalin and embedded in 
paraffin wax within 24 hours of removal.  Head-to-tail sections (5 μm lengthwise) or 7 μm 
spine sections were cut and incubated at 37C overnight on superfrost slides. Slides were 
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submerged sequentially in 100% [vol./vol.] xylene followed by decreasing concentrations of 
industrial methylated spirits for removal of paraffin wax. Antigen epitopes were then 
retrieved (de-crosslinked) in Tris-EDTA-0.05% [vol./vol.] Tween buffer (pH 9.0) or 10 
mmol/l sodium citrate (pH 6.0). Slides were subsequently blocked in 5% [vol./vol.] goat 
serum (Dako, ely, UK) in Tris buffered saline with 0.05% [vol./vol.] Tween (TBS-T) for 20 
min. at room temperature then incubated in a mixture of primary antibodies at the 
concentrations indicated at 4 C overnight (Appendix 3). After washing in TBS-T for three 
times of 5 min. each time, slices incubated with primary antibodies were either visualized 
with Alexa Fluor 568 or 488 conjugated IgG (1:500, Invitrogen, Paisley, UK) under 
fluorescent microscopy using a Zeiss Axiovert-200 confocal microscope with an 
Improvision/Nokigawa spinning disc and running Volocity
TM
 5.0 (Improvision, Coventry, 
UK) software or further incubated with biotinylated secondary antibodies (universal anti-
mouse/anti-rabbit antibody) and subsequently revealed with peroxidase substrate using 
diaminobenzidine (DAB); (Vector Laboratories, Peterborough, UK). 
For haematoxylin & eosin (H&E) staining, rehydrated slices were submerged in 
haematoxylin for 5 min. After washing in water, slices were dipped in 1% [vol./vol.] 
hydrogen chloride in 70% methanol [vol./vol.] five times, followed by staining with 1% eosin 
[wt./vol.] for 30 s.  
For luxol fast blue (LFB) staining, de-waxed sections were immersed in 0.1% luxol fast blue 
solution [wt./wol.] (Sigma Aldrich, Dorset, UK) at 60
o
C overnight. After washing 
subsequently in 95% methanol and distilled water, slices were brought in 0.05% lithium 
carbonate [wt./vol.] and 70% methanol. After washing in distilled water, slices were stained 
in 0.01% cresyl fast violet solution (Merck, Hoddesden, UK) at 60
o
C for 10 min. 
For periodic acid Schiff (PAS) staining, de-waxed sections were oxidized in 1% periodic acid 
[vol./vol.] for 5 min. After washing in distilled water, slices were immersed in Schiff buffer 
(VWR, Lutterworth, UK) for 10 min. Slices were subsequently counter-stained for nuclei 
with haematoxylin for 1 min.  
To quantify the number of “rosette-like” structures (e.g. 8-10 cells arranged concentrically 
around an identifiable central “hub”; see Figure 4.8a, b) in islets, we used E-cadherin and 
dapi staining of pancreatic sections. Structures were included where the void at the centre 
was negative for dapi. Ten islets from three pairs of mice per genotype were assessed. 
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To calculate single α and β cell size, the area of one hundred single α and β cells from five to 
ten islets of each genotype from E-cadherin and insulin or E-cadherin and glucagon co-
stained pancreatic sections were measured using Image J (http://rsbweb.nih.gov/ij/). To 
measure relative number of proliferating β cells, the number of Ki67-positive β cells per islet 
was divided by total β cell number. Fifteen to 20 islets per genotype were analyzed. 
For quantitative analysis of α and β cell mass (performed in collaboration with AstraZeneca), 
sections stained with insulin and glucagon antibody were imaged using a fluorescence image 
analysis system (Typhoon; GE Healthcare, Chalfont, UK) and ImagXpress Micro (Molecular 
Devices, Uckfield, UK). Wavelengths scanned for Typhoon were: BlueFAM 488 nm (For 
Dapi); Green AlexaFluro546 532 nm (For insulin); Red 633 nm (For glucagon). Whole 
pancreas mass were scanned by its autofluorescence. Image analysis software (Definiens, 
Munich, Germany) quantified all fluorescent images.  Typhoon (25 m per pixel) was used to 
estimate the cross-sectional area of α or β cells. Three to four slices per pancreas were 
analysed. Relative α and β cell mass were calculated by dividing the respective area by total 
pancreas mass. 
2.3.6. Isolated islets immunocytochemistry 
Dissociated islet cells were fixed in 3.7% formalin for 15 min. After permeabilized in 0.1% 
Triton in phosphate buffered saline (PBS) for 5 min. cells were subsequently blocked in 5% 
[vol./vol.] goat serum (Dako, ely, UK), 2% BSA in PBS for 20 min. at room temperature and 
then incubated in a mixture of primary antibodies at the concentrations indicated (Appendix 
3) at 4 C overnight. After washing in PBS for 5 min. three times, cells were either visualized 
with Alexa Fluor 568 or 488 conjugated IgG (1:500, Invitrogen, Paisley, UK) under 
fluorescent microscopy using a Zeiss Axiovert-200 confocal microscope with an 
Improvision/Nokigawa spinning disc and running Volocity
TM
 5.0 (Improvision, Coventry, 
UK) software. 
2.3.7. Optical Projection Tomography (OPT) and determination of relative β cell mass  
Whole pancreatic optical projection tomography, to 19 µm resolution, was performed as 
described (11). Briefly, whole pancreata fixed in 4% [wt./vol.] paraformaldehyde for 2-3 h at 
4 
o
C were dehydrated and subjected to five cycles of freezing and thawing (-80
o
C to room 
temperature). Pancreata were then blocked overnight in TBS (pH 7.5), containing 0.05% 
[vol./vol.] Tween, 0.01% [wt./vol.] sodium azide and 10% [vol./vol.] goat serum (Dako, Ely, 
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UK), before incubation with guinea pig anti-swine insulin antibody (Dako, 1:1000) dissolved 
in the above buffer further supplemented with 5% [vol./vol.] dimethylsulfoxide (DMSO) 
overnight at 4
o
C. To visualize insulin positive staining, Alexa 594 goat anti-guinea pig 
antibody (Invitrogen, 1:1000) was applied. The samples were then embedded in 1% [wt./vol.] 
low melting temperature agarose, dehydrated in methanol, and cleared in benzyl 
alcohol:benzyl benzoate [1:2] for optical tomographical scanning.  
All specimens were scanned using two fluorescent channels (excitation: 580 ± 15 nm and 
emission: 650 ±15 nm for insulin positive staining; excitation: 480 ± 9 nm and emission: 
650 ± 25 nm for autofluorescence); (performed in collaboration with Dr. James McGinty, 
Imperial College London, UK). The raw data for these two channels were reconstructed in a 
pair of 3D voxel data sets (voxel to μm = 1:19) using Matlab software and cell volumes (μm3) 
from each channel were measured using Volocity
TM
 5.0 (Improvision). Data from Volocity
TM
 
5.0 were further analyzed in Microsoft Excel to provide size frequency histograms and total 
volume graphs. Relative β cell mass was calculated by dividing the volume of insulin positive 
area (“total beta cell mass”) by that of the autofluorescence area (“total pancreatic mass”).  
 
2.4. Molecular biology 
2.4.1. DNA extraction and polymerase chain reaction (PCR) for genotyping studies 
Genomic DNA from mouse tail tips (<0.5 cm) or ear clips were obtained by lyzing samples 
in 75 μl alkaline lysis reagent (25 mmol/l NaOH, 0.2 mmol/l EDTA (pH 8.0)) at 98oC for 1 h. 
The reaction was neutralized with equal volume of 40 mmol/l Tris-HCl. The resulting DNA 
was then diluted in nuclease free water (1:1 [vol./vol.]), and 1 μl DNA was used for PCR. 
The PCR reaction was performed in 20 µl reaction mixture containing: 5x Phire
TM
 reaction 
buffer, 0.2 mmol/l dNTP, 0.5 µmol/l forward and reverse primers (see appendix 1 for list of 
primers used for genotyping), 0.4 μlPhireTM hot start DNA polymerase and 1 μl DNA (New 
England Biolab, Hitchin, UK). The reaction consists of a 30s 98
o
C pre-heating step, followed 
by 30 cycles of amplification step: 98
o
C for 5 s, 68-72
o
C for 5 s (see Appendix 1 for Tm of 
primers) and 72
o
C for 20 s. At the end of the last cycle, a prolonged extension step was 
carried out at 72
o
C for 1 min. 
2.4.2. Southern blot 
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Genomic DNA (10 µg) digested by SpeI overnight was loaded onto 0.8% agarose gel. The 
gel was then depurinated in 0.125 mol/l HCl for 10 min. and denatured in denaturation buffer 
(87.66 g/l NaCl and 20 g/l NaOH) for 30 min. The DNA was then transferred onto Hybond-
XL membrane (GE healthcare, Little Chalfont, UK). After fixing DNA to membrane at 80
o
C 
for 2 h, it was later hybridized with RIP2 specific probe generated by using Prime-It II 
Random Primer Labeling kit (Agilent Technologies, Stockport, UK) containing 43 ng RIP2 
fragment obtained by digesting AMPK-CA-expressing pBluescript II vector with NotI and 
EcoRI, 10 µl random primers, 10 µl dATP buffer, 1200 µCi/ml P
32
-[α]dATP and 0.1 U Exo-
Klenow fragment at 65
o
C overnight. After washing sequentially in 2x, 1x, and 0.1x nucleic 
acid transfer (SSC) (1xSSC buffer: 4.41 g/l Tri-sodium citrate and 8.77 g/l NaCl) buffer with 
0.1% [wt./vol.] SDS, intensity of hybridization signals was visualized by exposing the 
membrane to X-ray film (hyperfilm MP); (healthcare, Little Chalfont, UK). 
2.4.3. RNA extraction and reverse transcription (RT) PCR 
Total cellular RNA from mouse islets or other tissues was obtained using TRIzol reagent 
(Invitrogen, Paisley, UK), and RNA was further purified from DNA contamination with a 
DNA-free kit (Ambion, Applied biosystems, Warrington, UK). Total RNA (1.5-2 μg) was 
then reverse transcribed into cDNA with a high-capacity reverse transcription kit (Applied 
Biosystems) according to the manufacturer's instructions. The PCR reaction was performed 
in 25 µl of reaction mixture containing: 5x reaction buffer, 0.2 mmol/l dNTP, 0.3 µmol/l 
forward and reverse primers (see Appendix 1 for list of primers used), 0.2 U Taq polymerase 
(Promega, UK) and 100 ng DNA. The PCR reaction was preheated at 95°C for 2 min, and 
amplification was performed for 30 cycles under the following conditions: 94°C for 30 s, 53-
59°C for 30 s (see Appendix 1 for Tm used), and 72°C for 1 min. At the end of the last cycle, 
a prolonged extension step was carried out at 72°C for 10 min.  
2.4.4. Quantitative Real-Time PCR (qRT-PCR) 
The expression levels of genes (see Appendix 2 for list of genes and primers) were 
quantitated by real-time PCR using the SYBR green method. In 20 μl final volume, the 
reaction contained: 10 μl SYBR green master mix (Applied biosystems, Warrington, UK), 
0.3 µmol/l primers, and 20 ng cDNA. The PCR reaction was preheated at 60
o
C for 2 min and 
95
o
C for 10 min. PCR amplification was performed for 40 cycles of 95
o
C for 15s and 60
o
C 
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for 1 min. At the end of last cycle, a dissociation step consisting of 95
o
C for 15 s, 60
o
C for 1 
min and 95
o
C for 15 s was performed.  
The PCR cycle numbers required to genereate fluorescent signals for each gene were plotted 
in the equipment software (Fast 7500 v2.0.4, Applied biosystems) and showed a shape of 
sigmoidal curve (amplification curve). A horizontal line which intersected the exponential 
part of the amplification curve above the background was drawn and the corresponding cycle 
number (Ct) was selected. The relative gene expression against a house keeping gene, 
Cyclophilin was calculated by using the equation below (181;372):  
Relative gene expression = 2 
Ct (cyclophilin)-Ct (gene) 
2.4.5. Molecular cloning 
2.4.5.1. Restriction digestion, PCR purification, dephosphorylation and gel purification of 
vector 
Restriction digestion was performed by incubating 10 U of restriction enzyme with 1 μg of 
plasmid DNA at 37°C for 1-4 h. Digested vector was purified using Qiaquick PCR 
purification kit according to manufacturer‟s instructions (Qiagen, UK). The 
dephosphorylation of vector was performed in 50 μl mixture containing 40 μl purified vector, 
5 μl Shrimp alkaline phosphatise (SAP) and 5 μl multi-core buffer (New England biolab, 
Hitchin, UK). The dephosphorylation reaction was incubated at 37
o
C for 15 min. followed by 
74
o
C for 15 min. The dephosphorylated vector was further loaded onto agarose gel and 
purified using Qiaquick gel purification kit (Qiagen, UK).   
2.4.5.2. Ligation 
The ligation reaction was optimised using various ratios for each individual ligation and was 
based on the following equation: 
Insert (g) =
vector (ng) x size insert (kb)
Size vector (kb)
 
The DNA concentration of the linearised vector and the insert were estimated by agarose gel 
electrophoresis and comparison with DNA weight markers of known concentration. The 
ligation reaction mixture containing T4 DNA ligase (Promega, UK), and proportioned vector 
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and insert with appropriate vector:insert ratio was incubated overnight at 16C and 
terminated by incubation at 70C for 10 min. 
2.4.5.3. Transformation of E.coli 
The ligation reaction mix (10 μl ) was added to 200 ul of top 10 E.Coli chemically competent 
cells. This was then subject to a heat-shock at 42C for 30 s. Cells were allowed to recover 
for 2 min. on ice before incubation with 800 μl LB broth for 1 h at 37 C, with continuous 
shaking (200 r.p.m). Cells in LB broth (100 μl) were plated on a pre-warmed LB/agar plate 
containing the appropriate antibiotic and were incubated at 37
o
C overnight. Single colonies 
were amplified by mini preps and analyzed by DNA sequencing. 
2.4.5.4. Small (MINI prep) and medium scale plasmid preparation (MIDI prep) 
Small scale plasmid preparation was performed in order to screen bacterial positive 
transformant, and prepare DNA for sequencing using the GenElute Plasmid Miniprep Kit 
(Sigma-Aldrich, Dorset, UK). 
The large scale plasmid preparation was performed following the alkaline lysis protocol using 
the QIAGEN QIAfilter
TM
 Plasmid Midi Kit according to the manufacturer‟s instructions 
(Qiagen, UK). 
Restriction digests were performed to confirm that recombinant vectors had been generated. 
After MINI or MIDI prep, two enzymes were chosen such that they would produce fragments 
of appropriate size, which would indicate whether or not the DNA fragment had inserted into 
the vector correctly. In each reaction 5 μl of the miniprep DNA was used and incubated with 
2 U of restriction enzyme for 1 h at 37 C and subsequently analyzed by migrating the 
digested plasmid on an agarose gel (0.5-2%). 
2.4.5.5. DNA sequencing 
Plasmid DNA concentration was measured with a spectrophotometer (NanoDrop®, ND-100, 
LABTECH, UK), at 260 nm and 280 nm. Absorbance at 260 nm allowed the calculation of 
the concentration of DNA (considering that an Abs260 of 1.0 corresponds to approximately 
50 μg/ml of double strand DNA) and RNA (considering that an Abs260 of 1.0 corresponds to 
approximately 40 μg/ml). The ratio between absorbances at 260 nm and 280 nm provides an 
estimate of the purity of nucleic acid and DNA or RNA with ratio between 1.8 and 2.0 were 
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used. DNA constructs were sequenced in order to confirm both the accuracy of the construct 
and the open reading frame (Eurofins, Germany). 
2.4.6. Generation of adenovirus 
2.4.6.1. Production of adenovirus in HEK 293 cells 
GFP-expressing padtrack plasmid containing targeting cDNA (4 μg) was digested with PacI 
at 37
o
C for 1h and was transfected into HEK 293 cells in a T25 flask with 50-70% 
confluency using Lipofecatmine 2000 according to the manufacturer‟s instructions. After 
approximately 5-7 days, when GFP-expressing plaques appeared, cells were scraped off the 
flasks. After centrifugation at 2,000 r.p.m. for 3 min., cell pellets were resuspended in 2 ml 
PBS. After freezing in dry ice/methanol bath and thawing in 37
o
C water bath for four times, 
cells were sedimentated by centrifugation and supernatants were collected to infect another 
two 50-70% confluent HEK 293 cells in T25 flask. Cells were lyzed by four times 
freeze/thaw cycles as above and the supernatants were collected. 
2.4.6.2. Preparation of high titre virus 
Sixty percent confluent HEK 293 cells in a T75 flask were infected with virus at a 
multiplicity of infection (MOI) of 5-10 plaque-forming units (PFU) per cell. After 3-4 days, 
when 90% cells were expressing GFP and half of the cells were detached from the flask. The 
remaining cells were scraped off the flasks and collected in one 50 ml tube. Cells were 
centrifuged at 2,000 r.p.m. for 2 min. and cell pellets were re-suspended in 2 ml PBS. After 
freezing in a dry ice/methanol bath and thawing in 37
o
C water bath five times, cell lysates 
were used to re-infect 60% confluent HEK 293 cells in 20 T75 flasks. After 3-5 days, cells 
from 20 flasks were collected and one pellet was generated by centrifuging cell suspension at 
2,000 r.p.m. for 3 min. After the pellet had been re-dissolved in 5 ml PBS, another 3 rounds 
of freeze-thaw cycles were applied. The pellet suspension was mixed thoroughly with CsCl-
0.1M Tris-HCl (pH8.0) solution at a ratio of 5:3 and centrifuged at 60,000 r.p.m. 4
o
C 
overnight. Virus collected from the middle layer of the ultra-centrifuge tube was further 
washed four times in dialysis buffer (10% [vol./vol.] glycerol, 10 mmol/l Tris, 10 mmol/l 
MgCl2·6H2O and 150 mmol/l NaCl) and re-suspended in the same volume of storage buffer 
(70% [vol./vol.] glycerol, 0.133% [wt./vol.] BSA, 0.013 mmol/l NaCl and 1.3 mol/l MgCl2). 
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2.5. Statistical analysis 
Data are expressed as means ± SEM. Significance was tested by two tails unpaired or paired 
Student‟s t test using Excel, or by ANOVA using Graphpad 4.0. A value of p<0.05 was 
considered significant.  
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Chapter 3  
Ablation of AMPK α1 and α2 catalytic subunits from mouse 
pancreatic β cells and RIP2-Cre neurons suppresses insulin release in 
vivo 
Abstract  
Aims and Hypthosis: AMP-activated protein kinase (AMPK) is an evolutionarily-conserved 
enzyme and a target of glucose-lowering agents, including metformin. However, the precise 
role or roles of the enzyme in controlling insulin secretion remain uncertain.  
Methods: The catalytic α1 and α2 subunits of AMPK were ablated selectively in mouse 
pancreatic β cells and hypothalamic neurons (βAMPKdKO mice) by breeding Ampkα1 [also 
known as Prkaa1]-knockout mice, bearing flox‟d Ampkα2 [also known as Prkaa2] alleles 
(Ampkα1−/−, α2fl/fl), with mice expressing Cre recombinase under the rat Ins2 promoter 2 
(RIP2). RIP2 was also used to express constitutively-activated (CA) or dominant-negative 
(DN) forms of AMPK selectively in β cells in transgenic mice. Food intake, body weight and 
urinary catecholamines were measured using metabolic cages. Glucose and insulin tolerance 
were determined after intraperitoneal injection. β cell mass and morphology were analysed by 
optical projection tomography (OPT) and confocal immunofluorescence microscopy, 
respectively. Docked insulin granules were measured by transmission electron microscopy 
(EM)  and insulin secretion from isolated islets was examined by insulin radio-immuno assay 
(RIA).  
Results: Both male and female βAMPKdKO mice displayed elevated blood glucose and 
decreased plasma insulin levels. Intraperitoneal glucose injection of these mice revealed 
impaired glucose tolerance and dimished glucose stimulated insulin release in vivo, but 
normal body weight and food intake. However, Insulin tolerance tests revealed increased 
insulin sensitivity. Islets isolated from βAMPKdKO mice displayed increased glucose-
stimulated insulin secretion and docked granules suggesting a role for AMPK in regulating 
insulin granule mobility. Total β cell mass was unaltered, whilst mean islet and β cell volume 
were reduced in βAMPKdKO mice. Conversely, βAMPKCA transgenic mice were glucose-
intolerant and displayed defective glucose-stimulated insulin secretion in islets.  
Conclusion: Regulation of AMPK activity is important within the β cell to control glucose-
stimulated insulin secretion in vitro. However, the divergance of the in vivo and in vitro 
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results suggests that extrapancreatic AMPK in RIP2-expressing cells might also influence 
insulin secretion in vivo.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Part of this work has been published in: Sun G, Tarasov AI, McGinty J, McDonald A, da Silva Xavier 
G, Gorman T, Marley A, French PM, Parker H, Gribble F, Reimann F, Prendiville O, Carzaniga R, 
Viollet B, Leclerc I, Rutter GA. Diabetologia. 2010 May;53(5):924-36. 
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3.1. Introduction 
AMP-activated protein kinase (AMPK) is an evolutionarily conserved fuel-sensitive protein 
kinase implicated in the control of glucose homeostasis and peripheral insulin sensitvity 
(254;373;374). A role for AMPK has also been proposed in the control of insulin synthesis 
and secretion in the pancreatic β cell (253;256;257;311); (see Chapter 1). While the 
stimulation of AMPK activity in muscle and liver is now seen as a likely mechanism through 
which glucose-lowering agents, including metformin and thiazolidinediones, act to improve 
insulin sensitivity (375), the long-term effects of these agents on pancreatic β cell survival 
and insulin release are less clear (376).  
Mammalian AMPK is a trimeric protein comprising a catalytic α-subunit, encoded by one of 
two separate genes (Ampkα1 [also known as Prkaa1] and Ampkα2 [also known as Prkaa2]), a 
scaffold β- (β1 or β2) subunit and a regulatory γ-subunit (γ1, γ2 or γ3) (262;377); (see 
Chapter 1). The existence of two separate AMPKα subunit genes has so far hindered 
investigations of the role AMPK activity plays in controlling glucose homeostasis in vivo in 
mammals, since the unconditional deletion of both isoforms leads to early embryonic 
lethality in mice (260). By contrast, animals with global inactivation of the AMPKα1 isoform 
do not display significant metabolic abnormalities (260;360). Deletion of the Ampkα2 gene 
leads to insulin resistance and glucose intolerance, in part due to increased parasympathetic 
tone (362). Whereas insulin secretion was normal in islets isolated from whole body Ampkα2 
knockout mice, insulin release in vivo appeared to be diminished when measured at a single 
time point during oral glucose tolerance tests. However, no measurements were made during 
intraperitoneal glucose tolerance tests, where the complicating effects of potentially altered 
incretin release could be excluded. Importantly, since complexes containing the AMPKα1 
isoform are substantially (> ten fold) more abundant in β cell lines than AMPKα2 complexes 
(256), increases in the expression of the former may also, in part, have compensated for the 
loss of AMPKα2.  
The Rutter lab has previously demonstrated distinct roles in the pancreatic β cell for AMPK 
complexes containing differing catalytic subunits (256). Thus, the α2 subunit, which 
displayed substantial nuclear localisation (256;276), was implicated in the control of insulin 
gene expression, whereas α1-containing complexes, whose total activity exceeded that of α2-
containing complexes by five to ten fold (256), were almost exclusively cytosolic (276). The 
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role of the latter remains unclear, but may include regulation of plasma membrane ion 
channels, as proposed in oxygen-sensing cells in the carotid body (378).  
To assess the role of AMPK in insulin-expressing cells, we generated trigenic mice that were 
globally inactivated for Ampkα1 and had Ampkα2 deleted selectively in pancreatic β cells and 
in a small population of neurons, using the rat Ins2 promoter (RIP2); (345;352) and 
transgenic mice expressing activated AMPK selectively in β cells. Using these models we 
highlight multiple novel mechanisms through which AMPK controls insulin production and 
glucose homeostasis in mammals.  
 
3.2. Results 
3.2.1. βAMPKdKO mice have normal body weight but are hyperglycaemic 
Messenger RNAs encoding Ampkα1 and -α2 subunits were present in highly purified wild 
type mouse β cells (Figure 3.1). Ampkα1 mRNA was ∼15-fold more abundant than that 
encoding the -α2 subunit, in line with previous AMPK activity measurements in clonal β 
cells (256) and with the distinct roles of each isoform in these cells (256). Since mice deleted 
globally for either subunit display essentially normal insulin release in vitro (362;379), we 
generated trigenic mice inactivated for AMPKα1 and α2 subunits selectively in β cells and in 
a small population of hypothalamic neurons. Mice globally inactivated for Ampkα1 (360) 
were first crossed with animals bearing flox‟d Ampkα2 gene alleles (Figure 3.2a). Crossing 
with RIP2-Cre mice (353) led to a selective loss of the catalytic domain of the Ampkα2 
subunit (aa189-260) from islets and hypothalamus (Figure 3.2a, b). Consistent with the 
abundant expression in islets of the Cre transgene (Figure 3.2c) and selective deletion of the 
two catalytic subunits from β cells (13), the crossing of Ampkα2 flox‟d and RIP2-Cre mice 
resulted in a decrease in islet Ampkα2 mRNA of 60 to 70% (Figure 3.2d). Assessed at low 
glucose concentrations (to near-maximally stimulate the enzyme); (258), the apparent total 
islet AMPK activity was decreased by 93% in Ampkα1 −/− vs Ampkα1 +/− (α2fl/fl in each case) 
mice and by 95% in βAMPKdKO vs Ampkα1 +/− mice (Figure 3.2e). Male βAMPKdKO mice 
displayed entirely normal growth and normal food intake (Figure 3.2f, g), while females had 
a small reduction in body weight up to 10 weeks of age (Figure 3.4a). Assessed at 3 (Figure 
3.3a, c) and 6 months (Figure 3.3b) of age, βAMPKdKO mice of either sex, but not mice 
deleted for either Ampkα1 (360) or -α2 (Figure 3.5) alone, displayed markedly elevated 
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plasma glucose and decreased plasma insulin levels (Figure 3.3a-d, Figure 3.4b). 
Correspondingly, double knockout mice displayed abnormal glucose tolerance and insulin 
release in vivo, despite increased insulin sensitivity (Figure 3.3e-g, Figure 3.4c-e). No 
differences in glucose tolerance and insulin release or sensitivity were observed between 
Ampkα1+/+, α2+/+, Cre positive mice and Ampkα1+/−, α2fl/+, Cre positive (heterozygous) mice 
(Figure 3.6), so heterozygous mice were used as littermate controls during the study. 
Since mice with global homozygous deletion of Ampkα2 display abnormal insulin secretion 
in vivo and elevated catecholamine levels (362), we determined whether the latter variable 
may contribute to abnormal insulin secretion in βAMPKdKO mice. We detected no 
alterations in the levels of urinary catecholamines (the catecholamine measurement was 
performed in collaboration with Dr. Prendiville O. in Charing Cross hospital, Figure 3.7a), 
indicating that the above was not the case. Moreover, abnormal glucose tolerance was still 
observed, albeit diminished in extent, in the presence of the α-adrenoreceptor blocker, 
phentolamine (Figure 3.7b); (380). 
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Figure 3.1 Ampkα and Lkb1 gene expression in purified mouse pancreatic β and α cells. 
Real time qPCR analysis of mRNA levels of AMPK both α1 and α2, and LKB1 in purified FACS-
sorted mouse pancreatic β and α cells (performed in collaboration with Dr. Fiona Gribble, University 
of Cambridge). The sequences used to amplify Ampkα1 (white bars) and Ampkα2 (black bars) were as 
follows: -α1 forward: TGATGCCGAAGCTCAAGGA; -α1 reverse:GGGAGGTGACAGAGGTAAG 
G; -α2 forward: AACATGGGCGGGTTGAAGA; -α2 reverse: ATCCACGGCAGACAGGATCT. 
Data are presented as percentage of Cyclophilin and are expressed as means ± SEM; n=3 mice; 
*p<0.05. 
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Figure 3.2 Generation of βAMPKdKO mice.  
(a) RT-PCR analysis of the deletion of Ampkα1 and -α2 isoforms in islets from mice with the 
indicated genotypes (n=3-4) and (b) of Ampkα2 gene expression in hypothalamus (H), brain cortex 
(B), liver (L), spleen (S), kidney (K), muscle (M) and islet (I). cDNA generated by reverse 
transcription of extracted mRNA was analysed using primers targeting aa97-157 of AMPKα1 and 
aa189–260 of AMPKα2. For AMPKα1, pair of primers (Ampkα1a fwd and rev) was used and the 
product sizes were 588 and 408 bp for wild type (Wt); (Ampkα1+/+) and knockout alleles (Ampkα1-/-) 
respectively. For AMPKα2, pair of primers (Ampkα2 fwd and rev) was used and the corresponding 
values were 588 and 375 bp. (c) Cre mRNA levels in isolated islets and hypothalamic extracts and (d) 
analysis of deletion of Ampkα1 and Ampkα2 in pancreatic islets. Islets were incubated with RPMI 
media containing 10 mmol/l glucose for 24 h before RNA extraction. mRNA levels were quantified 
by qRT-PCR. The indicated genotypes refer to the AMPKα isoforms only. White bars, Wild type; 
grey bars, heterozygous; black bars, βAMPKdKO. Hypo, hypothalamus. (e) Total AMPK activities in 
pancreatic islets from control (Ctrl; Ampkα1+/−, α2 fl/fl), AMPKα1 whole-body knockout (α1 KO; 
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Ampkα1−/−, α2 fl/fl), βAMPKα2KO (α2 KO; Ampkα1+/−, α2 fl/fl,Cre positive) or βAMPKdKO (dKO; 
Ampkα1−/−, α2 fl/fl, Cre positive) mice. Islets incubated with RPMI media containing 10 mmol/l 
glucose for 48-72 h, were further incubated with RPMI media containing 3 mmol/l glucose for 1 h 
before analysis. (f) Body weight changes in βAMPKdKO (triangles) or heterozygous control (circles; 
Ampkα1+/−, α2 fl/+, Cre positive) mice. (g) Food intake in fed mice at age of 12 weeks old (see 
Methods). Het, heterozygous. Data are expressed as means ± SEM; n=3-5 (c, e) or n=7-9 (f, g); 
*p<0.05, **p<0.01, ***p<0.001.  
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Figure 3.3 Glucose homeostasis in βAMPKdKO male mice.  
Blood glucose (a, b) and plasma insulin (c, d) levels in 3- (a) or 3- and 6-month-old mice (b), or in 3-
month old mice (c, d). For b, d, mice were fasted for 15 h. White bars, heterozygous (Het); black 
bars, βAMPKdKO. (e) Glucose tolerance and (f) plasma insulin response, after intraperitoneal (IP) 
glucose injection, and (g) whole-body insulin sensitivity after IP insulin injection. Triangles, 
βAMPKdKO; circles, Het. Data are expressed as means ± SEM; n=7-9; *p<0.05, **p<0.01, 
***p<0.001.  
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Figure 3.4 βAMPKdKO female mice develop abnormal glucose tolerance and insulin secretory 
responses.  
(a) Growth curves of body weights in βAMPKdKO female mice. Circles, heterogygous; triangles, 
βAMPKdKO. (b) Blood glucose levels in 3-month-old female mice with free access to chow or fasted 
for 15 h. White bars, heterogygous; black bars, βAMPKdKO (c) Glucose tolerance and (d) plasma 
insulin response after intraperitoneal (IP) glucose injection, and (e) whole-body insulin sensitivity 
after IP insulin injection of βAMPKdKO vs heterozygous female mice. Circles, heterogygous; 
triangles, βAMPKdKO. Female mice aged 12–14 weeks old were used; n=5-6 mice per genotype. 
Data are expressed as mean ± SEM; *p<0.05, **p<0.01, ***p<0.001. 
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Figure 3.5 βAMPKα2KO male mice display mildly impaired glucose tolerance and insulin 
secretory responses.  
(a) Growth curves of body weights in βAMPKα2KO mice. Circles, heterozygous; triangles, 
AMPKα2KO. (b) Blood glucose and (c) plasma insulin levels in 3-month-old mice with free access to 
chow or fasted for 15 h. White bars, heterogygous; black bars, βAMPKα2KO. (d) Glucose tolerance 
and (e) plasma insulin response after intraperitoneal (IP) glucose injection, and (f) whole-body insulin 
sensitivity after IP insulin injection of βAMPKα2KO vs heterozygous mice. Data are expressed as 
means ± SEM; n=3-6 mice per genotype.  
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Figure 3.6 Male AMPK heterozygous and Cre-positive AMPK wild type mice display normal 
glucose tolerance and insulin secretory responses. 
(a) Growth curves of body weights of AMPK heterozygous mice and wild type Cre-positive mice. 
Empty square, AMPK heterozygous; Filled square, Cre-positive AMPK wild type control mice. (b) 
Glucose tolerance and (c) plasma insulin response after intraperitoneal (IP) glucose injection, and (d) 
whole-body insulin sensitivity after IP insulin injection. Data are expressed as means ± SEM; n=3-6 
mice per genotype. 
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Figure 3.7 Role of catecholamines in the control of insulin secretion in βAMPKdKO mice.  
(a) Urinary noradrenaline (Noradren, norepinephrine), adrenaline (Adren, epinephrine) and dopamine 
levels. Black bars, βAMPKdKO; white bars, heterozygous. (b) Glucose tolerance of βAMPKdKO 
(triangles) or heterozygous control (white circles) mice 30 min. after IP phentolamine injection. Male 
mice aged 12-14 weeks were used. Data are expressed as means ± SEM; n=6-8; *p<0.05.  
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3.2.2. βAMPKdKO mice have normal β cell mass but smaller β cells and islets 
Changes in relative β cell mass, which might have explained the marked decrease in insulin 
release in βAMPKdKO animals, were not observed as assessed by OPT of whole pancreases 
(11); (Figure 3.8a-d) or through analysis of pancreatic slices (performed in collaboration with 
AstraZeneca, data not shown); (381). However, the distribution of islet sizes between 
heterozygous and βAMPKdKO animals, as assessed by OPT, revealed a significant ∼34% 
decrease in the average volume of individual islets (Figure 3.8b, c, e).  
By contrast, no differences were apparent in the ratio of α to β cells within individual islets or 
in the relative disposition of the two cell types (Figure 3.9a). Similarly, despite proposed 
roles for AMPK and the upstream kinase liver kinase B1 (LKB1) in the control of β cell 
polarity (296;297;305), we observed no abnormalities in the formation of adherens (anti-E-
cadherin antibodies; Figure 3.9b) or tight (anti-zona occludins-1 [ZO-1] antibody) junctions 
(Figure 3.9c), and microfilament and microtubule structure were unchanged in islets from 
βAMPKdKO mice (not shown).  
AMPK is a known regulator of the mechanistic target of rapamycin (mTOR) complex, acting 
to phosphorylate the mTORC1 components Raptor and the upstream regulator tuberous 
sclerosis complex-2 (382). Since mTOR is involved in the regulation of cell size (383), we 
assessed the size of individual β cells, using anti-E-cadherin (Figure 3.9d, e) or anti-GLUT2 
(Figure 3.10) antibodies to label the plasma membrane. This revealed a ∼18% decrease in the 
average area of β cells, corresponding to a decrease in volume of ∼36%, closely in line with 
the reduction in average islet size. However, no changes in the phosphorylation state of the 
downstream targets of mTOR, ribosomal S6 subunits, were detected (not shown), arguing 
against changes in the activity of the latter pathway being responsible for the decrease in β 
cell volume. Unexpectedly, β cell proliferation was also substantially (more than two fold) 
increased, as assessed by Ki67 staining (Figure 3.9f, g). 
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Figure 3.8 βAMPKdKO mice have small islets.  
(a) Representative OPT images of a whole fixed and permeabilised pancreas. Red, insulin-positive 
structures (β cells within islets). The overall shape of the whole pancreas was visualised as 
autofluorescence and is apparent as white/grey shading. Het, heterozygous. Scale bar, 500 µm. (b) 
Distribution of islet volumes with marked (dotted lines) section magnified (c). Black bars, 
βAMPKdKO; white bars, heterozygous. (d) Relative β cell mass and (e) mean islet volume. Data are 
from n=3 whole mouse pancreata per genotype and are expressed as means ± SEM; *p<0.05.  
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Figure 3.9 Islet and β cell morphology in βAMPKdKO mice.  
Immunofluorescence staining of pancreatic sections with: (a) anti-insulin (1:200; red) and glucagon 
(1:100, green) antibodies; (b) the adherens junction marker E-cadherin (1:100; green); (c) tight 
junction marker ZO-1 (whole serum; green); and (d) representative E-cadherin staining of pancreatic 
sections and determination (e) of β cell size. Ten islets (containing ≥10 cells) from n=3 mice of each 
genotype were analysed. (f) Staining for proliferation marker Ki67 and quantification (g), based on 8-
10 islets per pancreas, n=3 per genotype. Scale bars: 75 µm (a-c, f), 12 µm (d). Data are expressed as 
means ± SEM; *p<0.05, **p<0.01, ***p<0.001.  
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3.2.3. Glucose-induced insulin secretion is enhanced in islets from βAMPKdKO mice in 
vitro 
The above analyses revealed a profound compromise in the capacity of an unchanged mass of 
morphologically normal β cells to release insulin in vivo. To determine whether this reflected 
a change in the intrinsic properties of β cells, we next analysed insulin release from isolated 
islets, and glucose-sensing by dissociated β cells. In contrast to what was observed in vivo, 
islets from βAMPKdKO mice displayed significantly elevated rates of glucose-stimulated 
insulin release compared with control (heterozygote) islets (Figure 3.10a), arguing for a 
restraining effect of AMPK on hormone release. Unexpectedly, the previously described 
inhibitory effects of AMPK activation with the AMPK activator and AMP analogue AICAR 
(257;311) were still preserved in βAMPKdKO mouse islets, indicating that the effects of this 
activator were largely independent of AMPK.  
To determine whether β cells from βAMPKdKO mouse islets show altered glucose sensing, 
as observed after LKB1 deletion (see Chapter 4), electrophysiological approaches were 
performed in collaboration with Dr Andrei Tarasov (381). While glucose-induced changes in 
the conductance of ATP-sensitive K
+
 channels revealed lower conductance of these channels 
at low (3 mmol/l) but not elevated (16.7 mmol/) glucose in βAMPKdKO beta cells compared 
with heterozygous controls, this did not translate into a difference in membrane potential 
changes (Data not shown) (381). Likewise, no differences were apparent in the extent of 
glucose or depolarisation- (KCl-) induced increases in intracellular free Ca
2+
 ions in 
heterozygous compared with βAMPKdKO β cells (in collaboration with Dr. Angela 
McDonald, data not shown) (381). Correspondingly, again in contrast to the impact of LKB1 
deletion (see chapter 4), no differences were observed in the levels or plasma membrane 
association of the liver/β cell glucose transporter Glut2 (Figure 3.10b); (58). By contrast, the 
number of morphologically docked granules was significantly increased in βAMPKdKO β 
cells (Figure 3.10c, d). 
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Figure 3.10 Enhanced granules docking and improved glucose-stimulated insulin secretion in isolated 
islets from βAMPKdKO mice.  
(a) Glucose-stimulated insulin secretion from six size-matched islets from βAMPKdKO and 
heterozygous mice (Het) statically incubated with 3 mmol/l (white bars) or 16.7 mmol/l (black bars) 
glucose or 400 µmol/l AICAR (Sigma Aldrich) for 0.5 h; n=3 per genotype. (b) Immunofluorescence 
staining of GLUT2 expression at the plasma membrane of pancreatic islet β cells; 15 islets from two 
pairs of mice of each genotype were analysed. Scale bar, 75 µm. Het, heterozygous. (c) Granule 
docking in control (Het) or βAMPKdKO β cells; 15 cells from four separate islets, two mice per 
genotype were analysed by transmission electron microscopy. Dotted line, plasma membrane; Arrow, 
docked insulin granules. The relative number of morphologically docked granules was calculated by 
dividing that of docked granules (those within 300 nm of the plasma membrane) by that of total 
cytosolic granule number and is quantified in bar graph (d), Scale bar, 2 µm. Data are expressed as 
means ± SEM; ***p<0.001.  
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Figure 3.11 AMPK deletion attenuates the deleterious effects of high-fat feeding on glucose 
tolerance.  
(a) Body weight changes in βAMPKdKO (triangles) and heterozygous (circles) mice over 2 to 
18 weeks on high-fat diet (60%). (b) Blood glucose levels in βAMPKdKO (black bars) and 
heterozygous (white bars) mice on high-fat diet for six weeks with free access to food or fasted for 
15 h. (c) Glucose tolerance after intraperitoneal (IP) glucose injection and (d) whole-body insulin 
sensitivity after IP insulin injection of βAMPKdKO mice on high-fat diet for six weeks. Triangles, 
βAMPKdKO; circles, heterozygous. (e) Glucose-stimulated insulin secretion of six size-matched 
islets from βAMPKdKO and heterozygous mice (Het) maintained on high-fat diet for 18 weeks. Islets 
were statically incubated at 3 mmol/l (white bars) and 16.7 mmol/l (black bars) glucose for 0.5 h. n=3 
mice per each genotype. Data are expressed as means ± SEM; *p<0.05, ***p<0.001.  
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We next determined whether AMPK present in β cells and RIP2-Cre neurons contributed to 
the deleterious effects of a high-fat diet on insulin release and glucose homeostasis (384). No 
differences in body weight gain were apparent between heterozygous and βAMPKdKO mice 
maintained on a high-fat diet (Figure 3.11a). However, after six weeks on high-fat diet, 
(sufficient to cause profound abnormalities in glucose-induced insulin secretion in C57BL/6 
mice); (384), the differences in glycaemia observed between heterozygote and βAMPKdKO 
mice observed on a normal diet (Figure 3.3a, b, e) were no longer significant (Figure 3.11b). 
This change reflected a more dramatic increase in glucose levels in the heterozygous mice on 
a high-fat diet than in those on normal chow (Figure 3.3a and figure 3.11b). Likewise, the 
difference in glucose tolerance observed between βAMPKdKO and heterozygous mice on 
normal chow (∼5 mmol/l at 60 min; Figure 3.3e) was substantially reduced when the 
comparison between genotypes was performed in mice maintained on high-fat diet 
(∼2 mmol/l at 60 min; Figure 3.10c). By contrast, the enhanced insulin sensitivity of 
βAMPKdKO mice (∼20% of the initial glucose level 30 min. post insulin injection; Figure 
3.3g) was maintained or enhanced on a high-fat diet (∼30% of initial glucose; Figure 3.10d). 
Strikingly, the 3.5-fold decrease in glucose-stimulated insulin secretion observed in islets 
from heterozygous mice maintained on high-fat diet for 18 weeks compared with normal 
chow (from ∼0.7 to 0.2% per 30 min; Figure 3.10a and figure 3.11e) was reduced in 
βAMPKdKO mouse islets to ∼0.6-fold (from ∼1.3 to 0.8% per 30 min.). Hence, 
βAMPKdKO mice were still susceptible to the effects of high-fat diet, albeit to a lesser extent 
than controls.  
3.2.4. Over-expression of constitutively-active AMPK in β cells causes glucose 
intolerance 
To determine whether increases in AMPK activity in pancreatic β cells and a subpopulation 
of RIP2-expressing neuron cells would show the opposite phenotypes to βAMPKdKO mice, 
we generated transgenic mice (Genoway, Lyon, France) in which the constitutively-active 
enzyme (AMPK-CA); (257) was expressed under the control of the RIP2 promoter (Figure 
3.12a). Of two founder mouse lines generated (Figure 3.12b), we examined in detail one line 
carrying two copies of the transgene. Over-expression of the Ampk mRNA was clearly 
evident in islets (Figure 3.12c, d) and under the control of glucose ex vivo (as expected for 
expression under the insulin promoter; Figure 3.12e), but barely (<0.001% of the islet level) 
in the hypothalamus or other tissues (Figure 3.12d, f). 
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Figure 3.12 Generation of βAMPK-CA and βAMPK-DN transgenic mice.  
(a) Schematic representation (not to scale) of RIP2-AMPK-CA and -DN constructs for generating the 
transgenic mice. Black square, c-myc sequence. Hatched square, poly A sequence. B, BssHII digestion 
site. (b) Southern blot analysis of tail DNA from offspring of βAMPK-CA founder mice. Expected 
fragment sizes of RIP2-AMPK-CA constructs with linearisation of head-to-tail (1.9 kb) or of head-to-
head (3.5 kb) in the mice genomic DNA after SpeI digestion and hybridisation with indicated probe 
situated in the RIP2 promoter are shown. P, two equivalent copies of RIP2-AMPK-CA vectors 
(4.7 kb). (c) RT-PCR analysis of AMPK transgene expression in islets and (d) hypothalamus (H), 
brain cortex (B), liver (L), spleen (S), kidney (K), muscle (M) and islet (I) from βAMPK transgenic 
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mice and their wild-type controls. The forward and reverse primers located in the c-myc (myc fwd) 
and the AMPK-CA sequences (CA_RT rev) respectively were used for detecting the expression of 
AMPK-CA transgene. For the AMPK-DN transgene, the same forward primer as above (myc fwd) and 
the reverse primer located in the AMPK-DN sequence (DN_RT rev) were used. Product sizes were 
157bp and 431bp for CA and DN respectively. C, βAMPK-CA mice; D, βAMPK-DN mice; dashed 
bar, wild-type; P, 5 ng AMPK-CA plasmid used for generating transgenic mice. (e) Quantification of 
real-time PCR analysis of AMPK transgene expression in islets and (f) hypothalamus from transgenic 
mice and their wild-type controls. Islets were incubated for 24 h at 3 mmol/l (white bars) or 
16.7 mmol/l (grey bars) glucose before RNA extraction. Primers targeting the c-myc sequence were 
used. n=3 mice per genotype. RNA was extracted from hypothalamic extracts immediately after 
isolation. (g) Total AMPK activities in islets from transgenic mice and their wild-type littermate 
controls. Islets were incubated for 24 h at glucose concentrations as above (e, f) prior to extraction and 
assay. Data are presented as percentages of activities of transgenic mice to control mice islets at 3 
mmol/l glucose and (h) percentages of activities of βAMPK-CA compared to their control mice islets 
at 16.7 mmol/l glucose and βAMPK-DN compared to control mice islets at 3 mmol/l glucose. Male 
mice aged from 12 to 14 weeks old were used. n=3-5. Results are from three or more independent 
experiments and are expressed as mean ± SEM; *p<0.05, ***p<0.001.  
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Islets from transgenic mice over-expressing AMPK-CA displayed a significant increase in 
total (α1+α2 complex) AMPK activity at elevated (16.7 mmol/l), but not at low (2.8 mmol/l) 
glucose concentrations, where the endogenous enzyme was strongly activated (Figure 3.12g, 
h); (258). Conversely, AMPK activity was reduced at low glucose concentrations in islets 
from AMPK-DN transgenic mice, generated in parallel with βAMPK-CA mice (Figure 3.12g, 
h). Assuming approximately equal endogenous AMPK levels in β compared with islet non-β 
cells (Figure 3.1) and an islet β cell content of 60-70% (13), AMPK activity was increased by 
36% and reduced by 50%, in β cells by over-expression of AMPK-CA or AMPK-DN 
respectively.  
Maintained on normal chow, βAMPK-CA and βAMPK-DN transgenic mice displayed 
normal body weight increases (Figure 3.13a, b). Whereas male βAMPK-CA transgenic mice 
displayed abnormal glucose tolerance at three (Figure 3.13c), but not six (Figure 3.13e) 
months, no abnormalities were seen in βAMPK-DN transgenic animals (Figure 3.13d, f) or in 
female βAMPK-CA mice (not shown). The abnormalities in βAMPK-CA transgenic mice 
were not associated with any alterations in insulin sensitivity (Figure 3.13g, h), but with 
decreased fasting and stimulated plasma insulin levels (Figure 3.13i, j) and a 25% decrease in 
β cell area (0.09 ± 0.02% in wild-type vs. 0.068 ± 0.04% in transgenic littermates; performed 
in collaboration with Dr. Gabriela da Silva Xavier, data not shown). No significant changes 
in these variables were observed in βAMPK-DN transgenic mice.  
To determine whether the alterations in insulin secretion in βAMPK-CA mice also resulted 
from defects at the level of the β cell, we performed studies with isolated islets. Insulin 
release stimulated by 16.7 mmol/l glucose was decreased by >60% (Figure 3.13k), a similar 
change to that observed after maintenance of mice for 18 weeks on high-fat diet. Indeed, 
islets from βAMPK-CA transgenic mice maintained on a high-fat diet displayed no further 
diminution in glucose-stimulated insulin secretion compared with wild type littermates on the 
same diet (Figure 3.13k). Conversely, glucose-stimulated insulin release was significantly 
enhanced in islets from βAMPK-DN transgenic mice (Figure 3.13l), reminiscent of the effect 
of deleting AMPKα1 and -α2 subunits (Figure 3.10a), although in this case the improved 
secretion was eliminated in islets from animals fed a high-fat diet. 
 
 102 
0 20 40 60 80 100 120
0
5
10
15
20
Time (min post IP injection)
B
lo
o
d
 g
lu
c
o
s
e
 (
m
m
o
l/
l)
Ctrl
βAMPK-CA
c
0 15 30 45 60
20
40
60
80
100
βAMPK-CA
Ctrl
B
lo
o
d
 g
lu
c
o
s
e
 (
%
 i
n
it
ia
l)
0 15 30 45 60
20
40
60
80
100
βAMPK-DN
Ctrl
0 20 40 60 80 100 120
0
5
10
15
20
βAMPK-DN
Ctrl
B
lo
o
d
 g
lu
c
o
s
e
 (
m
m
o
l/
l)
* ***
**
* *
g
βAMPK-DN
Ctrl
i
3 mM
16.7 mM
[glucose]
k
Ctrl CA Ctrl CA
0.0
0.2
0.4
0.6
0.8
1.0
In
s
u
lin
 (
s
e
c
re
te
d
/t
o
ta
l 
%
)
*
*
HFD
Ctrl DN Ctrl DN
0.0
0.1
0.2
0.3
0.4
0.5
In
s
u
lin
 (
s
e
c
re
te
d
/t
o
ta
l 
%
)
*
HFD
6 mo
0 20 40 60 80 100 120
0
5
10
15
20
βAMPK-CA
Ctrl
B
lo
o
d
 g
lu
c
o
s
e
 (
m
m
o
l/
l)
6 mo
0 20 40 60 80 100 120
0
5
10
15
20
βAMPK-DN
Ctrl
B
lo
o
d
 g
lu
c
o
s
e
 (
m
m
o
l/
l)
3 mo 3 mo
Time (min post IP injection)
Time (min post IP injection) Time (min post IP injection)
Time (min post IP injection) Time (min post IP injection)
Time (min post IP injection)
e
6 8 10 12 14 16 18 20 22 24
15
20
25
30
35
b AMPK-CA
Ctrl
Age (week)
B
o
d
y 
w
e
ig
h
t 
(g
)
6 8 10 12 14 16 18 20 22 24
15
20
25
30
35
40
bAMPK-DN
Ctrl
Age (week)
B
o
d
y 
w
e
ig
h
t 
(g
)
a
βAMPK-CA βAMPK-DN
βAMPK-CA
Ctrl
*
*
Time (min post IP injection)
0 15 30
0
40
80
120
160
P
la
s
m
a
 i
n
s
u
lin
 (
p
m
o
l/
l)
0 15 30
0
50
100
150
200
250
300
P
la
s
m
a
 i
n
s
u
lin
 (
p
m
o
l/
l)
b
d
f
h
j
l
3 mo 3 mo
B
lo
o
d
 g
lu
c
o
s
e
 (
%
 i
n
it
ia
l)
3 mo 3 mo
 
 103 
Figure 3.13 βAMPK-CA transgenic mice display mild glucose intolerance and reduced insulin 
secretion.  
(a) Growth curves of body weights of βAMPK-CA mice and (b) βAMPK-DN mice aged 6 to 
24 weeks old. (c) Glucose tolerance at 3 months (3 mo) in βAMPK-CA and (d) βAMPK-DN mice, 
and (e, f) at 6 months (6 mo) respectively. (g) Whole-body insulin sensitivity in βAMPK-CA and (h) 
βAMPK-DN mice, with (i, j) insulin response of respective 3-month-old (3 mo) mice assessed by 
intraperitoneal (IP) injection and measurements of glucose in tail vein at the indicated times. White 
symbols (a-j), controls; black symbols, βAMPK-CA or βAMPK-DN mice. (k) Glucose-stimulated 
insulin secretion assessed in islets from βAMPK-CA and (l) βAMPK-DN transgenic mice and their 
wild-type littermate controls on normal chow or high-fat (60%) diet (under the bar below HFD) for 
18 weeks. Male mice aged 12–14 weeks were used; n=8-13 (a-j), n=3-5 (k, l). Data are expressed as 
means ± SEM; *p<0.05, **p<0.01, ***p<0.001.  
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3.3. Discussion 
The principal aim of this study was to determine the physiological impact of complete and 
selective loss of both catalytic isoforms of AMPK from pancreatic β cells. This is an 
important question, given the likely role of AMPK as a target for glucose-lowering drugs and 
uncertainties surrounding the role of AMPK in the β cell (256;257;314;315;319;324;326). To 
achieve this, we used RIP2-Cre expressing mice as the deleter strain to generate conditional 
knockout mice lacking AMPK both α catalytic subunits in pancreatic β cells. We note that 
Cre expression has been found in several extrapancreatic locations, including those sites 
where glucose sensing and satiety-controlling neurons might reside, using this particular 
strain (345). However, when the project started (2006) RIP2-Cre mice were the only 
established strain to drive expression of Cre in pancreatic β cells (343;345). Nontheless, due 
caution has been taken when the in vivo phenotypes were interpreted.     
3.3.1. Selection and limitation of the control mice 
To achieve double AMPK knockout mice in this study, we crossed the mice with whole body 
AMPK α1 knockout with AMPK α2 flox‟d and RIP2-Cre positive transgenic mice. Due to 
the complexicity of the genotypes, we used double AMPK heterozygous mice as an 
intermediate control for the βAMPKdKO mice. Therefore, βAMPKdKO display an impaired 
glucose homeostasis compared to the heterozygous mice. However, we considered the 
possibility of an alteration of glucose homeostasis in heterozygous mice compared to wild 
type Cre-positive mice, which might potentially change the interpretation of the results from 
βAMPKdKO mice compared to their gnenuine controls (wild type Cre-positive mice). 
However, similar glucose homeostasis between heterozygous and wild type Cre positive mice 
suggested that complete, but not half ablation of AMPK in RIP2-Cre expressing cells is 
necessary to cause impaired glucose metabolism. 
When the project started, the AMPKα1 flox‟d mice were not available. Alternatively, to 
achieve double AMPK α deletion in pancreatic β cells, we crossed AMPK α1 whole body 
knockout mice with mice deleted for AMPK α2 in RIP2-Cre cells. Nevertheless, we 
considered the possibility that deletion of AMPK α1 in other tissues other than RIP2-Cre 
expressing cells might contribute to the drastic changes of glucose homeostasis in 
βAMPKdKO mice. However, no changes in glucose metabolism were reported in AMPK α1 
whole body mice arguing against such possibility (360). 
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3.3.2. AMPK inhibits glucose-stimulated insulin secretion in pancreatic β cells in vitro 
Examined here in isolated islets, total ablation or reduction of AMPK activity led to a 
potentiation of glucose-induced insulin secretion (Figure 3.10a and Figure 3.13i). However, 
glucose-induced KATP channel closure and increases in intracellular Ca
2+
 in AMPK-deleted β 
cells were unaltered (data not shown); (381), suggesting that the loss of an inhibitory effect of 
AMPK-mediated phosphorylation of kinesin light chains (88;312) and increased granule 
translocation to the plasma membrane (Figure 3.10c, d) may underlie the enhanced secretion. 
Conversely, selective activation of AMPK in β cells in βAMPK-CA transgenic mice 
decreased glucose-stimulated insulin secretion. These findings are consistent with previous 
results involving the over-expression in islets of AMPK-CA in vitro (319), as well as with the 
effects of pharmacological activation of AMPK in clonal β cells and isolated islets using 
AICAR or metformin (257;258;311;385). Furthermore, a diminished number of docked 
granules was observed in MIN6 cells over-expressing AMPK-CA (312). Shortly after our 
observations on βAMPKdKO mice were published, Beall and colleagues (386) also 
published studies describing mice lacking AMPK in β cells using the same strategy. 
Although both studies reported AMPK deletion abolishes insulin secretion in vivo, glucose-
stimulated insulin secretion from islets in vitro revealed important differences between the 
two reports. Thus, insulin secretion from double AMPK (α1, α2; dKO) knockout mouse islets 
was reduced and β cells were hyperpolarised in the study of Beall et al. (386) which is in 
sharpe contrast to our own data (381). These important apparent discrepancies are likely to 
reflect differences in the protocols used for the culture of islets (e.g. glucose concentrations), 
and the selection of islets for studies (size, “condition”).  A definitive answer is likely to 
come only from (a) studies using the perfused pancreas (the most physiological ex vivo 
preparation for the study of insulin secretion), (b) more β cell selective knockout, achieved 
for example using MIT-Cre or Pdx1-Cre-ER
TM
 deleter strains (346;352) and (c) a fuller 
understanding of the effects of neuronal AMPK deletion on insulin secretion by 
stereotactically injecting adeno-associated virus (AAV) carrying RIP2-Cre into the 
hypothalamus of both the heterozygous and AMPK α1 null and α2 flox‟d mice.  
We also show here that AMPK deletion led to a decrease in cell volume, an effect strikingly 
different from that of deleting the upstream kinase, LKB1. Indeed, β cells lacking LKB1 as a 
result of excision mediated either by RIP2-Cre (see Chapter 4) or Pdx1-Cre-ER
TM 
(296;387) 
were larger than wild-type β cells. LKB1 and AMPK appear therefore to engage substantially 
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distinct downstream signalling pathways in β cells, the former acting at least to a large extent 
via polarity-regulating kinase partitioning-defective 1/microtubule affinity-regulating kinase 
2 (PAR1B/MARK2); (296;298).  
3.3.3. Central effect of AMPK on insulin release in vivo 
In the present study, inactivation of AMPK in RIP2-Cre neurons exerted no apparent effect 
on body mass or food intake. However, βAMPKdKO mice displayed defective glucose 
homeostasis due to abnormalities in the capacity of a preserved β cell mass to secrete insulin 
in response to hyperglycaemia. This deficiency was only partially compensated for by an 
increase in insulin sensitivity, probably due to inhibitory effects of AMPK in hypothalamus 
on liver glucose production, since infusion of adenovirus carrying a dominant-negative form 
of AMPK in the medial basal hypothalamus into the rat reduced hepatic glucose output (341). 
It is noted that although no insulin responses were found in βAMPKdKO in vivo in response 
to glucose injection (Figure 3.3f), glucose levels in these mice dropped from the peak levels 
after two hours of glucose injection (Figure 3.3e). These results suggested that insulin 
responses at early time point (2-5 min. after glucose injection) in βAMPKdKO might be 
preserved. However, due to the difficulty of extracting and storing blood from tail vein in 
such a short time frame, such possibility can not be examined here. We considered the 
possibility that decreases (~20%) in β cell and islet size (~40%) contributed to this deficiency 
in insulin secretion in vivo. However, the absence of impaired insulin release from islets in 
vitro (in fact, the opposite was observed, ~40% increase at 16.7 mmol/l glucose) and similar 
pancreatic β cell mass makes it unlikely that these changes are responsible for the drastically 
impaired insulin release observed in vivo in βAMPKdKO mice. One possible explanation for 
these data is that a signal or signals emanating from RIP2-Cre neurons controls the activity of 
β cells in vivo. Indeed, central administration of leptin has previously been shown to inhibit 
insulin secretion in vivo (388) and it is conceivable that this involves RIP2-Cre neurons and 
intracellular signalling pathways modulated by AMPK. 
In this study, we also used transgenic mice over-expressing a constitutively-active form or a 
dominant-negative form of AMPK under the same RIP2 promoter to examine whether the 
increase or decrease of AMPK activities in the same populations of cells where RIP2-Cre is 
expressed would show the opposite (in the case of βAMPK-CA) or similar (in the case of 
βAMPK-DN) in vivo and in vitro phenotypes. Unlike RIP2-Cre, whose expression leads to 
almost complete removal of the flox‟d gene in any cells expressing these constructs, the 
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effects of RIP2-AMPK-CA or -DN in the RIP2-expressing cells depend on the expression 
levels of these constructs. Because the expression of RIP2-AMPK-CA in hypothalamus was 
almost undetectable (Figure 3.12f); (Since βAMPK-DN mice have the same copies of inserts 
as βAMPK-CA, we assume that the expression of RIP2-AMPK-DN should be comparable to 
CA construct, thus also low in hypothalamus), it is conceivable that the in vivo phenotypes we 
observed in these transgenic mice are largely reflected by their effects on pancreatic β cells. 
To this end, the absence of the „opposite‟ (e.g. improved glucose intolerance) in βAMPK-CA 
or glucose intolerance in βAMPK-DN as observed in βAMPKdKO mice respectively (Figure 
3.13c, d) suggested that the signals transmited from extrapancreatic cells are likely to explain 
the discrepancy of the in vivo and in vitro phenotypes observed in βAMPKdKO mice.  
Nevertheless, further and more definitive studies are needed to ascertain whether and by what 
means RIP2-Cre neurons may influence insulin secretion.  
3.3.4 AMPK α2 in RIP2-Cre expressing cells affects whole body glucose homeostasis 
To assess which isoform of AMPK α subunits in RIP2-Cre expressing cells is more important 
to regulate glucose homeostasis, we also examined the effects of deletion of AMPK α2 alone 
in these cells. Although mice deleted for AMPK α1 in RIP2-Cre cells are not available, 
whole body AMPK α1 mice show normal glucose homeostasis (360). By contrast, βAMPK 
α2 mice displayed mildly impaired glucose tolerance and insulin response to glucose 
challenge (Figure 3.5d, e), albeit to a much less extent compared to βAMPKdKO. These 
results suggested that AMPK α2 in RIP2-Cre cells might also regulate glucose metabolism, 
and the phenotypes observed in βAMPKdKO mice might be partially contributed by deletion 
of AMPK α2.  
3.3.5. Effects of β cell AMPK on high fat diet-induced toxicity  
A further interesting finding of the present studies is that mice lacking AMPK in the β cell 
were somewhat less susceptible to the deleterious effects of high-fat diet on glucose 
metabolism and insulin secretion in vitro. These results are consistent with the previously 
demonstrated role of AMPK (314) in the actions of cytokines (316) on β cell function and 
mass.  
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3.5. Conclusions 
The results presented here suggest that AMPK is an inhibitor of glucose-stimulated insulin 
secreation in pancreatic β cells in vitro, but that activation of AMPK in extrapancreatic cells 
plays distinct roles in the control of insulin release in vivo.  
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Chapter 4 
LKB1 deletion with the RIP2-Cre transgene modifies pancreatic β 
cell morphology and enhances insulin secretion in vivo 
Abstract 
Aim and Hypothesis: The tumor suppressor liver kinase B1 (LKB1), also called STK11, is a 
protein kinase mutated in Peutz-Jeghers syndrome. LKB1 phosphorylates AMP-activated 
protein kinase (AMPK) and several related protein kinases. Whereas deletion of both 
catalytic isoforms of AMPK from the pancreatic β cell and hypothalamic neurons using the 
rat insulin promoter RIP2-Cre transgene (βAMPKdKO) diminishes insulin secretion in vivo, 
deletion of LKB1 in the β cell with an inducible Pdx1-Cre-ERTM transgene enhances insulin 
secretion in mice. To determine whether the differences between these models reflect 
genuinely distinct roles for the two kinases in the β cell or simply differences in the timing 
and site(s) of deletion, we have therefore created mice deleted for LKB1 with the RIP2-Cre 
transgene.  
Results: In marked contrast to βAMPKdKO mice, βLKB1KO mice showed diminished food 
intake and weight gain, increased concentrations of plasma insulin, unchanged insulin 
sensitivity, and improved glucose tolerance. In line with the phenotype of Pdx1-Cre-ER
TM
 
mice, total β cell mass and the size of individual islets and β cells were increased and islet 
architecture was markedly altered in βLKB1KO islets. Signaling by mammalian target of 
rapamycin (mTOR) to ribosomal S6 was also enhanced. In contrast to the reported effects of 
Pdx1-Cre-ER
TM
-mediated deletion, the expression of Glut2 was sharply reduced in 
βLKB1KO mouse islets and the stimulation of insulin secretion was modestly inhibited.  
Conclusion: LKB1 and AMPK play distinct roles in the control of insulin secretion. The 
timing of LKB1 deletion, and/or its loss from extrapancreatic sites, may influence the final 
impact on β cell function in vivo.  
 
 
Part of this work has been published in: Sun G, Tarasov AI, McGinty JA, French PM, McDonald A, 
Leclerc I, Rutter GA. Am J Physiol Endocrinol Metab. 2010 Jun;298(6):E1261-73. 
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4.1. Introduction 
Liver kinase B1 (LKB1, also called STK11) which is a potent tumor suppressor (288) is 
capable of activating AMPK by phosphorylating the latter at Thr 172 site (287); (see Chapter 
1). Compelling evidence for a conserved role for an LKB1-AMPK signaling cassette comes 
from studies in C. elegans, where inactivation of the corresponding homologs (PAR4- 
AAK2) leads to reversal of the dauer phenotype (389), characterized by metabolic inhibition 
and growth arrest. LKB1 and AMPK are also implicated in the control of cell polarity. Thus, 
deletion of the LKB1 homologues in D. melanogaster (dLKB1) and C. elegans (PAR4) 
disrupts epithelial cell polarity (390;391). Although forced over-expression of LKB1 induces 
cell polarization in intestinal epithelial cancer cell lines (292), the requirement for LKB1 in 
maintaining the polarity of mammalian cells is less clear (392). However, there is also 
growing evidence that the effects of LKB1 in mammalian cells may be, at least in part, 
independent of AMPK, since LKB1 phosphorylates 11 further kinases of the AMPK 
subfamily in vitro (294;376).  
In Chapter 3, I have demonstrated that deletion of both catalytic isoforms of AMPK from the 
pancreatic β cell between E9 and E11.5 days and subpopulations of neurons in the central 
nervous system by use of the rat Ins2 promoter (RIP2)-Cre transgene (βAMPKdKO mouse) 
leads to impaired glucose tolerance and defective insulin secretion in vivo but enhanced 
glucose-stimulated insulin secretion from isolated islets. However, and in marked contrast, Fu 
et al. (296) and Granot et al. (297) have demonstrated that deletion of LKB1 from the 
pancreatic β cell (and probably intestinal incretin-producing cells) from adult mice by means 
of an inducible Pdx1-Cre-ER
TM
 transgene leads to increased insulin production and enhanced 
β cell size. To determine whether these markedly divergent phenotypes may reflect true 
biological differences in the roles of LKB1 and AMPK in the pancreatic β cell, rather than 
being the result of differences in the timing and sites of deletion, we have therefore generated 
mice in which LKB1 is deleted in the β cell using the RIP2-Cre-expressing mice.  
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4.2. Results 
4.2.1. βLKB1KO mice are lean and hypophagic and display improved glucose tolerance 
To generate mice lacking LKB1 selectively in the pancreatic β cell from midgestation (E9-
11.5) and in a subset of hypothalamic neurons (“RIP2-Cre neurons”); (345), we crossed 
animals bearing flox‟d Lkb1/Stk11 alleles with RIP2-Cre mice (Figure 4.1a). Demonstrating 
efficient deletion from β cells, levels of endogenous Lkb1 mRNA were markedly reduced in 
islets from homo- (Lkb1
fl/fl
) vs. heterozygous (Lkb1
+/fl
) mouse islets in the presence of the Cre 
transgene, with the consequent increase in the level mRNA encoded by the null allele (Figure 
4.1b). Similarly, the null transcript was also present in hypothalamic extracts of hetero- and 
homozygous mice (Figure 4.1b). Levels of Lkb1mRNA (Figure 4.1c) and immunoreactivity 
(Figure 4.1d) in islets from mice of each genotype were compared next. Each parameter was 
decreased by 70-80% in islets from βLKB1KO (Lkb1fl/fl, Cre positive) vs. wild type (Lkb1+/+, 
Cre positive) mice, consistent with deletion from the islet β cell compartment. Levels of Lkb1 
mRNA and immunoreactivity in βLKB1het mouse islets were intermediate between those in 
βLKB1Wt and βLKB1KO mouse islets (Figure 4.1c, d).  
Since LKB1 is likely to be the major upstream kinase for AMPK in islets (Table 1.1, page 
119), AMPK activities were also measured as a further readout of LKB1 activity. Because the 
LKB1 immunoreactivities in βLKB1het vs. βLKB1Wt mice are similar (Figure 4.1d), the 
AMPK activities from βLKB1het and βLKB1KO were compared. Total cellular AMPK 
activity in isolated islets was reduced by ~75% in βLKB1KO vs. βLKB1het (Figure 4.1e). 
AMPK activities were reduced by 25% in hypothalamic extracts from from βLKB1KO vs. 
βLKB1het mice (Figure 4.1f), consistent with deletion from a subset of RIP2-Cre neurons 
within this tissue.  
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Figure 4.1 Generation of βLKB1KO mice.  
(a) Schematic representation of deletion of flox‟d Lkb1 exons (exons 3-6) driven by RIP2-Cre 
expression. Location of primers used for PCR as indicated. Black arrows, flox sites; gray bar, Lkb1 
exons. (b) RT-PCR analysis of Lkb1 transcript levels in pancreatic islets and hypothalamus (Hypo) of 
βLKB1KO mice. Product sizes were 864 and 300 bp for flox‟d and null alleles, respectively. NS, 
nonspecific. qRT-PCR (c) and Western (immuno-) blot analysis (d) of Lkb1 mRNA and protein levels 
in pancreatic islets of βLKB1KO mice and their heterozygous (het) and wild type (Wt) controls. Total 
AMPK activity in islets (e) and hypothalamus (f) of βLKB1KO and βLKB1het mice.  Islets incubated 
with RPMI media containing 10 mmol/l glucose for 48-72 h, were further incubated with RPMI 
media containing 3 mmol/l glucose for 1 h before analysis. Data are expressed as means ± SEM; n=4-
5 mice per genotype. *p<0.05, **p<0.01, ***p<0.001. 
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Examined at 6-8 weeks of age, male (Figure 4.2) and female (Figure 4.3) βLKB1KO mice 
displayed decreased fed body weight (Figure 4.2a and 4.3a) and daily food intake (Figure 
4.2b and 4.3b) compared with βLKB1Wt or βLKB1het mice. In addition, after 15 h of 
starvation, βLKB1KO male mice tended to eat less in the first 30 min. after refeeding (Figure 
4.2c). Reduced hypothalamic expression of the orexigenic peptide neuropeptide Y mRNA 
(NPY) (Figure 4.4a), and the increased anorexigenic peptide proopiomelanocortin (POMC) 
protein levels (Figure 4.4b), were observed in βLKB1KO mice compared to βLKB1Wt 
animals.  
Fasting and fed blood glucose levels were significantly decreased in βLKB1KO mice (Figure 
4.2d, e and Figure 4.3c, d), a change accompanied by substantial increases in plasma insulin 
levels in the fed state (Figure 4.2f). Correspondingly, βLKB1KO mice displayed dramatically 
improved glucose tolerance (Figure 4.5a) and insulin release (Figure 4.5b) in vivo compared 
with βLKB1Wt or βLKB1het mice but unchanged insulin sensitivity (Figure 4.5c).  
4.2.2. LKB1 controls β cell size, morphology, and islet architecture 
To examine in detail the possible mechanisms behind the hyperinsulinism in βLKB1KO 
mice, we used optical projection tomography (OPT); (11). This technique, which we have 
previously validated by comparison with conventional measurements of β cell mass based on 
histochemistry (Chapter 3); (381), allowed us to determine the mean and total volume, size, 
distribution, and number of islets within the entire pancreas (Figure 4.6a-d). Total β cell mass 
was markedly increased with respect to βLKB1Wt mice, and the mean volume of individual 
islets was significantly elevated by ~30% in βLKB1KO vs. βLKB1het and ~20% in 
βLKB1KO vs. βLKB1Wt pancreata. The most marked increase was apparent in the number 
of the largest islets present (>10
7
 μm3; ~10,000 cells) and certain small islets (Figure 4.6b). 
Although there were no apparent changes in the distribution of β and α cells within islets 
(Figure 4.7a), we observed a significant 40% increase in the surface area of individual β cells, 
as identified by staining with E-cadherin antibodies (Figure 4.7b). Demonstrating an increase 
in β cell proliferation, Ki67 staining was markedly increased in βLKB1KO islets (Figure 
4.7c).  
Since mTOR signaling (393) is implicated in controlling cell growth and protein synthesis, 
phosphorylation of ribosomal protein subunit S6 (rpS6) within islets was measured. As 
expected, increased phospho-rpS6 was detected in βLKB1KO mice islets compared with 
βLKB1Wt or βLKB1het mouse islets (Figure 4.7d). 
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Figure 4.2 Food intake and glucose homeostasis in male βLKB1KO mice.  
(a-c) body weight (a) and food intake of βLKB1KO mice fed (b) or refed after fasting for 15 h (c). 
(d–f) blood glucose (d and e) and plasma insulin (f) of βLKB1KO mice fed or fasted for 15 h. Male 
mice from 6-8 week old were used. Data are expressed as means ± SEM; *p<0.05, **p<0.01; n=7-10 
mice per genotype. 
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Figure 4.3 Food intake and glucose homeostasis in female βLKB1KO mice. 
(a, b) Fed body weight (a) and food intake of female βLKB1KO mice (b). (c, d) Blood glucose of 
female βLKB1KO mice fed (c) or fasted for 15 h (d). Female mice from 6-8 week old were used. 
Data are expressed as means ± SEM; *p<0.05, n=3-5 mice per genotype. 
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Figure 4.4 βLKB1KO mice have lower NPY and higher POMC levels in hypothalamus. 
(a) Real-time qPCR analysis of neuropeptide Y (NPY) mRNA expression level and (b) Western 
(immuno-) blot analysis of proopiomelanocortin (POMC) protein levels in the hypothalamus from 
βLKB1KO and βLKB1Wt mice. Data are expressed as means ± SEM; *p<0.05, n=4 mice per 
genotype for (a). 
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Figure 4.5 Glucose and insulin tolerance of βLKB1KO mice.  
Glucose tolerance (a), and plasma insulin response (b) after intraperitoneal (IP) glucose injection, and 
whole body insulin sensitivity (c) monitored after IP insulin injection of βLKB1KO or control mice. 
Male 6- to 8-week-old mice were used. Data are expressed as means ± SEM. For a and b, *p<0.05, 
**p<0.01 for βLKB1KO vs. βLKB1Wt, +p<0.05 for βLKB1KO vs. βLKB1het; in c, *p<0.05 with 
respect to time 0 for all genotypes; n=7-10 mice per genotype. 
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Figure 4.6 Altered islet morphology in βLKB1KO mice.  
(a) Representative optical projection tomographic (OPT) images of whole pancreas. OPT was 
performed as described under General Methods (Chapter 2). Red staining indicates insulin-positive 
structures (islets), while the outline of the whole pancreas was apparent as autofluorescence and is 
presented as white/gray shading. Note the presence of particularly large islets in the βLKB1KO 
pancreas (right image, arrow head). (b) Distribution of islet volumes with marked (dotted lines) 
section magnified. (c) Relative β cell mass; (d) Mean islet volume. Data are from 5-6 mice per 
genotype. Scale bar, 500 μm. Data are expressed as means ± SEM. *p<0.05, **p<0.01. In b, *p<0.05, 
for βLKB1KO vs. βLKB1Wt, $p<0.05 for βLKB1KO vs. βLKB1het. 
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Figure 4.7 Increased β cell size and proliferation in βLKB1KO mice. 
(a) Hematoxylin-eosin (H&E) and immunofluorescent staining of pancreatic sections using guinea pig 
anti-insulin (1:200; green) and rabbit anti-glucagon (1:100; red) antibodies. Nuclei are shown with 
DAPI (blue) staining. Scale bar, 75 μm. (b) Representative E-cadherin staining of pancreatic sections 
and quantification of single islet β cell sizes. Average area of 100 single β cells from five islets of 
each genotype, co-stained in pancreatic sections for E-cadherin and insulin, were analyzed. Scale bar, 
12 μm. (c) Staining for proliferation marker Ki67 and quantification, based on 15-20 islets per 
pancreas; n=3 mice per genotype. (d) Western blot analysis of mTOR signaling pathway markers 
phospho-ribosomal protein S6 (P-rpS6) of pancreatic islet extracts from βLKB1KO and control mice. 
Islets extracted from fed mice were incubated in RPMI supplemented with 11 mM glucose for 16 h 
and lysed for analysis. Data are expressed as means ± SEM. *p<0.05, **p<0.01. 
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Figure 4.8 β Cell polarity is enhanced in βLKB1KO mice with increased rosette-like (“islet acini”) 
structures and accumulation of cell junction proteins.  
(a-e) Immunofluorescence staining of pancreatic sections for the adherens junction marker (a and b) 
E-cadherin (1:100, green), (c) actin filament (1:50, red; note imaged areas were confirmed as lying 
over an islet by inspection of corresponding bright field images), (d) β-tubulin (1:100, green), (e) tight 
junction marker zona occludins 1 (ZO1, whole serum; green) or capillary marker (f) VEGFR2 (1:100, 
green). White square, voids at center of rosettes. (g) Quantification of rosette-like structures per islet 
in βLKB1KO mice based on E-cadherin and DAPI staining. Such structure in islet is counted as one 
by E-cadherin staining where the voids at the center of the rosette is absent of DAPI staining. Ten 
islets from three pairs of mice per genotype were assessed. Data are expressed as means ± SEM. 
**p<0.01, ***p<0.001. Scale bars, 50 μm (a), 12 μm (b), 10 μm (c), and 25 μm (d–f). 
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To determine whether LKB1 may be critical for the establishment of basolateral-apical 
polarity of β cells, we examined the distribution of the adherens junction marker E-cadherin, 
as well as actin, tubulin, and the tight junction protein zona occludins 1 (ZO1). Unexpectedly, 
polarization was not compromised in LKB1-deficient β cells (Figure 4.8). Instead, mutant 
islets displayed a significant increase in the number of rosette-like structures or “islet acini” 
(394) identified by E-cadherin and ZO1 staining in which 8-10 cells were arranged around a 
central void (16); (Figure 4.8a, b, e, g). Strikingly, nuclei were positioned in the cells 
comprising these rosettes away from the apical pole, while actin and tubulin staining were 
concentrated at the junctional zones (Figure 4.8c, d). Whereas the apical “voids” were devoid 
of staining for VEGFR, this was enriched at the basolateral surface, indicating the presence of 
capillaries at the latter site (Figure 4.8f). 
4.2.3. LKB1 deletion diminishes β cell responses to glucose ex vivo 
To determine whether the dramatic improvements in glucose tolerance in vivo might also in 
part reflect enhanced β cell glucose sensitivity, we isolated islets and single cells from 
βLKB1KO, βLKB1het and βLKB1Wt mice. Glucose-stimulated insulin secretion (GSIS) 
under static incubation was diminished in βLKB1KO mouse islets by ~30% compared to 
βLKB1Wt mouse islets (Figure 4.9a), although the absolute insulin output, as assessed from 
six size-matched islets, was not significantly different between the genotypes (Figure 4.9a). 
By contrast, the insulin content of similarly sized islets from βLKB1KO mice was 
substantially increased (2.5-fold vs. βLKB1Wt and 1.5-fold vs. βLKB1Het; figure 4.9a). 
Correspondingly, Ins1 gene expression level was increased significantly (Figure 4.10e). 
Glucose-stimulated changes in the conductance of ATP-sensitive K
+
 channels (GKATP), 
membrane depolarization (Vm), and increases in intracellular free Ca
2+
 concentration were all 
markedly attenuated in β cells from βLKB1KO islets (performed by Drs Andrei Tarasov and 
Angela McDonald, data not shown); (387).  
Providing a possible contribution to the impaired GSIS from βLKB1KO islets, we observed a 
substantial decrease in the level of GLUT2 (slc2a2) immunoreactivity at the plasma 
membrane of LKB1-deleted cells (Figure 4.9b) and a correspondingly large (>90%) reduction 
in Glut2 mRNA in isolated islets (Figure 4.10b). Likewise, the levels of mRNAs encoding 
the ATP-sensitive KATP channel subunit kir6.2 (Kcnj11); (Figure 4.9c), but not SUR1 
(ABCC8) were substantially (>80%) decreased in βLKB1KO vs. βLKB1wt islets. By 
contrast, we observed no significant decreases in the expression of other genes involved in  
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Figure 4.9 βLKB1KO β cells display abnormal secretory responses and decreased GLUT2 
immunoreactivity at the plasma membrane. 
(a) Glucose-stimulated insulin secretion and total insulin content of six size-matched islets statically 
incubated with indicated glucose for 0.5 h from βLKB1KO, heterozygous, and wild type mice; n=3 
mice per genotype. (b) Immunofluorescence staining and quantification of GLUT2 expression at the 
plasma membrane of pancreatic islet β cells. Fifteen islets from two pairs of mice per genotype were 
examined. Scale bar, 75 μm. Data are expressed as means ± SEM. *p<0.05, **p<0.01, ***p<0.001, 
NS, not significant. 
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Figure 4.10 Pancreatic islet marker gene expression. 
Real-time qPCR analysis of Pdx1 (a), Glut2 (b), Kir6.2, Sur1 (c), Ki67 (d), Ins1 (e), Ins2, Gcg 
(Glucagon) (f), and Gk (g) gene expression in isolated islets from βLKB1KO mice. n=4 mice per 
genotype. *p<0.05, **p<0.01, ***p<0.001. 
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maintaining the differentiated function of β cells, including Pdx1, neuroD1 or MafA 
(βLKB1KO vs. βLKB1KO, not shown) nor in glucokinase (Gk; Figure 4.9a, c, g), suggesting 
that a generalized decrease in β cell differentiation or glycolysis did not occur. 
4.2.4. Effects of metabolic stress on βLKB1KO vs. wild type mice 
Since LKB1 and AMPK are implicated in cellular stress responses, we determined how 
LKB1 deficiency in β cells and hypothalamus may impact on the diabetogenic effects of a 
high-fat diet (384). After six weeks on a high-fat diet, differences in glucose tolerance (Figure 
4.11a) or insulin secretion (Figure 4.11b) were no longer apparent between genotypes, 
consistent with a greater susceptibility of βLKB1KO mice to the effects of this metabolic 
stress.  
 
4.3. Discussion 
4.3.1. LKB1 regulates β cell size and islet architecture 
The principal aim of the present study was to determine whether, when compared using a 
near-identical strategy for deletion from β cells with that used previously for AMPKα 
subunits (Chapter 3); (381), the loss of LKB1 may lead to similar changes in insulin secretion 
and glucose homeostasis in vivo and in vitro. This has seemed important given the 
dramatically different phenotypes of mice deleted for LKB1 in adults using a Pdx1-Cre-ER
TM
 
transgene which can be readily switched on by intraperitoneally injection of tamoxifen into 
mice (296;297) and those deleted for AMPK using the RIP2-Cre transgene (381), with the 
latter strategy resulting in earlier (midgestational) deletion and some loss from hypothalamic 
nuclei. Although the genetic background of the LKB1-deleted mice generated here 
(FVB/129S6/C57BL6) and in earlier studies (296;297) differs slightly from that of those 
deleted for AMPK (C57BL6); (381), it seems unlikely to us that this difference could explain 
the markedly different phenotypes of mice deleted for LKB1 vs. AMPK in the β cell.  
Our findings confirm the view that LKB1 is a critical regulator of β cell development and 
function. First, we demonstrated that the size of individual β cells was considerably 
increased, as was that of individual islets, as assessed by OPT. Interestingly, and as shown in 
Figure 4.6d, the mean islet volume, as determined by OPT, was increased by ~40% in 
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Figure 4.11 In vivo metabolic advantages of LKB1 deletion from insulin-expressing cells are lost on a 
high-fat diet.  
Glucose tolerance after IP glucose injection (a) and plasma insulin during normal fed status (b) of 
βLKB1KO mice on a high-fat diet for six weeks. 
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βLKB1KO vs. wild type islets. This compares with an increase in average (single) β cell area 
of ~60% (Figure 4.7b), equivalent to an increase in volume of more than two fold. The 
difference between these values seems likely to be due to the contribution of an unchanged 
volume of other cell types within the islets, and/or a lowered number of β cells per islet.  
As also recently reported (11), the distribution of islets in wild type mouse pancreata was 
highly nonuniform, with the largest islets representing as much as 50% of the total β cell 
mass. Using the same approach in βLKB1KO islets, we demonstrated that the abundance of 
the largest islets was significantly increased. This shift seems likely to be the result, at least in 
large part, of an increase in the average volume of individual β cells (~60%), as well as 
increases in β cell proliferation. TSC1/2 deletion in β cells, using the same RIP2-Cre mice, 
led to increased β cell mass (395), a phenotype similar to what we describe here in LKB1KO 
mice. Increased phosphorylation of rpS6 in βLKB1KO mice islets suggested that the 
increased β cell size and islet volume are likely to be due to elevated mTOR signalling 
(Figure 4.12b).  
The present results also confirm the view (296;297) that LKB1 is involved in the 
establishment of cell polarity in mammalian epithelial cells, consistent with findings from 
Shorning et al. (392) in intestine Paneth and goblet cells, as well as the findings in β cells 
(296;297). Thus, we found that rosette-like arrangements of β cells (16), containing strikingly 
polarized β cells, were twice as frequently observed in βLKB1KO islets (Figure 4.12). We 
considered the possibility that this may be due simply to an increase in the size of individual 
cells. Arguing against this possibility, no increase in the number of rosettes were observed in 
other models where increases of β cell volume are induced, e.g. transgenic over-expression of 
mTORC1 in pancreatic β cells (396). Similarly, such structures did not appear to be more 
abundant in the islets of transgenic mice expressing the cell cycle regulator CDK4/R24C 
under the RIP2 promoter, in which a massive increase in β cell mass (to almost 20% of 
pancreatic volume) was observed, in this case due to enhanced proliferation (397).  
We have considered the possibility that the effects of LKB1 deletion reflect the requirement 
for this enzyme to activate AMPK. However, deletion of the AMPKα1 and α2 subunits in β 
cells by use of the RIP2-Cre transgene led to defective insulin release in vivo, with none of 
the changes in β cell mass or cellular architecture observed here in βLKB1KO islets (Chapter 
3); (381). What would be the downstream kinase(s) of LKB1 regulating such changes in β 
cell mass or cellular architecture? Of the 11 other AMPK-related kinases (398), Snf related 
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kinase (SNRK), NUAK1/2 (also called AMPK-related protein kinase 5 (ARK5)) and 
MARK1-3 were found highly expressed in pancreatic islets at the mRNA level (387). Only a 
very low level of expression of salt inducible kinase 1/2 (SIK1/2) was apparent whilst BR 
serine/threonine kinase 1/2 (BRSK1/2); (also called sporadic Alzheimer‟s disease A/B kinase 
(SAD-A/B) in the central nervous system) mRNA was undetectable (Table 1.1); (387). 
Notebly, Par-1b (MARK2) was recently shown to promote cell-cell adhesion and association 
of E-cadherin with the actin cytoskeleton (399). A loss of this interaction may be involved in 
the relocalization of the latter to the apical pole as observed in βLKB1KO β cells. 
Par1b/MARK2 has also recently been shown to regulate glucose metabolism by adipose 
tissue in vivo (400), possibly by interacting with syntaxin-4 (399) to control vesicular 
trafficking of GLUT4 to the plasma membrane. As syntaxin-4 is implicated in the second 
phase of GSIS (401), it is possible that abnormal phosphorylation of Par1b/MARK2 in the 
absence of LKB1 may also influence the trafficking of β cell secretory granules to the cell 
surface (Figure 4.12b). Most importantly, β cells from mice deleted globally for 
Par1b/MARK2
−/−
 display a similar redistribution of nuclei to that described here (297). 
Studies of MARK2 and other AMPK-like kinases in pancreatic β cells, for example using β 
cell specific knockout mouse models, may reveal the possible roles of these kinases in 
controlling pancreatic β cell function and growth downstream of LKB1. 
4.3.2. LKB1 inhibits insulin secretion in islets 
As indicated above, whilst our paper was in revision, two other studies were published 
describing the effects of LKB1 deletion in pancreatic β cells using slightly different strategies 
(296;297). These authors crossed LKB1 flox‟d mice with mice expressing Cre recombinase 
under inducible Pdx1 promoter (Pdx1-Cre-ER
TM) so that LKB1 in the pancreatic β cells can 
be removed after IP injection of tamoxifen into adult mice. Both these two studies, and our 
own showed similar in vivo phenotypes e.g. improved glucose tolerance and increased insulin 
release in mice lacking LKB1 in pancreatic β cells. However, dramatic differences were 
observed when glucose stimulated insulin secretion was compared in isolated islets. 
Therefore, in their studies, deletion of LKB1 in pancreatic islets in adult mice led to enhanced 
insulin secretion per islet (296) or per total islet protein (297) whilst glucose-stimulated 
insulin secreted from six size-matched islets from our models were not significantly different 
from wild type. In fact, when the insulin levels were normalized to total insulin contents, 
βLKB1KO mice islets showed a modest decrease of insulin secretion in response to elevated 
glucose concentration (Figure 4.9a). Although neither of the two studies using 
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 Table 1.1 Relative abundance of LKB1-target kinases in pancreatic islets 
Pancreatic islets isolated from 12 week-old, wild-type male C57Bl/6 mice by collagenase digestion 
and histopaque gradient purification as described (258) were incubated in RPMI supplemented with 
11 mM glucose for 16h. 400-600 ng of total cellular RNA extracted from the islets using RNAeasy kit 
(Qiagen, UK) was used for microarray analysis (performed in collaboration with Prof. Torben F. 
Ørntoft, Aarhus University Hospital, Denmark). Four independent hybridizations were performed on 
Mouse 430 2.0 chip (Affymetrix, Santa Clara, CA, USA). Data were exported to GeneSpringX to 
perform quality control and subsequent downstream analysis. Robust multichip average (RMA) 
summary and quantile normalisation was employed to produce expression values for the probe sets. 
Data are expressed as means of observations on islets from four separate mice which agreed within 
10%. A, absent. 
Protein kinase mRNA level (relative intensity) 
LKB1/STK11 404 
CaMKK2β 152 
  
AMPKα1 (PRKAA1) 416 
AMPK α2 (PRKAA2) 104 
  
Snf related kinase (SNRK) 396 
Nuak1/Snf-1 like kinase-1/ARK5 314 
Nuak2/SNARK 172 
salt inducible kinase 1 (SIK1/MSK/SNF1LK1) 35 
salt inducible kinase (SIK2/QIK/ SNF1LK2) 54 
MARK1 214 
MARK2 (PAR1B) 422 
MARK3 (PAR1A/TAK1/MAP3K7) 568 
MARK4   A 
BRSK1 (SAD-A) A 
BRSK2 (SAD-B) A 
 
 129 
Pdx1-Cre-ER
TM
 to delete LKB1 in adult mice islets examined the levels of expression of β 
cell-specific genes in detail or involved studies of glucose sensing at the single β cell level, 
the subcellular distribution of GLUT2 immunoreactivity within individual β cells was 
reportedly altered by LKB1 deficiency (297). Nevertherless, we suspect that the duration of 
LKB1 deletion might contribute to these differences. Therefore, short-term deletion of LKB1 
in pancreatic β cells 
reported by Fu‟s and Granot‟s work might preserve/enhance the β cell function whilst long-
term deletion of LKB1 in these cells reported here poses deleterious effects on glucose 
sensing of β cells. Notebly, although insulin secretion per total insulin content from six islets 
was reduced in βLKB1KO mice observed here, it was not completely abolished. The 
relatively well-preserved stimulation of insulin secretion by glucose in these mice islets 
(Figure 4.9a), despite changes in KATP channel conductance, resting membrane potential, and 
a marked (~50%) decrease in the rise in intracellular free Ca
2+
 in response to the sugar (data 
not shown); (387), may suggest a compensatory increase in “KATP-independent” (57) 
mechanisms of activation, serving to enhance the sensitivity of the secretory machinery to 
Ca
2+
 changes. A more detailed assessment of this possibility will require further analysis, 
including a comparison of the transcriptome of islets from βLKBKO mice generated here and 
those generated by using Pdx1-Cre-ER
TM
. It should also be stressed, however, that the 
substantial increase in β cell size and mass (~4-fold; figure 4.4c, d) seems likely to 
predominate over the relatively more minor changes in β cell glucose sensing in LKB1-
deleted β cells and to underlie the substantial increase in vivo in insulin release under glucose 
challenge (Figure 4.12a, b).  
We have also noted that such an inhibition of glucose-stimulated insulin secretion in islets 
from βLKB1KO mice was not reflected in islets from βAMPKdKO mice (Chapter 3); (381), 
which showed an increase of insulin secretion without changes of Glut2 expression, 
intracellular Ca
2+
 and electrical activity (Figure 4.12a, b). This observation again implies that 
LKB1 and AMPK are engaged in two distinctive signalling pathways in regulating insulin 
secretion from isolated islets.  
4.3.3. Does LKB1 control neuronal function to regulate food intake and body weight? 
A striking finding of the present study was that deletion of LKB1 using the RIP2-Cre 
transgene led to a decrease in body weight and feeding. We have considered the possibility 
that these changes may simply reflect the increased levels of insulin, with the latter serving as 
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a satiety factor (402). However, we suspect that the metabolic and cellular changes resulting 
from LKB1 deficiency in the brain and in the pancreas are, at least in large part, independent. 
Thus, mice inactivated for LKB1 in pancreatic β cells by using Pdx1-Cre-ERTM deleter strain 
mentioned above showed similar increases in circulating insulin levels and marked 
improvements in glucose tolerance without a change in body weight.  
Importantly, we show that changes in food intake and body mass in βLKB1KO mice were 
accompanied by small but detectable increase and decrease in the hypothalamic expression of 
the anorexigenic peptide POMC and orexigenic peptide NPY, suggesting that RIP2-Cre 
neurons may control the activity of neighboring cells in the melanocortin circuitry to regulate 
feeding behaviour (403). Further studies will be necessary to explore this possibility and the 
mechanisms through which deletion of LKB1 in RIP2-Cre neurons, not usually thought to 
express either NPY or POMC (353;404), may influence the levels of these peptides in the 
ventromedial hypothalamus. Interestingly, deletion of insulin receptor substrate-2 (IRS2), 
using an identical strategy to that used here, has previously been shown to cause hyperphagia, 
diminished β cell mass, and glucose intolerance in mice (405). Conversely, potentiation of 
insulin signaling by deletion in RIP2-Cre cells of the inositol phospholipid 5′-phosphatase 
PTEN (406) led to diminished growth and body weight. LKB1 deletion in the same nuclei 
thus led to a strikingly similar phenotype to the latter model. This similarity suggests that 
LKB1 may also oppose insulin signaling in RIP2-Cre neurons to enhance appetite and body 
weight. Surprisingly, however, deletion of TSC1, also expected to enhance mTOR signaling 
in the same neuronal population, led to hyperphagia and obesity (407), suggesting that LKB1 
may engage other signaling pathways to influence the activity of these and associated 
neurons in the melanocortin network (Figure 4.12b).  
Interestingly, although βLKB1KO mice displayed clear decreases in hypothalamic and β cell 
AMPK activity (Figure 4.1), mice deleted for both AMPK catalytic subunits in the same cells 
did not display a feeding or body weight phenotype (Chapter 3); (381), indicating that the 
hypothalamic effects of LKB1 may be mediated by alternative downstream kinases (294); 
(Table 1.1) or other effectors (Figure 4.12b). In any case, we stress that further studies will be 
required in the future, perhaps involving the selective deletion of LKB1 in the hypothalamus 
by the stereotactic injection of adeno-associated virus (AAV) carrying Cre recombinase into 
this brain region in LKB1 flox‟d mice, to formally confirm or refute the possibility of distinct 
roles for central and pancreatic islet LKB1 in the control of glucose homeostasis and food 
intake.  
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4.4. Conclusion 
Using an identical strategy for tissue-selective deletion in mice, we have shown that LKB1 
plays a distinct role(s) from that of AMPK in controlling β cell mass and insulin secretion in 
vivo and in vitro. Further dissection of the signaling pathway(s) through which LKB1 acts at 
each site may provide exciting new modalities for the treatment of metabolic diseases 
including type 2 diabetes.   
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Figure 4.12 Proposed pathways for the impact of LKB1 and AMPK in pancreatic β cells on glucose-
stimulated insulin secretion. 
(a) Increases in ATP:ADP ratios after glucose metabolism in pancreatic β cells inhibits AMPK 
activity and increases proximity of docked insulin granules. This effect is probably through inhibitory 
effect of AMPK on kinesin light chain phosphorylation (1). Inhibition of LKB1 activities, on the other 
hand, decreases glucose-stimulated insulin secretion by interrupting Glut2 expression (2). LKB1 also 
affects pancreatic β cell polarity by reorganizing microtubules, actin filaments and tight junctions (3). 
However, it is not clear whether these effects are involved in the regulation of glucose-stimulated 
insulin secretion from β cells. Image was taken from Sun G and Rutter G.A. Diabetes Management. 
2011 May; 1(3): 333-347. (b) The roles of LKB1 and AMPK in RIP2-expressing cells for the control 
of insulin release from pancreatic β cells and whole body glucose metabolism. 
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Chapter 5 
LKB1 inhibits autophagy and cell death in pancreatic β cells through 
AMPK-independent mechanisms 
Abstract 
Background: Tight regulation of autophagy is necessary to maintain pancreatic β cell mass 
and dysregulation of this process has recently been implicated in the development of type 2 
diabetes (T2D). Whilst liver kinase B1 (LKB1) and the downstream kinase AMP-activated 
protein kinase (AMPK) regulate autophagy in various cell types, their roles in controlling 
these processes in β cells are still poorly defined.  
Results: Using mice lacking LKB1 (βLKB1KO), or both catalytic α subunits of AMPK 
(βAMPKdKO), selectively in this cell type, we show here that LKB1 regulates autophagy, 
mitochondrial morphology, endoplasmic reticulum (ER) stress and apoptosis independently 
of AMPK. Thus, βLKB1KO mice displayed an increase in the number of β cells containing 
crinophagic and autophagic vacuoles, and an increase in that of enlarged mitochondria which 
was four times greater than the increase seen after AMPK deletion. Furthermore, LC3-II 
conversion was up-regulated in LKB1 but not AMPK-null β cells. An unfolded protein 
response (UPR), and evidence of ER stress, was also found in βLKB1KO mouse islets, as 
revealed by increases in Xbp-1 splicing and Chop mRNA levels.  
Conclusion: Thus, LKB1 is a key regulator of several adaptive and cell survival responses in 
β cells and acts through mechanisms which are largely independent of AMPK activation.  
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5.1. Introduction 
Autophagy is a dynamic self-protective mechanism by which cells self-digest damaged 
organelles (138). Thus, under metabolic stress, a double-membraned “phagophore” surrounds 
damaged or dysfunctional organelles to create an autophagosome. The fusion of lysosomes 
with the autophagosome then leads to the release of digestive enzymes into the latter, with the 
consequent degradation of the cargo (138). Formation of phagophore membranes is initiated 
by two complexes, the ULK1/2 complex including FIP200, Atg13, ULK1/2 and Atg101, 
called the FIP200-ULK1 complex (408) and the class III phosphatidylinositol 3‟ kinase 
(PI3K) complex (including Atg14, p150, Vps34 and Beclin1); (409). Following the action of 
these complexes the Atg12-Atg5-Atg16 complex and microtubule-associated protein light-
chain 3 (LC3-II) are sequentially recruited (410;411). Upon completion of autophagosome 
formation, the Atg12-Atg5-Atg16 complex is released back into the cytosol, whilst LC3-II 
remains on the autophagosome (411;412). To form the LC3-II complex, Atg7 and Atg3-
dependent conjugation of phosphatidylethanolamine (PE) with LC3-I, derived from LC3 (a 
mammalian homolog of Atg8) after cleavage of the C-terminus, is required (412).  
Type 2 diabetes (T2D) is characterised by the dysfunction of pancreatic islet β cells (413) and 
reduced β cell mass reflecting increased cell death and decreased cell proliferation (414). 
Although the self-digestion of mature insulin granules in these cells was described a number 
of years ago (415), a requirement for autophagy in the preservation of adequate pancreatic β 
cell mass has only recently been reported, with the demonstration that deletion of Atg7 
selectively in these cells leads to insulin insufficiency and glucose intolerance in mice (416).  
On the other hand, increased cell death was also reported to be associated with enhanced 
autophagy under certain conditions (417). Thus, adequate levels of “basal” autophagy seem 
likely to be necessary for the maintenance of normal β cell viability. On the other hand, the 
over-activation of this process may be detrimental for cell survival and/or normal function. 
For example, signs of increased autophagy were described recently in pancreatic islet β cells 
from T2D patients and were associated with β cell loss (141). Accumulation of autophagic 
vacuoles is also observed in pancreatic islet β cells from both T2D patients (141) and Zucker 
diabetic fatty rats (418) and it has been suggested that clearance of damaged organelles might 
serve as a defence mechanism (142). Correspondingly, β cells in mice heterozygous for the 
inactivation of Pdx1, a key transcription factor involved in the development and survival of 
these cells (419), display increased autophagy and cell death, and the latter changes were 
reversed by reducing the levels of Beclin1 (Becn1); (420). Whether the increase in autophagy 
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in these setting contributes to, or ameliorates, β cell loss, remains unclear. Nonetheless, better 
understanding of the mechanisms, which control this process in this metabolically critical cell 
type, would appear important for the development of new therapeutic strategies towards 
diabetes.  
LKB1 and AMPK have recently been implicated in the activation of autophagy in various 
cell types. Thus, dephosphorylation and activation of tuberculosis sclerosis complex 1 and 2 
(TSC1/2) is thought to inhibit mammalian target of rapamycin (mTOR1); (302), leading to 
the inactivation of ribosomal S6 kinase and eukaryotic translation initiation factor 4E-binding 
protein 1 (4E-BP1). This, in turn, leads to decreases in protein synthesis and the suppression 
of cell growth. AMPK-mediated activation of TSC1/2 and phosphorylation of Raptor, which 
then dissociates from mTOR (421), may also contribute to the inhibition of protein synthesis. 
Importantly, mTOR1 is a known inhibitor of autophagy (422), such that the above AMPK-
mediated events are expected to enhance the latter process. Finally, four independent 
laboratories have very recently demonstrated the direct binding and phosphorylation of 
ULK1, a mammalian Atg1 homolog, by AMPK (303;423-425). 
Metabolic stress activates the LKB1-AMPK signalling pathway, resulting in induction of 
autophagy in epithelial and several cancer cell types (417;426). Hence, the removal of LKB1-
AMPK signalling under conditions of stress may lead to apoptosis with an attenuation of 
autophagy (417). This effect has been proposed to be mediated via phosphorylation of p27, a 
cyclin-dependent kinase inhibitor, by AMPK and LKB1 (417). In other settings, LKB1 and 
AMPK signalling is suggested to inhibit autophagy and apoptosis (427;428). For example, 
the absence of AMPK is associated with the induction of autophagy and apoptosis in AMPK-
null mouse embryonic fibroblasts (MEFs) during glucose starvation (428) and the deletion of 
LKB1 from bone marrow haematopoietic cells was shown very recently to induce LC3-II 
formation and apoptosis (427). Therefore, the role of AMPK in controlling autophagy and 
apoptosis needs to be further dissected.  
In Chapters 3 and 4, I have demonstrated that LKB1 and AMPK unexpectedly play sharply 
distinct roles in the control of pancreatic β cell mass in mice. Thus, LoxP/Cre-mediated 
deletion of LKB1 selectively from β cells led to improved glycemia, driven by β cell 
proliferation and growth, prompting enhanced insulin output (296;387); (Chapter 4). By 
contrast, deletion of AMPK with an identical strategy lowered β cell size and suppressed 
insulin secretion in vivo (381;386); (Chapter 3).  Moreover, a recent study using RNAi-based 
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inactivation and pharmacological tools suggested that AMPK activation inhibits autophagy in 
β cells (429). However, the role of LKB1 in controlling autophagy and apoptosis in islet β 
cells, and the possible role of AMPK as the effector kinase for any such role, has not 
previously been examined.  
In light of the above findings, we sought here to better understand the respective roles of 
LKB1 and AMPK in the control of autophagy in the β cell. To this end, we have used mice 
inactivated selectively for either kinase(s) in this cell type (381;387). We show that LKB1 
deletion, whilst leading to overall increases in β cell mass, also simultaneously activates 
autophagy and cell death, and this is associated with altered mitochondrial morphology and 
ER stress.  By contrast, β cells lacking both catalytic isoforms of AMPK (and hence null for 
AMPK activity) display increased apoptosis and non-apoptotic cell death, but no evidence of 
increased autophagy. Thus, LKB1 inhibits autophagy and death in the β cell through 
mechanisms which are substantially independent of AMPK activation.  
 
5.2. Results 
5.2.1. Deletion of LKB1 or AMPK causes distinct effects on autophagy in pancreatic 
islet β cells 
To investigate whether LKB1 and AMPK may also impact β cell mass by differentially 
controlling “degradative” pathways, including autophagy, endoplasmic reticulum (ER) stress 
and apoptosis, we isolated islets from mice deleted selectively in the β cell for LKB1 
(βLKB1KO); (Chapter 4) or AMPK catalytic subunits (βAMPKdKO); (Chapter 3) or their 
wild type or heterozygous controls, and performed transmission electron microscopy (EM) 
analysis (performed in collaboration with Prof. Piero Machetti, University of Pisa, Italy). 
βLKB1KO mouse islets displayed an increase in the number of β cells containing at least one 
autophagic (non-granule organelle-containing; Figure 5.4a) or crinophagic (secretory 
granule-containing; Figure 5.1a) vacuoles (16% in βLKB1 KO, 16 out of 100 cells vs. 5% in 
wild type controls, 6 out of 127 cells, Figure 5.1a and Figure 5.4a). Thus, β cells from 
βLKB1KO mice showed a 5-8 fold increase in the number and total volume of such 
structures compared to their wild type controls (Figure 5.1b, c).  
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Figure 5.1 Increased autophagic/crinophagic vacuoles in βLKB1KO, but not βAMPKdKO mouse 
islet β cells. 
(a) Representative electron microscopy (EM) analysis of pancreatic islet β cells from βLKB1KO and 
βAMPKdKO mice and their wild type or heterozygous (het) controls. The black squared areas 
highlight autophagic or crinophagic vacuoles containing insulin granules. (b) Quantification of 
numbers of autophagic/crinophagic vacuoles per 70 μm2 intracellular β cell area and (c) volume 
density of such vacuoles per total β cell volume from βLKB1KO and βAMPKdKO mice and their 
littermate wild type or heterozygous (het) controls based on electron micoscopy analysis. Data are 
means ± SEM from 24 β cells of three islets for each genotype. *p<0.05.  
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However, the number of β cells containing autophagic or crinophagic vacuoles in βAMPK 
dKO mice islets was minimal (3% in βAMPKdKO vs. 0% in Het) arguing against a role of 
LKB1 in controlling autophagy via AMPK (Figure 5.1b, c). 
5.2.2. Increased autophagy in βLKB1KO mouse islets was associated with increased 
LC3-II conversion 
The modification of LC3 is a commonly used marker for autophagy (430). Upon induction of 
autophagy, cytosolic LC3-I is converted into LC3-II after conjugation with 
phosphatidylethanolamine and is recruited onto autophagosome to form punctate structures 
(412). To assess LC3 conversion in βLKB1KO islet β cells, pancreatic sections were co-
stained with LC3 and insulin. In line with the above EM analysis (Figure 5.1), βLKB1KO 
islets showed an increased number of LC3 puncta compared to wild type controls, whilst the 
level of LC3 puncta was similar in βAMPKdKO and heterozygous controls (Figure 5.2a). 
Western (immuno-) blot analysis also revealed increased LC3 conversion in βLKB1KO 
islets, with a relative band intensity of LC3-II to tubulin of 1.08 ± 0.34 in KO islets vs. 0.54 ± 
0.11 in wild type controls (n=3, p<0.05; Figure 5.2b, c). 
Since LC3-II is recruited to autophagosomes during the formation of vacuolar structures 
(412), over-expression of GFP-tagged LC3 can be used to monitor this process in living cells 
by epi-fluorescence microscopy (430). Dissociated islet cells from control or βLKB1KO 
mice were therefore infected with GFP-LC3-expressing adenovirus (kindly provided by Dr. 
Sharon Tooze) and the number of cells containing at least three puncta per cell was 
determined. We note that this analysis counted all islet cells of which 70-80 % could be 
shown by immunostaining to be insulin-positive β cells (431). Puncta formation was 
markedly increased by LKB deletion from 15.8 ± 1.5% of wild type islet cells to 50.3 ± 3.3% 
of βLKB1KO cells (p<0.001). Moreover, βLKB1KO cells displayed an increased number of 
puncta per cell (5.4 ± 0.3 in βLKB1 KO vs. 3.4 ± 0.07 in wild type control islets, p<0.01) 
such that the level in βLKB1KO cells was similar to that in cells treated with 1 mmol/l LiCl3 
(43.4 ± 5.6% of cells containing at least three puncta per total cell and 4.3 ± 0.3 puncta per 
cell); (Figure 5.3a-c).  
The class 3 phosphatidylinositol-3‟ kinase (PI3K) inhibitor, wortmannin is known to reduce 
autophagy by interrupting WIPI2-mediated early autophagosome formation (430), decreasing 
Atg5-12-16 and LC3 recruitment. Treating dissociated islet β cells from βLKB1KO mice 
with 0.1 or 1 μmol/l wortmannin for 2 h reduced both the number of cells containing LC3 
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Figure 5.2 Up-regulation of LC3 puncta and LC3-II cleavage in βLKB1KO mouse islets. 
(a) Representative immunofluorescence staining of pancreatic section for LC3 (green) and insulin 
(red). The white squared area was magnified. (b) Western (immuno-) blotting analysis of LKB1, LC3-
I and LC3-II protein levels in pancreatic islets from βLKB1KO mice and their littermate wild type 
controls. (c) Quantification of relative LC3-II band intensity to α-tubulin from Western blotting 
analysis. Data are means ± SEM of three separate experiments using 100-150 islets from three mice 
per genotype. 
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Figure 5.3 Up-regulation of LC3 puncta in βLKB1KO mouse β cells. 
(a) Representative immunofluorescence staining of dissociated pancreatic islet β cells infected with 
GFP-tagged LC3-expressing adenovirus for 48 h for insulin (red). Dissociated wild type islet β cells 
were incubated with 1 mmol/l LiCl3 for 24 h after LC3 virus infection for 24 h as a positive control. 
Scale bar, 5 µm. (b) Quantification of GFP (LC3) puncta positive cells per total cells and (c) average 
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number of puncta per cell in GFP (LC3) puncta positive cells based on immunofluorescence staining. 
(d) Representative fluorescence image of dissociated pancreatic islet β cells infected with GFP-tagged 
LC3-expressing adenovirus for 24 h before treated with 0.1 or 1 µmol/l wortmannin (wort) for 2 h. (e) 
Quantification of GFP (LC3) puncta positive cells per total cells and (f) average puncta per cell in 
GFP (LC3) puncta positive cells based on fluorescent images obtained from cells treated with 0.1 or 1 
μmol/l wortmannin (wort). Data are means ± SEM of three separate experiments counting 50-70 cells 
per experiment. *p<0.05, **p<0.01, ***p<0.001. 
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positive puncta (40.2 ± 1.2% at 0.1 μmol/l wortmannin and 26.0 ± 5.6% at 1 μmol/l 
wortmannin vs. 50.3 ± 3.3% without treatment, n= 50-70 cells from three separate 
experiments., p<0.05 for the effects of 0,1 and 1 umol/l wortmannin respectively) and the 
number of puncta per cell (4.3 ± 0.2 at 0.1 μmol/l wortmannin and 4.2 ± 0.4 1 μmol/l 
wortmannin vs. 5.4 ± 0.3 without treatment n= 50-70 cells from three separate experiments, 
p< 0.05 for the effects of 0,1 and 1 umol/l wortmannin respectively); (Figure 5.3d-f). 
5.2.3. LKB1 and AMPK regulate mitochondrial morphology in β cells 
Our previous studies (387) revealed that deletion of LKB1 reduces glucose-stimulated 
electrical activity and Ca
2+
 influx in βLKB1KO mouse islet β cells. Since the closure of ATP-
sensitive K
+
 channels is central to their responses (56), these findings were consistent with 
defective ATP generation and thus dysfunction of mitochondria. AMPK has recently been 
implicated in the regulation of mitochondrial morphology and volume, acting in hepatocytes 
via the phosphorylation of ULK1 (424). To determine whether LKB1 and/or AMPK deletion 
may also affect mitochondrial structure or biogenesis in β cells, we examined βLKB1KO and 
βAMPKdKO mouse islet cells using electron microscopy. Enlarged mitochondria were more 
abundant after the deletion of either gene(s) when examined in islet cells from KO mice 
compared to the corresponding wild type or heterozygous littermate controls (Figure 5.4a). 
Moreover, enlarged mitochondria were almost four fold more abundant in βLKB1KO mouse 
islet β cells (32% of 100 total β cells counted vs. 0 % of total 127 cells counted in controls,) 
than in βAMPKdKO mouse islet β cells (8% of total 61 β cells counted vs. 0% in controls; 
p<0.01 vs. βLKB1KO) suggesting the involvement of LKB1 downstream kinases other than 
AMPK in regulating mitochondrial morphology (Figure 5.4b, c). AMPK-mediated ULK1 
phosphorylation at Ser 555 has been suggested to regulate mitophagy and to lead to the 
appearance of enlarged mitochondria (424). Therefore, ULK1 phosphorylation was examined 
in LKB1-ablated islet β cells by Western (immuno-) blotting analysis. The abundance of 
phosphorylated ULK1 (Ser 555) in β cells deleted for LKB1 was significantly lower than in 
cells from wild type control animals, suggesting LKB1 might regulate mitochondrial 
morphology via ULK1 (Figure 5.4d).  
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Figure 5.4 βLKB1KO and βAMPKdKO mouse islet β cells contain enlarged mitochondria. 
(a) Representative electron microscopy (EM) analysis of mitochondria of pancreatic islet β cells from 
βLKB1KO and βAMPKdKO mice and their littermate wild type or heterozygous (het) controls. (b) 
Quantification of volume density of mitochondria per total β cell volume and (c) number of 
mitochondria per 70 μm2 intracellular β cell area based on electron microscopy analysis. (d) Western 
(immuno-) blotting analysis of phospho-ULK1 (Ser555), COX IV and phospho-ACC (Ser179) protein 
levels in pancreatic islets from βLKB1KO mice and their littermate wild type controls. GAPDH was 
used as a loading control. Data are means ± SEM from 24 β cells of three islets for each genotype. 
*p<0.05.  
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Nonetheless, quantification of the total volume density of mitochondria (Figure 5.4b) and 
Western blotting analysis for a mitochondrial marker, COX IV (Figure 5.4d) did not provide 
any evidence for an overall increase in mitochondrial volume. By contrast, the number of 
mitochondria per 70 μm2 cytosolic area was decreased in both βLKB1KO and βAMPKdKO 
mice compared to their controls (Figure 5.4c). These results suggested that these kinases may 
act in islet β cells rather on the fission-fusion processes which influence mitochondrial 
morphology (for example through the action of remodelling proteins such as Fis1 or 
mitofusin); (432) than to change the overall number of mitochondria. 
5.2.4. LKB1 regulates the unfolded protein response (UPR) in β cells 
When the synthesis of secretory or membrane proteins exceeds the capacity of the ER for 
folding, an unfolded protein response (UPR), ER stress and eventually cell death ensues 
(433). Since a remarkable increase of islet insulin content is observed in βLKB1KO mouse 
islets (387); (Chapter 4), we next explored the possibility that a UPR may occur in response 
to LKB1 deletion. Examined after culture for 16 h in 11 mmol/l glucose, spliced Xbp-1 
mRNA was significantly more abundant in islets from βLKB1 null than wild-type islets 
(Figure 5.5a). Quantification of the PCR products revealed an increased ratio of spliced to 
total Xbp-1 mRNA from 18.7 ± 0.4% in wild type to 21.6 ± 0.2% in KO islets (n=3, p<0.05); 
(Figure 5.5b). In addition, the levels of mRNAs encoding CHOP and the chaperone proteins 
GRP78 were both markedly elevated (~2 fold) in βLKB1KO mouse islets incubated at 11 
mmol/l glucose while the levels of these mRNA were reduced or unchanged respectively in 
βLKB1 vs. wild type islets after culture at 3 mmol/l glucose (Figure 5.5c, d). 
Correspondingly, we observed the appearance of insulin granules in crinophagic vacuoles in 
βLKB1KO mouse islet β cells after culture at 11 mmol/l glucose (Figure 5.1a) consistent with 
the hyper-production of insulin in these islets, and hence increased ER stress (Figure 5.5c, d). 
We did not examine UPR in βAMPKdKO mouse islets as the insulin content of these islets 
was not altered compared to controls (381).  
5.2.5. LKB1 and AMPK are necessary to maintain β cell viability 
Mitochondrial dysfunction and ER stress have been reported to lead to apoptosis (433;434) 
while prolonged induction of autophagy is associated with a distinct, non-apoptotic form of 
cell death (139). EM analysis revealed an increased number of dead or dying cells, both with 
and without signs of apoptosis (nuclear condensation and fragmentation; Figure 5.6a),  in β 
cells from βLKB1KO and βAMPKdKO mice compared to the corresponding controls. Thus, 
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Figure 5.5 Unfolded protein response in βLKB1KO mouse islets.  
(a) PCR analysis of spliced Xbp-1 levels in βLKB1KO mouse islets incubated with 3 (G3) and 11 
mmol/l (G11) glucose for 24 h using primers flanking the spliced site of Xbp-1. PCR products of 
unspliced Xbp-1 (170bp) and spliced Xbp-1 (144bp) were indicated. (b) Quantification of percentage 
of relative spliced Xbp-1 to total Xbp-1 levels based on PCR analysis. (c) Real time qPCR analysis of 
mRNA levels of Chop and (d) Grp78 levels from βLKB1KO mouse islets incubated with 3 (G3) and 
11 mmol/l (G11) glucose for 24 h. Data are means ± SEM from three mice for each genotype. 
*p<0.05. **p<0.01. 
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Figure 5.6 Increased apoptotic and non-apoptotic cell death in βLKB1KO and βAMPKdKO mouse β 
cells. 
(a) Representative electron microscopy (EM) analysis of apoptotic and non-apoptotic pancreatic islet 
β cells from βLKB1KO and βAMPKdKO mice. Arrows highlight the insulin granules indicating that 
the dead cell is a pancreatic β cell. (b) Quantification of percentage of dead β cells with 
morphological sign of apoptosis and signs other than apoptosis (c) based on electron microscopy 
analysis. Data are means ± SEM from 24 β cells of three islets for each genotype. **p<0.01. 
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the number of apoptotic cells (8.7 ± 1.8% in βAMPKdKO vs. 1.3 ± 1.3% in controls; 5.0 ± 
1.5% in βLKB1KO mice vs. 0% in controls, n=3 islets, p<0.05); (Figure 5.6b) and non-
apoptotic dead cells in βAMPKdKO mice (16.3 ± 3.8% vs. 0% in controls) and βLKB1KO 
mice (9.0 ± 1.0% vs. 0% in controls); (Figure 5.6c) was increased after deletion of either 
kinase.  
 
5.3. Discussion 
5.3.1. LKB1 regulates autophagy in pancreatic islet β cells 
We have previously generated mice deleted for LKB1 in pancreatic islet β cells and in a 
subpopulation of neurons in the CNS (387); (Chapter 4). These mice displayed increased β 
cell mass largely due to both β cell hyperplasia and hypertrophy. The above changes were 
also associated with an up-regulation of the mTOR signalling pathway (387); (Chapter 4). 
However, deletion of AMPK, which is an important downstream target of LKB1, resulted 
unexpectedly in a markedly different phenotype (381); (Chapter 3). Thus, mice with β cells 
null for AMPK contained smaller islets compared to controls (381); (Chapter 3), arguing 
against a conventional LKB1-AMPK signalling pathway as mediating the effects of LKB1 in 
the control of β cell mass. The chief aim of the present study was, therefore, to determine 
whether LKB1 controls autophagy and primary islet β cell death, and whether and to what 
extent these effects may be mediated by AMPK. This question has seemed important to us 
given the fact that a proper balance between cell proliferation and death is key to maintaining 
β cell mass in healthy individuals (381;387). 
Firstly, our findings provide evidence that long term deletion of LKB1 from an early 
gestational stage (E11) in pancreatic β cells induced the formation of autophagic vacuoles 
containing damaged organelles (Figure 5.1a and 5.4a) and crinophagic vacuoles containing 
mature insulin granules (Figure 5.1a). This increase of autophagic and crinophagic vacuoles 
was accompanied by increased in situ formation of LC3 puncta in LKB1 deleted pancreatic 
islets β cells and LC3-II conversion from islets isolated from βLKB1KO mice (Figure 5.2). 
Noted, accumulation of LC3-II at static states, might be caused by enhanced autophagic flux 
(on-rate) or reduced autophagic rate due to blockage of atuophagic degradation by lysosome 
(off-rate) (138;139;435). These two processes can be distinguished by treating cells with 
lysosomal potease inhibitors, such as pepstatin A and E64D (429), or an inhibitor of 
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vascuolar-type H
+
-ATPase, bafilomycin A, which prevents fusion of the autophagosome with 
the lysosome (436). Thus, a further accumulation of LC3-II in the presence of these 
compounds indicates an increase in the autophagic influx. Such measurement will be needed 
for β cells deleted for LKB1 to determine which part of the autophagic processes was 
affected in these cells. Nonetheless, our findings are reminiscent of those reported in a recent 
study by Gurumurthy and colleagues (427) showing that LKB1 inhibits LC3-II accumulation 
in haematopoietic stem cells. Our observations are also very similar to those described in 
heterozygous Pdx1 knockout mice in which LC3 punta and LC3-II conversion in pancreatic 
islets were increased (420). However, Pdx1 gene expression was not altered in βLKB1KO 
pancreatic islets (Sun, G. and G.A.R., unpublished results) indicating that an alteration in 
Pdx1 levels is unlikely to explain the observation of enhanced autophagy in LKB1 null β 
cells.  
The maintenance of normal insulin content and secretion requires that insulin synthesis and 
degradation be balanced (415). Indeed, it has been suggested that crinophagy might work as a 
housekeeper to clear away “old” (e.g. unfused) insulin granules, should the trafficking of 
insulin granules be blocked, as appears to occur in Rab3A knockout mice (437). As 
previously described in βLKB1KO mice (387); (Chapter 4), LKB1 deletion increased insulin 
content by up-regulating Ins1 gene expression and probably through a general increase in 
protein synthesis prompted by the activation of mammalian target of rapamycin (mTOR). At 
the same time, islets from these mice displayed a reduced percentage of secreted over total 
insulin after glucose stimulation, possibly due to the reduced expression of Glut2 and other 
“glucose-sensing” genes (387). It is, therefore, likely that up-regulated crinophagy in these 
cells was triggered by unknown mechanisms in response to an increase in the number of 
insulin granules per cell.  
We have previously demonstrated impaired electrical activity and Ca
2+
 influx in LKB1- 
ablated pancreatic islet β cells, suggesting that the mitochondrial generation of ATP may be 
defective (387). The enlargement of mitochondria is often taken as an indicator that these 
organelles are dysfunctional and may serve as a stimulus for activating their autophagy 
(“mitophagy”); (438). Deletion of ULK1 has previously been shown to increase the number 
of enlarged mitochondria in hepatocytes (424), though in this earlier study, and in contrast to 
our own findings in response to LKB1 deletion in β cells, an overall increase in 
mitochondrial volume was also apparent, at least on a Balbc or fvb genetic background 
(434;439). In fact, the reduction of numbers of mitochondria observed in both βLKB1KO and 
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βAMPKdKO mice may reflect a more general activation of mitophagy in the β cell model. 
Whether ULK1 (or ULK2) regulate mitochondrial mass (or structure) positively or negatively 
in the β cell remains to be determined. 
5.3.2. LKB1 deletion induces cell death in pancreatic islet β cells 
The present study confirmed that LKB1 is an inhibitor of both apoptotic and non-apoptotic 
cell death in pancreatic islet β cells (Figure 5.6). This result was supported by the findings 
that deletion of LKB1 led to increased cleavage of caspase 3 in haematopoietic stem cells 
(427). ER stress has been reported to cause apoptotic cell death in pancreatic islet β cells via 
different pathways including Xbp-1-induced c-Jun N-terminal kinase (JNK) activation and 
CHOP activation-mediated Bcl2 inhibition (135). The increase of ER stress in LKB1 deleted 
β cells suggested that increased apoptotic cells in βLKB1KO islets might thus reflect ER 
stress-induced apoptosis.  
5.3.3. LKB1 regulates autophagy and cell death independently of AMPK   
We considered here the possibility that the effects of LKB1 deletion on autophagy and cell 
death may reflect the inactivation of AMPK. However, despite recent discoveries that 
metabolic stress-stimulated AMPK activation induces autophagy by phosphorylating ULK1 
(303;423-425), deletion of AMPK both α catalytic subunits did not affect autophagy in 
pancreatic islet β cells (Figure 5.1 and 5.2). This result is in sharp contrast to that of Han and 
colleagues (429) that a reduction of AMPK activity in islets using compound C or siRNA 
increased autophagy after 72 h exposure of cells to high glucose (30 mmol/l); (429). 
However, it may be argued that the effects of compound C in this earlier study might in part 
reflect off-target effects of the inhibitor. Whilst the βLKB1KO and βAMPKdKO mice used 
here were bred on slightly different genetic backgrounds, it would seem unlikely that this 
difference could explain the dramatic differences in phenotype described previously 
(381;387); (Chapters 3, 4) and in the present study. 
Of interest, AMPK deletion in hepatocytes led to the dephosphorylation of ULK1 at serine 
555, and this change was associated with an increased number and total volume of enlarged 
mitochondria and reduced autophagy (mitophagy); (424). In the present study, we discovered 
that AMPK deletion in islet β cells also led to the appearance of enlarged mitochondria 
without increasing total mitochondrial volume (Figure 5.4b), suggesting that LKB1 might 
regulate mitochondrial morphology partially through AMPK in pancreatic β cells. What is 
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intriguing is that despite the absence of autophagy and small percentage of cells containing 
enlarged mitochondria, AMPK-deleted islets showed a dramatic increase of cell death, with 
the percentage of dead cells being almost two fold higher than that in LKB1-deleted β cells 
(Figure 5.6). This result contrasts with our own (316) and others‟ (313;324) evidence from 
studies on rodent islets treated with AMPK activator or an adenovirus over-expressing a 
constitutively-active form of AMPK, and with transgenic mice over-expressing active AMPK 
selectively in the β cell (381) that AMPK serves as a pro-apoptotic kinase in pancreatic islet β 
cells.  Instead, these findings indicate that maintenance of normal β cell functions requires an 
appropriate degree of AMPK expression and deviations above or below this level are 
deleterious.  
 
5.4. Conclusion 
Using two β cell knockout mouse models, we demonstrate here that LKB1 leads to changes 
in autophagic flux and cell death via a signalling pathway distinct from that (those) regulated 
by AMPK in pancreatic islet β cells. Further dissection of other downstream targets of LKB1 
and autophagy-related protein will be needed to better understand the pathology of autophagy 
and its role in type 2 diabetes.   
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Chapter 6 
Ablation of LKB1 or AMPK α catalytic subunits from mouse 
pancreatic α cells regulates glucagon secretion and whole body 
glucose homeostasis   
Abstract 
Background and Aim: Normal secretion of glucagon is essential for the maintenance of blood 
glucose and responses to acute hypoglycaemia. The tumour suppressor LKB1 (STK11), and 
the downstream kinase AMP-activated protein kinase (AMPK), are critical regulators of 
cellular metabolism in a range of tissues. Here, we sought to understand the roles of these two 
kinases in the control of glucagon secretion in vivo and whole body glucose metabolism.  
Methods: LKB1 (αLKB1KO), or the α catalytic subunits of AMPK (αAMPKdKO, -α1KO, -
α2KO) were ablated selectively in pancreatic α cells by breeding LKB1 or AMPK α1 and/or 
α2 flox‟d mice with mice expressing Cre recombinase under the preproglucagon promoter 
(PPG).  
Results: Male αLKB1KO mice displayed overall lower glycaemia during intraperitoneal 
glucose (1g/kg), aminoimidazole carboxamide ribonucleotide (AICAR) (0.175g/kg) and 
arginine tolerance (3g/kg) tests, together with reduced fasting plasma glucagon and glucagon 
secretion in response to L-arginine stimulation at 8 weeks of age. Correspondingly, LKB1 
deletion in pancreatic α cells decreased glucagon secretion from isolated islets incubated with 
3 mmol/l glucose by 60.2±6.8% (p<0.05) and increased the secretion from islets incubated 
with 17 mmol/l glucose by 3.1-fold without altering secretion at 0.1 mmol/l glucose, or 
insulin secretion at all glucose concentrations tested. In marked contrast to what was 
observed in LKB1-deleted β cells, no changes in α cell morphology or relative α cell mass 
were observed between genotypes. 
Although αAMPKdKO and -α1KO mice also exhibited decreases in fasting plasma glucagon 
levels, they showed normal responses to glucose, insulin and AICAR tolerance tests. 
Correspondingly, αAMPKdKO and -α1KO mouse islets displayed a decrease in glucagon 
secretion at 3 mmol/l glucose with no changes at 0.1 or 17 mmol/l glucose. Activation of 
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AMPK in pancreatic α cells using AMPK activator or adenovirus carrying a constitiutively-
active form of AMPK (CA) increased glucagon secretion in vitro.   
Conclusion: LKB1 serves as a positive regulator of glucagon secretion, acting at least in part 
upstream of AMPKα1 to mediate the effects of glucagon on glucose metabolism. Defects in α 
cell LKB1 or AMPK signalling may contribute to abnormal glucagon release in some forms 
of diabetes. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Part of this work has been published in: Leclerc I, Sun G, Morris C, Fernandez-Millan E, Nyirenda M, 
Rutter GA. Diabetologia. 2011 Jan;54(1):125-34.                 
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6.1. Introduction 
Glucagon, which is secreted by the pancreatic α cells in islets of Langerhans is the key anti-
hypoglycaemic hormone (158). Unregulated glucagon secretion has been implicated in both 
types of diabetes (158;160;160;161;161;243);(165-167); (see Chapter1). Therefore, 
understanding how glucagon release is regulated in pancreatic α cells will be useful to 
identify drug targets to treat diabetes.  
Hypoglycaemia induces glucagon release both as a result of changes in parasympathetic 
(440) and sympathetic tone (441),  increases in circulating adrenaline levels (169;442;443), 
and through direct effects of glucose on pancreatic α cells (444). The exact nature of the latter 
effects is still debated, and how glucose exerts its action on individual α cells is still unclear. 
It seems that, at least in the mouse, a direct effect of glucose (186;192) and an indirect effect 
of gamma amino butyric acid (GABA) (207;208) and insulin (172;186), released from β 
cells, are the principal means through which glucagon secretion is regulated. By contrast, 
roles for released Zn
2+
 ions appear to be less important in the mouse (186;204) and in man 
(247). 
AMP-activated protein kinase (AMPK) is a highly conserved multisubstrate serine/threonine 
protein kinase, which acts as a nutrient sensor (245;246;445) that has evolved to execute 
responses to starvation (254). In yeast, AMPK allows growth in the absence of glucose and 
switches cellular metabolism to use alternative carbon sources (245;446). In plants, AMPK 
allows survival in alternate cycles of light and darkness, as opposed to light only (447). 
Finally, in C. elegans, the enzyme preserves lipid stores to allow long-term survival during 
periods of fasting (389). In the mammalian brain, AMPK is activated by neuroglucopenia and 
is necessary for triggering the counter-regulatory response (CRR) to correct hypoglycaemia 
(448). In rats, prior intracerebroventricular (i.c.v.) administration of compound C (an AMPK 
inhibitor); (449) attenuated hypoglycaemia-induced increases in the plasma concentrations of 
corticosterone, glucagon and catecholamines, resulting in severe and prolonged 
hypoglycaemia (328;449).  Counter-regulatory hormone responses were impaired by 
recurrent neuroglucopenia induced by daily i.c.v. injections of 2-deoxy-D-glucose (2DG) and 
were partially restored by i.c.v. injection of AICAR before 2DG (327). Moreover, during 
hypoglycaemic clamp studies, stimulation of AMPK within the ventromedial hypothalamus 
(VMH) by AICAR was found to amplify hormonal CRR and increase endogenous glucose 
production (450).  
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Consistent with its pre-eminent role in preserving glucose levels in periods of food 
deprivation, our lab, and others, have also shown that AMPK activation by low glucose 
inhibits insulin vesicle dynamics and insulin secretion in β cells of pancreatic islets of 
Langerhans (257;258;312;385), whilst AMPK activation in vivo diminishes transplanted islet 
survival in diabetic mice (326) and insulin secretion in transgenic mice expressing an 
activated form of the enzyme selectively in the β cell (381); (Chapter 3). However, little 
knowledge has been obtained so far regarding the roles of AMPK or its upstream kinases 
including LKB1 in controlling glucagon secretion in pancreatic α cells. These questions 
appear to be important given the high levels of expression of LKB1 in pancreatic α cells 
(Figure 3.1) and the opposite phenotypes observed in mice with deletion of either AMPK and 
LKB1 in pancreatic β cells using the RIP2 deleter strain (Chapters 3 and 4); (381;387). 
Here we describe the creation of mice deleted for LKB1 (αLKB1KO) or AMPK single α 
catalytic subunits (αAMPKα1KO, -α2KO) or both (αAMPKdKO) selectively in pancreatic α 
cells using PPG-Cre deleter mice. We show that LKB1 and AMPK α1 are essential for the 
normal regulation of glucagon secretion by glucose in vitro and are necessary to maintain 
glucose homeostasis in response to hypoglycaemia.  
 
6.2. Methods 
6.2.1. Adenoviruses  
Adenoviruses encoding CMV-GFP (null) or PPG-AMPK-CA were generated with the help 
from Dr. Isabelle Leclerc and are described in (257;451) respectively. PPG-AMPK-CA also 
expressed GFP under a distinct CMV promoter.   
6.2.2. GLP1 measurment 
DPP IV inhibitor (final concentration: 100μM, Millipore) was added to blood (~100 μl) 
collected from normal fed mice using cardiac puncture. Plasma was obtained by using high 
speed (13,200 r.p.m., 5 min. at 4
o
C) centrifugation in EDTA-coated microvette tubes 
(Sarstedt, Leicester, UK). Plasma GLP1 levels were assessed by ELISA by Dr. Keith Burling, 
Cambridge University Hospitals NHS Foundation Trust, UK, using MesoScale Discovery 
human total GLP-1 kit, version 2, Gaithersburg, USA. 
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6.3. Results 
6.3.1. Generation of α cell-specific LKB1 knockout mice 
α cell-specific LKB1 knockout mice (αLKB1KO) were created by crossing Lkb1 flox‟d mice 
with animals expressing Cre recombinase under the preproglucagon promoter (PPG); (Figure 
6.1a). αLKB1KO mice were born with expected mendelian ratio and exhibited no observable 
abnormalities during six months‟ post-natal period. Excision of exon 3 to 6 via Cre 
recombination in pancreatic α cells (Figure 6.1b) led to a reduction of Lkb1 mRNA levels by 
33% (ratio of Lkb1 mRNA to Cyclophilin: 0.014 ± 0.001 in αLKB1KO vs. 0.02 ± 0.003 in 
wild type, p<0.05, n=12); (Figure 6.1c)  in line with the expected proportion of α cells within 
murine islets (20-30%) and the higher expression levels of LKB1 in α cells than β cells (Ratio 
of Lkb1 mRNA to Cyclophilin: 0.36 ± 0.09 in α cells vs. 0.11 ± 0.03 in β cells, p<0.05); 
(Chapter 3, Figure 3.1). Consequently, the total AMPK activity was reduced by nearly 40% 
in islets of αLKB1KO mice (60.5 ± 8.1% of wild type, p<0.05); (Figure 6.1d). 
LKB1immunoreactivity in pancreatic sections of αLKB1KO mice was abolished selectively 
in glucagon-positive cells which were located mainly at the mantle of the islets. These results 
confirmed that the reduction of AMPK activity in islets from αLKB1KO mice was likely to 
be the result of ablation of LKB1 in the α cells.  
The preproglucagon promoter is also active in enteroendocrine L cells where the insulin 
secretagogue, glucagon like peptide-1 (GLP1) is produced (172). We therefore examined 
plasma GLP1 levels in the fed αLKB1KO mice and their wild type littermate controls. No 
significant differences of this parameter were observed between genotypes (19.2 ± 4.8 pg/ml 
in αLKB1KO mice vs. 19.5 ± 1.5 pg/ml in Wt; n=3-5), either indicating no effect of LKB1 on 
GLP1 secretion or that the levels of Cre expression in L cells were insufficient to cause 
LKB1 deletion. Proglucagon may also be processed into GLP1 and GLP2 in the 
hypothalamus which might affect central feeding behaviour (174;452). However, αLKB1KO 
mice exhibited no significant differences of body weight or daily food intake compared to 
their wild type littermate controls (Figure 6.2a, b). 
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Figure 6.1 Generation of αLKB1KO mice. 
(a) Schematic representation of deletion of flox‟d Lkb1 exons (exons 3-6) driven by PPG-Cre 
expression. Location of primers used for PCR as indicated. Black arrows, flox sites; gray bar, Lkb1 
exons. Whole islet RT-PCR (b) and qRT-PCR analysis (c) of Lkb1 mRNA levels in pancreatic islets 
of αLKB1KO mice and their wild type controls (Wt). Product sizes were 864 and 300 bp for flox‟d 
and null alleles respectively. Islets were incubated with RPMI media containing 10 mmol/l glucose 
for 24 h before RNA extraction. (d) Total AMPK activity in islets of αLKB1KO and wild type control 
mice (Wt). Islets incubated with RPMI media containing 10 mmol/l glucose for 48-72 h, were further 
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incubated with RPMI media containing 3 mmol/l glucose for 1 h before analysis. (e) Representative 
immunofluorescence staining of pancreatic sections using mouse anti-glucagon (1:2000; red) and 
rabbit anti-LKB1 (1:100; green) antibodies. Nuclei are shown with DAPI (blue) staining. Scale bar, 
75 μm. Data are expressed as means ± SEM; n=12 (c) and 4 (d) mice per genotype. *p<0.05, 
**p<0.01, ***p<0.001. 
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6.3.2. αLKB1KO male mice display lower blood glucose and plasma glucagon levels, 
and improved glucose and AICAR tolerance.  
αLKB1KO male mice tended to maintain lower overnight fasting (4.88 ± 0.17 mmol/l in 
αLKB1KO vs. 5.26 ± 0.18 mmol/l in wild type, p=0.08) and fed (9.58 ± 0.47 mmol/l in 
αLKB1KO vs. 10.63 ± 0.35 mmol/l in wild type, p=0.09) blood glucose levels compared to 
their wild type littermate controls at the age of 8 weeks (Figure 6.2c, d). Consistent with these 
findings, fasting plasma glucagon levels from αLKB1KO mice were significantly decreased 
(40.2 ± 4.6 pg/ml in αLKB1KO vs. 54.1 ± 5.9 pg/ml in wild type, p<0.05); (Figure 6.2e), 
whereas the levels in the fed state were comparable between genotypes (Figure 6.2f). Thus, a 
relatively higher fasting blood insulin to glucagon ratio was apparent in αLKB1KO mice than 
their wild type littermate controls (15.9 ± 8.6 in αLKB1KO vs. 8.6 ± 2.0 in wild type); 
(Figure 6.2g, h).  Moreover, 8 week old male αLKB1KO mice displayed improved glucose 
tolerance with peak glucose levels significantly lower than their wild type littermate controls 
after 1g/kg intraperitoneal (IP) glucose injection (Figure 6.3a). Insulin tolerance also tended 
to be lower in 8 week old fed male αLKB1KO mice than wild type littermate controls (15 
min. post injection: 62.8 ± 3.8% of initial value in αLKB1KO vs. 70.9 ± 4.3% in wild type, 
p=0.1); (Figure 6.3c). To achieve hypoglycaemia without using insulin, which may exert an 
inhibitory effect on glucagon secretion (453), we challenged the mice with the AMP mimetic, 
aminoimidazole carboxamide ribonucleotide (AICAR) which increases peripheral glucose 
uptake by activating AMPK (365;454;455). As shown in Figure 6.3e, administration of 
0.175g/kg AICAR sharply reduced blood glucose levels in overnight-fasted male control 
mice at the age of 8 weeks from 5.72 ± 0.29 mmol/l at 0 min. to 3.37 ± 0.21 mmol/l at 40 
min. post injection, whilst the same compound lowered blood glucose from 5.50 ± 0.30 
mmol/l to 2.70 ± 0.22 mmol/l in αLKB1KO mice, (a 45% decrease vs. 40% decrease in the 
wild type, p=0.04) suggesting either an enhanced peripheral sensitivity to AICAR in the 
latter, or a blunted glucagon response. However, none of the above changes were present in 
the female (Figure 6.4) or older αLKB1KO male (20 weeks old) mice (Figure 6.3 b, d, f).  
Binding of glucagon to its receptor on liver cells increases glucose production by increasing 
glycogen break-down and gluconeogenesis, whilst inhibiting glycolysis (216). To examine 
whether a long-term reduction of fasting plasma glucagon levels (Figure 6.2e) and the 
consequent decrease of blood glucose levels (Figure 6.2c, d) in αLKB1KO mice produced 
changes of expression of gluconeogenic (i.e. PEPCK, G6Pase and PGC-1α) and glycolytic 
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Figure 6.2 αLKB1KO male mice display lower blood glucose and glucagon levels. 
Body weight (a), daily food intake (b), blood glucose (c, d) and plasma glucagon levels (e, f) of 
αLKB1KO mice and their wild type littermate controls (Wt) fasted for 16 h (a, b, d, f) or in the fed 
state (c, e). Plasma insulin levels (g) and relative insulin to glucagon levels (h) of 8-week-old 
αLKB1KO mice and their wild type littermate controls (Wt) fasted for 16 h. Data are expressed as 
means ± SEM; n=5-12 mice per genotype. *p<0.05. 
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Figure 6.3 αLKB1KO male mice develop improved glucose tolerance, AICAR and arginine 
sensitivity. 
Intraperitoneal glucose (a, b), insulin (c, d), AICAR tolerance test (e, f) and arginine tolerance test (g-
i) of αLKB1KO male mice and their wild type littermate controls at 8 and 20 week-old. Data are 
expressed as means ± SEM; n=6-12 mice per genotype. *p<0.05. 
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Figure 6.4 αLKB1KO female mice displayed normal fasting blood glucose and tolerance to 
intraperitoneal glucose or insulin. 
Body weight (a) and blood glucose levels (b) of normal fed or overnight fasted αLKB1KO female 
mice and their wild type littermate controls at 8 week-old. Intraperitoneal glucose (c) and insulin 
tolerance (d) of αLKB1KO female mice and their wild type littermate controls at 8 week-old. Data are 
expressed as means ± SEM; n=4-6 mice per genotype. 
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Figure 6.5 Liver gene expression in αLKB1KO mice. 
Real time qPCR analysis of liver gluconeogenic (a) and glycolytic gene (b) expression of 24 weeks 
old male αLKB1KO mice and their wild type littermate controls fasted for 16 h. Data are expressed as 
means ± SEM; n=4-6 mice per genotype. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 163 
genes (i.e. GK and L-PK) in the liver, we analyzed the latter in 24 week old male αLKB1KO 
mice and their littermate controls. However, none of these genes showed significant changes 
in expression levels between genotypes (Figure 6.5).  
6.3.3. L-arginine sensitivity in αLKB1KO mice 
Because L-arginine stimulates both glucagon and insulin secretion from pancreatic α and β 
cells respectively (190), we examined the levels in blood glucose and islet hormonal release 
in αLKB1KO mice and wild type littermate controls in response to L-arginine. Blood glucose 
levels rose from 5.78 ± 0.27 to 6.95 ± 0.29 mmol/l in wild type control mice and from 5.57 ± 
0.27 to 5.68 ± 0.41 mmol/l in αLKB1KO at 10 min after 3g/kg IP L-arginine injection 
(Figure 6.3g, KO vs. wild type, p=0.007). Consistent with this result, we observed a decrease 
of plasma glucagon:insulin ratio (0.097 ± 0.04 in αLKB1KO vs. 0.22 ± 0.04 in wild type, 
p=0.04) in the knockout mice at the same time point. Plasma glucagon levels were 290.5 ± 
46.8 pg/ml in αLKB1KO vs. 389.9 ± 38.9 pg/ml in wild type at 10 min. post injection 
(p=0.07); (Figure 6.3h), whilst the insulin levels were 3.57 ± 0.82 μg/l in αLKB1KO vs. 2.62 
± 0.75 μg/l in wild type (p=0.4); (Figure 6.3i).  
6.3.4. Deletion of LKB1 from pancreatic α cells does not alter cell morphology, relative 
mass or single cell size 
Deletion of LKB1 from pancreatic β cells expands islet volume drastically, largely due to 
increases in proliferation and β cell size (296;387); (Chapter 4). To examine whether deletion 
of LKB1 may exert the same effects on α cell growth and morphology, we performed 
immunohistochemical analysis of the pancreatic sections from αLKB1KO mice and wild type 
littermate controls (Figure 6.6a, c); (α and β cell mass analysis were performed in 
collaboration with Gorman Tracy and Anna Marley in AstraZeneca). Pancreata from KO or 
control mice showed the typical morphology of islets with β cells concentrated in the core 
and α cells located mainly in the mantle (Figure 6.6a). Quantification of relative α cell mass 
and single α cell size did not reveal significant differences of these parameters between 
genotypes (Figure 6.6b, d).  
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Figure 6.6 αLKB1KO mice show normal α cell morphology, mass and single cell size. 
(a) Representative immunofluorescent staining of pancreatic sections using guinea pig anti-insulin 
(Green, 1:200) and mouse anti-glucagon antibodies (Red, 1:2000). (b) Quantification of relative α and 
β cell mass based on immunofluorescent staining of pancreatic sections. Relative islet cell mass was 
calculated by dividing total glucagon (α cell) or insulin (β cell) positive area by total pancreatic area 
(autofluorescence). Three to four sections per pancreas were analyzed. (c) Representative glucagon 
(Red) and E-cadherin (Green) staining of pancreatic sections. (d) Quantification of single α and β cell 
size (see Chapter 2 General Methods, 2.3.5). Scale bar, 40 μm. Data are from 4 mice of each genotype 
and are presented as mean ± SEM.  
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6.3.5. Impaired glucose-stimulated glucagon secretion and glucagon gene expression in 
islets from αLKB1KO mice 
The above in vivo analyses revealed a compromise in fasting glucagon release and a loss of 
response to hypoglycaemia in αLKB1KO mice with relatively well preserved pancreatic α 
cells. To determine whether these effects might be the consequence of defects in α cell gluose 
sensing and secretory machinery, we isolated the islets from mice at the age of 8-10 weeks 
and studied the regulation of glucagon secretion in vitro. Consistent with our previous study 
(186), glucagon secretion was readily detected from islets of wild type mice incubated with 
either 0.1 or 3 mmol/l glucose for 1 h , whilst 17 mmol/l glucose drastically inhibited 
glucagon release (Figure 6.7a, b). Examined in islets from αLKB1KO mice, glucagon release 
at 0.1 mmol/l was comparable to wild type mouse islets. By contrast, glucagon secretion from 
αLKB1KO mouse islets was inhibited substantially at 3 mmol/l glucose, such that 17 mmol/l 
glucose elicited no firther effects on glucose release (Figure 6.7a, b). The stimulatory effects 
of 5 μmol/l epinephrine were, however, preserved in αLKB1KO mice (Figure 6.7a, b). 
Insulin secretion in response to glucose was not significantly different between genotypes 
(Figure 6.7c, d), arguing against the possibility that the inhibitory effect of 3 mmol/l glucose 
in αLKB1KO mouse α cells was caused by an increase in insulin release from neighbouring β 
cells. 
To examine the effects of glucose on glucagon gene expression in αLKB1KO mice, we 
incubated the islets from KO and littermate control mice with 3 or 17 mmol/l glucose for 24 h 
before RNA extraction and quantification. As shown in Figure 6.8, wild type mouse islets 
incubated with 17 mmol/l glucose displayed lower levels of glucagon gene expression 
compared to islets incubated at 3 mmol/l glucose. By contrast, glucose no longer modulated 
glucagon mRNA levels in αLKB1KO islets. These results suggest that loss of LKB1 
signalling may exert broad effects on pancreatic  cell glucose sensing. 
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Figure 6.7 αLKB1KO mouse islets secrete less glucagon in response to 3 mmol/l glucose. 
(a, b) Glucagon and (c, d) insulin secretion of 12 size-matched islets from αLKB1KO and their wild 
type controls statically incubated with 0.1 (white bar), 3 mmol/l (grey bars), 16.7 mmol/l (black bars) 
glucose or 16.7 mmol/l glucose in the presence of 5 μmol/l epinephrine for 1 h. n=3 per genotype. 
Data are presented as total glucagon (or insulin) secreted or percentage of secreted over total glucagon 
(or insulin) by 12 islets and are expressed as means ± SEM; *p<0.05, **p<0.01, ***p<0.001. 
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Figure 6.8 Pancreatic islet glucagon gene expression in αLKB1KO. 
Real time qPCR analysis of glucagon gene expression in islets from αLKB1KO and their wild type 
littermate controls. Islets were cultured in RPMI containing 3 and 17 mmol/l glucose for 24 h before 
being lyzed for RNA extraction. Data are expressed as means ± SEM; n=4-6 mice per genotype. 
*p<0.05. 
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6.3.6. α cell-specific AMPK knockout mice exhibit reduced blood glucose and plasma 
glucagon levels 
To determine whether the changes observed in glucose-regulation of both glucagon release 
and gene expression in LKB1KO mice were mediated by AMPK, we created the 
conditional knockout mice with deletion of AMPK both (αAMPKdKO) or single α catalytic 
subunits (αAMPKα1KO and -α2KO) selectively in pancreatic α cells by crossing either 
double AMPK α1 and α2 or single α isoform flox‟d mice with PPG-Cre deleter mice as 
described above. Cre-mediated recombination of α isoform(s) in pancreatic α cells led to 
decreases of AMPK activities by ~37%, ~32% and ~27% in islets from αAMPKdKO, -α1KO 
and -α2KO mice respectively (Figure 6.9a, b), the latter more modest change possibly 
reflecting compensatory changes in the expression of the non-deleted isoform or other 
kinase(s). We also examined the possible effects of AMPK deletion on GLP1 secretion from 
intestinal L-cells. As observed for αLKB1KO mice (see above), no changes in plasma GLP1 
levels were seen in fed αAMPKdKO mice (11.45 ± 0.23 pg/ml, n=6) compared to wild type 
littermate controls (13.88 ± 1.97 pg/ml, n=4). Body weight of mice deleted for AMPK 
isoforms in pancreatic α cells were not different compared to the corresponding wild type 
littermate controls (Figure 6.9c). 
Both αAMPKdKO and -α1KO male mice exhibited lower fasting glucagon levels compared 
to wild type littermate controls (48.19 ± 14.13 pg/ml in dKO vs. 85.82 ± 11.33 pg/ml in Wt, 
n=9, p=0.059 and 39.06 ± 1.38 pg/ml in α1KO vs. 58.78 ± 11.91 pg/ml in Wt, n=6, p=0.092); 
(Figure 6.10c). By contrast, fasting blood glucose levels in the two KO mouse models were 
not different (5.65 ± 0.33 mmol/l in dKO vs. 6.31 ± 0.35 mmol/l in Wt, n=8, p=0.19 and 5.11 
± 0.26 mmol/l in α1KO vs. 5.64 ± 0.40 mmol/l in Wt, n=6, p=0.20); (Figure 6.10a). No 
differences in plasma glucagon or glucose levels were seen in αAMPKdKO or -α1KO mice 
compared to their littermate controls in the fed state (Figure 6.10b, d) or between 
αAMPKα2KO mice and wild type littermate controls in either fed or fasted state (Figure 
6.10). 
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Figure 6.9 Generation of AMPK α cell knockout mice. 
(a) RT-PCR analysis of whole islets Ampkα1 and -α2 transcript levels in islets from αAMPKdKO 
mice. Islets were incubated with RPMI media containing 10 mmol/l glucose for 24 h before RNA 
extraction. For Ampkα1, the pair of primers (Ampkα1b fwd and rev) used generated the expected 
product sizes of 568bp for wild type and 335 bp for knockout (null) alleles. For Ampkα2, the pair of 
primers (Ampkα2 fwd and rev) used produced the expected product sizes of 588bp for wild type and 
375bp for knockout (null) alleles (b) Total AMPK activities in islets of αAMPKdKO, -α1KO, -α2KO 
mice and corresponding wild type controls (Wt). Islets incubated with RPMI media containing 10 
mmol/l glucose for 48-72 h, were further incubated with RPMI media containing 3 mmol/l glucose for 
1 h before analysis. (c) Body weight of ad libitum fed αAMPKdKO, -α1KO, -α2KO mice and their 
corresponding wild type littermate controls. Data are expressed as means ± SEM; n=3 (b) and 6-10 (c) 
mice per genotype. *p<0.05, **p<0.01. 
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Figure 6.10 αAMPKdKO and -α1KO mice display reduced fasting plasma glucagon levels. 
Blood glucose (a, b) and plasma glucagon levels (c, d) of αAMPKdKO, -α1KO and -α2KO mice and 
their wild type littermate controls fasted for 16 h (a, c) or during random fed status (b, d). Data are 
expressed as means ± SEM; n=5-10 mice per genotype. 
 
 
 
 
 
 
 
 
 
 
 170 
6.3.7. α cell-specific AMPK knockout mice display normal glucose, AICAR tolerance 
and insulin sensitivity 
Unlike αLKB1KO mice, none of the male AMPK knockout mice displayed altered glucose or 
insulin tolerance at 8 weeks of age (Figure 6.11a-f). However, AICAR tolerance tests 
revealed a mild decrease of blood glucose levels in αAMPKα1KO mice at 60 min after 
injection compared to littermate controls (2.56 ± 0.24 mmol/l in α1KO vs. 3.3 ± 0.16 mmol/l 
in Wt, n= 5-8, p=0.034); (Figure 6.11h), whilst the responses to this compound in the other 
two knockout mouse models examined were similar compared to wild type littermate controls 
(Figure 6.11g, i).  
6.3.8. Inactivation of AMPK in pancreatic α cells does not alter pancreatic α cell mass 
or single cell size  
Inactivation of AMPK in pancreatic β cells reduces individual β cell size (Chapter 3); (381). 
To assess whether such an effect would be recapitulated in pancreatic α cells, we examined 
pancreatic sections stained with insulin and glucagon (performed in collaboration with 
AstraZeneca). Neither α nor β cell mass was changed in αAMPKdKO mice compared to wild 
type controls (Figure 6.12a). Moreover, single α and β cell sizes were also comparable 
between genotypes (Figure 6.12b). 
6.3.9. Impaired glucose-stimulated glucagon secretion in α cell specific AMPKdKO and 
-α1KO mice 
To determine whether the reduction of fasting plasma glucagon levels in αAMPKdKO and -
α1KO mice may reflect defects in the regulation of glucagon secretion by glucose from α 
cells, we incubated islets isolated from mice with either double or single deletion of AMPK α 
subunits at various glucose concentrations. Remarkebly, glucagon secretion was reduced in 
islets incubated in 3 mmol/l glucose from αAMPKα1KO (0.094 ± 0.02% in α1KO vs. 0.042 ± 
0.01% in wild type, p=0.02) and αAMPKdKO mice (0.14 ± 0.014% in dKO vs. 0.092 ± 
0.006% in wild type, p=0.038), but not from αAMPKα2KO mice (Figure 6.13).  Indeed, 
deletion of AMPKα1 subunits from pancreatic α cells significantly reduced both total 
glucagon release and the percentage of glucagon secreted over total in islets incubated with 3 
mmol/l glucose compared to wild type controls. By contrast, glucagon secretion in response 
to 0.1 or17 mmol/l glucose was similar between genotypes (Figure 6.13b, e). No changes in 
glucagon secretion were seen in islets from αAMPKα2KO mice at the glucose concentrations  
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Figure 6.11 AMPK α cell knockout mice exhibit normal glucose and insulin tolerance, and 
αAMPKα1KO mice develop increases in AICAR sensitivity. 
Intraperitoneal glucose (a-c), insulin (d-f) and AICAR tolerance test (g-i) of αAMPKdKO, -α1, α2 
male mice and their corresponding wild type littermate controls at 8 week-old. Data are expressed as 
means ± SEM; n=6-12 mice per genotype. *p<0.05. 
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Figure 6.12 Normal pancreatic α cell mass and single cell size in αAMPKdKO mice. 
(a) Quantification of relative α and β cell mass based on immunofluorescent staining of pancreatic 
sections. Relative islet cell mass was calculated by dividing total glucagon (α cell) or insulin (β cell) 
positive area by total pancreatic area (autofluorescence). Three to four sections per pancreas were 
analyzed. (b) Quantification of single α and β cell size (see Chapter 2 General Methods, 2.3.5). Data 
are from 6 mice of each genotype and are presented as mean ± SEM. 
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Figure 6.13 αAMPKdKO and αAMPKα1KO mouse islets secreted less glucagon in response to basal 
glucose stimulation. 
Glucagon secretion of 12 size-matched islets from αAMPKdKO (a, d), -α1KO (b, e) and -α2KO (c, g) 
and their corresponding wild type controls statically incubated with 0.1 (white bar), 3 mmol/l (grey 
bars), 16.7 mmol/l (black bars) glucose for 1 h. n=3-4 per genotype. Data are presented as total 
glucagon secreted or percentage of secreted over total glucagon by 12 islets and are expressed as 
means ± SEM; *p<0.05, **p<0.01, ***p<0.001. 
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tested. These data suggest that AMPK α1 is probably the major isoform regulating glucagon 
secretion from pancreatic α cells (Figure 6.13c, f). 
6.3.10. Activation of AMPK in a murine α cell line stimulates glucagon secretion  
To determine whether activation of AMPK may impose the opposite effects on glucagon 
secretion as those observed in αAMPKdKO and -α1KO mice, we stimulated AMPK in 
murine αTC cells with various pharmaceutical AMPK activators. Metformin and phenformin 
are biguanides that are thought to activate AMPK activity through inhibition of complex I of 
the mitochondrial respiratory chain (449;456), therefore increasing cellular AMP/ATP ratios. 
By contrast, a new compound from Abbott Laboratories, A-769662, is a thienopyridone drug 
that selectively activates AMPK allosterically by targeting β1-containing complexes 
(280;457). As shown in Figure 6.14a and 6.15a, incubation of αTC1-9 cells for 16 h (to allow 
sufficient time for intracellular accumulation of the drug); (258) with concentrations of 
metformin ranging from 10 to 500 μmol/l resulted in a dose-dependent increase in AMPK 
and ACC phosphorylation. Incubation with metformin also markedly increased glucagon 
secretion, which was no longer suppressed by elevated glucose concentrations (Figure 6.14b). 
Compound A-7769662 (Figure 6.14c) and phenformin (Figure 6.14e and 6.15b) also 
increased AMPK and ACC phosphorylation in αTC1-9 cells, after 30 to 60 min. incubation, 
and stimulated glucagon secretion at both permissive (0.1 mmol/l) and inhibitory (17 mmol/l) 
levels of glucose (Figure 6.14d, f). By contrast, compound C (an AMPK inhibitor); (449) 
inhibited both AMPK and ACC phosphorylation and glucagon release (Figure 6.14e, f).  
We subsequently modulated AMPK activity molecularly by using adenoviruses encoding 
constitutively-active form of the kinase (322). Firstly, αTC1-9 cells were transduced for 48h 
at a MOI of 100 units/cells with either Null-GFP or AMPK-CA adenoviruses before 
incubation in 0.1 or 17 mmol/l glucose and subsequent cell lysis, for measurement of AMPK 
activity (Figure 6.16a), or assay of glucagon secretion (Figure 6.16b).  Strikingly, forced 
activation of AMPK activity at 17 mmol/l glucose was sufficient to stimulate glucagon 
secretion (Figure 6.16a, b). 
In order to extend the findings above in clonal cells to a more physiological preparation, we 
next modulated AMPK activity specifically in primary α cells within intact mouse islets and 
measured glucagon release in response to changes in glucose concentration. Isolated mouse 
islets were infected with an adenovirus in which constitutively-active AMPK was expressed 
under the control of the preproglucagon promoter (PPG-AMPK-CA), 48 h before glucagon 
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Figure 6.14 Effects of pharmacological activation and inhibition of AMPK activity on AMPK and 
ACC phosphorylation and glucagon secretion in TC1-9 cells.  
(a) Western (immuno-) blotting analysis of αTC1-9 cells treated with metformin. αTC1-9 cells 
incubated for 16 h in Dulbecco‟s modified eagle‟s media (DMEM) containing 17 mmol/l glucose plus 
metformin at the concentrations indicated were subject to Western (immuno-) blotting analysis. (b) 
Glucagon secretion from αTC1-9 cells treated with metformin. Cells pre-treated with 500 µmol/l 
metformin in DMEM-based media containing 17 mmol/l glucose for 16 h were pre-incubated in KBH 
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solution containing 10 mmol/l glucose at 37
o
C with agitation (120 rpm) for 30 min. prior to 
incubation in KBH solution supplemented with 0 or 17 mmol/l glucose in the presence or absence of 
500 µmol/l metformin for 30 min. (c, d) αTC1-9 cells were incubated for 1 h in KBH solution 
containing the indicated glucose concentrations and 500 µmol/l A-769662, as shown, before cell lysis 
and immunoblotting (c) or glucagon assay (d). (e, f) Western (immuno-) blotting analysis (e) and 
glucagon secretion (f) in αTC1-9 cells treated with phenformin or compound C. αTC1-9 cells 
pretreated as above were incubated in KBH solution containing 0 and 17 mmol/l glucose in addition 
of 1 mmol/l phenformin or 20 μmol/l compound C at 37oC with agitation (120 rpm) for 1 h prior to 
Western (immuno-) blotting or glucagon secretion analysis.  Shown are blots representative of ≥ 3 
independent experiments. Data are means ± SEM. *p<0.05, **p<0.01, and ***p<0.001. 
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Figure 6.15 Quantification of AMPK and ACC phosphorylation in αTC1-9 cells.  
Relative phospho-AMPK and -ACC band intensity from Western (immuno-) blotting analysis of 
αTC1-9 cells treated with metformin as in Figure 6.15a (a), and phenformin or compound C as in 
Figure 6.15e (b). Data are from blots of ≥ 3 independent experiments. Data are means ± SEM. 
*p<0.05, **p<0.01, and $p=0.051. 
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Figure 6.16 Effects of molecular modulation of AMPK activity on glucagon secretion in TC1-9 
cells.  
(a) AMPK activity in αTC1-9 cells over-expressing AMPK-CA (α1312 T172D). αTC1-9 cells were 
infected with Null-GFP (expressing GFP only) or AMPK-CA viruses at multiplicity of infection 
(MOI) of 100 units/cell for 48 h prior to glucose stimulation at 0.1 and 17 mmol/l for 2 h in DMEM 
media. After being washed in PBS containing 0.1 and 17 mmol/l glucose three times, cells were lysed 
and 20 µg whole cell lysates were used for AMPK measurements as described in Chapter 2 (General 
Methods 2.3.4). (b) Glucagon secretion assay in αTC1-9 cells following adenoviral over-expression 
of AMPK-CA. TC1-9 cells were infected with null-GFP or AMPK-CA adenoviruses at a MOI of 100 
for 48 hours as above before glucagon assays were performed at the indicated glucose concentrations 
as described in Chapter 2 (General Methods 2.2.3). Data are means ± SEM of ≥ 3 separate 
experiments. *p<0.05, **p<0.01. 
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assay. In order to assess the efficiency of α cell transduction with the PPG-AMPK-CA 
adenovirus, infected mouse islets were dissociated and the alpha cells identified by 
immunocytochemistry using an anti-glucagon antibody. As shown in Figure 6.17a, about 
60% of the α cells (as identified with an anti-glucagon primary antibody and a texas-red 
conjugated secondary antibody) were transduced with the adenovirus (identified via GFP 
fluorescence; note that whereas viral infection and expression of GFP under the CMV 
promoter was not limited to glucagon-expressing cells, that AMPK-CA expression was 
expected to be restricted to α cells by the PPG promoter). Even with this relatively low 
transduction of the α cells, we observed a significant increase in glucagon secretion, 
selectively at high (inhibitory) glucose concentrations, in islets infected with PPG-AMPK-CA 
adenovirus compared to those infected with null-GFP virus (Figure 6.17b). By contrast, no 
significant difference was apparent in the release of insulin from AMPK-CA vs. null-GFP 
islets (Figure 6.17c), excluding an indirect effect via altered paracrine signalling from β to α 
cells.  
6.3.11. Stimulation of glucagon secretion after AMPK activation in αTC1-9 cells is 
independent of intracellular Ca
2+
 changes  
Determing intracellular free calcium ion concentration ([Ca
2+
]i) in live primary islet α cells is 
challenging, because it requires the selective loading of α cells with a fluorescent dye. To 
circumvent this problem, we therefore used clonal αTC1-9 cells. We examined changes in 
[Ca
2+
]i in this cell line in response to glucose or depolarisation with KCl after imposing 
changes in AMPK activity with adenoviral infection of AMPK-CA. As assessed using the 
intracellularly-trappable Ca
2+
 probe fura-red, expression of AMPK-CA did not modify the 
[Ca
2+
]i increases induced by low glucose or by KCl as compared to those in null virus-
infected cells (Figure 6.18a-e). 
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Figure 6.17 α cell-targeted expression of AMPK-CA stimulates glucagon secretion from mouse 
pancreatic islets.  
(a) Immunofluorescence staining of dissociated mouse pancreatic islets infected with PPG-AMPK-CA 
virus. Mouse pancreatic islets infected with PPG-AMPK-CA virus, also expressing GFP under a 
distinct CMV promoter, for 48 h at a MOI of 100 units/cell, were dissociated into single cells and 
stained with rabbit anti-glucagon antibody (1:1000) and mouse anti-myc antibody (1:100). Infected 
cells are shown in green (expressing GFP), glucagon-positive cells are shown in red and cells 
expressing myc-tagged AMPK-CA were shown in blue. Scale bar, 5 µm. (b) Glucagon secretion of 
mouse pancreatic islets infected with PPG-AMPK-CA virus. Thirteen size-matched mouse pancreatic 
islets infected with Null-GFP or PPG-AMPK-CA virus at multiplicity of infection (MOI) of 100 
units/cell for 48 h were pre-incubated in KBH solution containing 10 mmol/l glucose for 30 min. then 
incubated in KBH supplemented with 0.1 or 17 mmol/l glucose for 1 h at 37
o
C with agitation (120 
rpm). Glucagon assay was performed as described in Chapter 2 General Methods. (c) Insulin assay 
performed on the islets described in (b). Data are means ± SEM of 3 separate experiments. *p<0.05, 
NS, not significant.  
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Figure 6.18 Effects of forced changes in AMPK activity on cytosolic Ca
2+
 influx in αTC1-9 cells.  
(a, b) [Ca
2+
]cyt measurement in αTC1-9 cells over-expressing AMPK-CA (α1
312
 T172D). αTC1-9 cells 
were infected with null-GFP (a) or AMPK-CA (b) viruses at a multiplicity of infection (MOI) of 100 
units/cell 48 h prior to [Ca
2+
]cyt measurement with 200 nmol/l Fura-Red AM dissolved in KBH 
solution containing 10 mmol/l glucose was loaded onto cells 30 min. before cells were perfused with 
KBH solution supplemented with glucose and KCl as indicated. These are representative traces of ≥ 3 
separate experiments. (c)  Peak levels and area under the curve (AUC) (d) of cytosolic Ca
2+
 responses 
to 0.1 mmol/l glucose and 8 mmol/l KCl in αTC1-9 cells over-expressing AMPK-CA.  Data were 
normalized to [Ca
2+
]i (R0) levels at the beginning of perfusion of 10 mmol/l glucose. (e) Mean 
values of cytosolic Ca
2+
 (R[Ca
2+
]i) levels in αTC1-9 cells over-expressing AMPK-CA compared to 
cells over-expressing GFP only  as measured at 10 mmol/l glucose. Data are means ± SEM of 3 
separate experiments containing 19-23 cells per experiment for each virus. 
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6.4. Discussion 
An elevated plasma glucagon:insulin ratio in diabetes suggests the potential approach of 
treating this metabolic disorder by controlling glucagon levels (160;161). This idea was 
recently encouraged by the observations from two separate studies in which mice null for 
glucagon receptors were shown to be resistant to streptozotocin-induced diabetes (163;164). 
The tumour suppressor, LKB1 and its downstream kinase, AMPK, have divergent roles in a 
wide range of glucose-sensing tissues including insulin-producing pancreatic β cells 
(296;297;359;373;381;386;387;458;459). Here we provide evidence that LKB1 regulates 
glucagon secretion from pancreatic α cells possibly via AMPKα1, and that such regulation is 
required for maintaining glucose responses to hypoglycaemia in vivo.  
6.4.1. LKB1 regulates glucagon secretion from pancreatic α cells  
In pancreatic α cells, the mechanism of induction of glucagon secretion by glucose is less 
well understood. Opening of low voltage-gated Ca
2+
 and Na
+
 channels, and the consequent 
activation of high voltage-gated Ca
2+
 channels, are thought to play major roles in stimulating 
glucagon secretion at low glucose concentrations, whilst closure of these channels at high 
glucose inhibits glucagon secretion (201;460;461). We show here that mice null for LKB1 in 
pancreatic α cells exhibited reduced total plasma glucagon levels after an overnight fasting 
(Figure 6.2c) and during hypoglycaemic challenges (Figure 6.3e). Examined in isolated islets, 
inactivation of LKB1 completely masked the stimulatory effects on glucagon secretion at 
3mmol/l glucose, reminiscent of the reduction of plasma glucagon levels seen in fasted 
αLKB1KO mice (Figure 6.7). This result was in drastic contrast to the inactivation of this 
kinase in pancreatic β cells, where increases (short-term inactivation of LKB1 in adult β 
cells); (296;297) or mild decreases of glucose stimulated insulin secretion (long-term 
inactivation from E9-11 in β cells) were seen (Chapter 4); (387). In the latter study where 
LKB1 was deleted from embryonic stage (E9-11.5) in β cells using RIP2-Cre deleter strain, 
we found that the decreased glucose sensing and the resulting reduction of Ca
2+
 influx might 
contribute to such defects in β cells null for LKB1 (Chapter 4) (387). L-arginine stimulates 
both insulin and glucagon secretion (190). Whilst the mechanism of its stimulatory effect on 
glucagon secretion in pancreatic α cells are still not well established, L-arginine appears to 
stimulate insulin secretion in pancreatic β cells largely by elevating intracellular Ca2+ 
concentration (462;463). By injecting αLKB1KO mice with L-arginine, we showed here that 
glucagon secretion was reduced in these mice compared to the controls (Figure 6.3h). 
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Therefore, deletion of LKB1 in pancreatic α cells might inhibit glucagon secretion also by 
interfering with mechanisms by which L-arginine stimulates glucagon secretion. In any case, 
the present results suggest that the absence of LKB1 from α cells elicits a marked left-shift in 
sensitivity to glucose. The mechanism involved will require further investigation in the 
future, but may involve alteration in the expression of transporter and enzymes (eg. 
glucokinase) believed to be critical in glucose sensing (202). Such studies are likely to 
require the purification of αLKB1KO and wild type α cells, and transcriptomic and proteomic 
analyses, and were out with the scope of the present study.  
6.4.2. Deletion of LKB1 does not alter pancreatic α cell size 
Inactivation of  LKB1 in pancreatic β cells dramatically enhanced total insulin output in mice 
containing these cells largely due to increases of β cell size and proliferation (Chapter 4); 
(296;387). This was accompanied by upregulation of mTOR signalling probably 
(296;297;387). Strikingly, the pancreatic content of α + β cells was not altered by deletion of 
LKB1 from the former, and α cell mass and single α cell size were similar to controls (Figure 
6.6). It is thus unlikely that the well maintained α cell mass would contribute to the decreases 
of total glucagon output seen in αLKB1KO mice. Would lack of impact on mTOR in α cells 
null for LKB1 account for the observations? The role of mTOR in regulating pancreatic α 
cells have not been examined and require the staining of pancreatic sections for proteins 
involved in mTOR signalling, such as phospho-S6 ribosomal protein (rpS6) and its upstream 
kinase p70 S6 kinase (S6K).  
6.4.3. Inhibition of glucagon release in αLKB1KO mice affects counter-regulatory 
response to hypoglycaemia 
Glucagon is the first line defense against hypoglycaemia (158). However, in advanced type 1 
and end-stage type 2 diabetes, where glucagon release in response to hypoglycaemia is 
impaired, the ability of patients to deal with the risks of hypoglycaemia during anti-diabetic 
treatment with drugs such as insulin and sulfonylureas are decreased (158;159;165;166;169). 
To assess the possibility that decreased glucagon output in αLKB1KO mice may lead to a 
defective glucose response to hypoglycaemia, we imposed hypoglycaemia with two 
paradigms. Firstly, we subjected αLKB1KO mice to an overnight fast and found that these 
mice tended to decrease their blood glucose levels (Figure 6.2a). With the second paradigm, 
we injected mice with AICAR to achieve more severe hypoglycaemia (~3 mmol/l) than 
overnight fasting. αLKB1KO mice showed a relative delay in the recovery of glucose levels 
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from hypoglycaemia compared to controls (Figure 6.3e). Notably, it seems unlikely that the 
increases of insulin sensitivity in these mice requires switching off genes encoding proteins 
that are important to upregulate glucose production in the liver, as the expression levels of 
gluconeogenic and glycolytic genes in the livers between genotypes were similar (Figure 
6.5). However, we noted that the overall differences of glucose and glucagon release in the 
plasma between genotypes were small (Figure 6.2c, e). Given almost complete inhibition of 
glucagon secretion in response to 3 mmol/l glucose from islets isolated from αLKB1KO mice 
(Figure 6.7a, b), it is likely that a compensatory mechanism was developed in vivo so that 
factors secreted from tissues other than pancreatic α cells might stimulate glucagon secretion 
from pancreatic α cells to prevent mice from hypoglycaemia caused by α cell dysfunction. 
However, investigation into such possibility is currently out of the scope of this study. Taken 
together, inactivation of LKB1 in pancreatic α cells inhibited glucagon secretion resulting in 
reduction of total glucagon output in the blood and making mice containing such α cells more 
susceptible to hypoglycaemia.  
6.4.4. LKB1 modulation of pancreatic α cell function is mimicked by AMPK1 deletion. 
AMPK is the best studied downstream target of LKB1, due to its pre-eminent roles in 
controlling the effects of anti-diabetic drug, metformin on liver (359;375;464). Deletion of 
AMPK in pancreatic β cells resulted in completely different phenotype compared to that 
observed after deletion of LKB1 in the same cell populations (Chapter 3 and 4); (381;387). 
Therefore, we examined here whether the effects of LKB1 on glucagon secretion in 
pancreatic α cells would be similar to or different from those of AMPK. AMPKα1 may be 
functionally the dominant α catalytic subunit isoform. Thus, inactivation of LKB1 in 
pancreatic α cells led to the AMPK activities in islets similar to those observed in αAMPKα1 
mouse islets (Figure 6.19).  
Pancreatic α cells deleted for AMPKα1 showed an impaired response of glucagon secretion 
to low glucose concentrations (3 mmol/l). In line with these results, fasting plasma glucagon 
levels were reduced in αAMPKα1KO mice. When hypoglycaemia was induced by AICAR 
injection, αAMPKα1KO mice displayed apparent delays of recovery from hypoglycaemia 
reminiscent to those in αLKB1KO mice. Conversely, activation of AMPK achieved with 
pharmacological AMPK activator or adenovirus expressing constitutively active form of 
AMPK in murine α cell line or primary islet α cells significantly stimulated glucagon 
secretion at inhibitory (17 mmol/l) glucose concentration confirming the stimulatory effects 
of AMPK on glucagon secretion in pancreatic α cells. By what molecular mechanisms might 
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these occur? Since intracellular free Ca
2+
 levels were not affected by AMPK activation at 
either low or high glucose (Figure 6.18) it seems unlikely that this manoeuvre alone is 
sufficient to depolarise the plasma membrane and elicit glucagon secretion during glucose 
deprivation.  
We have suggested that the inhibitory effect of AMPK on insulin secretion may be the result 
of phosphorylation by AMPK of kinesin light chain-1 (KLC1), which occurs vigorously in 
vitro but whose impact on KLC-1 activity and vesicle mobility remains unproven (465). 
Although the relative importance of vesicle recruitment (e.g. subcellular translocation to sites 
of exocytosis) and the stimulated exocytosis of predocked glucagon granules in the response 
of α cells to glucose deprivation is as-yet undefined, our data strongly indicate that AMPK 
activates glucagon secretion downstream of Ca
2+
 increases, either by increasing the number 
of docked granules or their competence for fusion. Further studies will be necessary to 
address these complex mechanistic questions. Intriguingly, deletion of both AMPK α 
catalytic subunits only caused mild decrease of glucagon secretion in islets at 3 mmol/l 
glucose, in sharp contrast to marked decrease of this parameter in islets from αAMPKα1KO 
mice. This result implies that other regulators of glucagon secretion might be affected when 
AMPK activities in α cells were completed abolished. Taken together, changes in AMPK 
alone also affect glucagon secretion and influence whole body glucose response to 
hypoglycaemia. AMPKα1 seems to be the dominant α isoform mediating these effects. 
 
6.5. Conclusion 
We provide evidence for a role for the LKB1-AMPK signalling in the control of glucagon 
secretion from pancreatic α cells. We propose that altering this signalling pathway and the 
resulting hormonal release from α cells may provide a potential therapeutic approach to both 
type 1 and type 2 diabetes. 
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Figure 6.19 Proposed pathways for the impact of LKB1 in pancreatic α cells on glucose-regulated 
glucagon secretion.  
Increases in glucose concentration inhibit AMPKα1 activities and glucagon secretion from pancreatic 
α cells. LKB1 might regulate glucose-stimulated glucagon secretion from α cells possibly by 
modulating AMPK α1 activities.  
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Chapter 7  
RIP2-mediated LKB1 deletion causes axon degeneration in the spinal 
cord and hind-limb paralysis  
Abstract 
Background: Axon degeneration is observed in neurodegenerative diseases and 
neuroinflammatory disorders, such as Alzheimer‟s disease, Parkinson‟s disease and multiple 
sclerosis. The molecular basis of this process remains largely unknown.  
Results: Here, we show that mice deleted for the tumour suppressor LKB1 (also called 
STK11) in the spinal cord, some parts of the brain and in the endocrine pancreas (βLKB1KO 
mice) develop hind-limb dysfunction and axon degeneration at about seven weeks. 
Demyelination and macrophage infiltration were observed in the white matter of these mice, 
predominantly in the bilateral and anterior funiculi of the thoracic segment of the spinal cord, 
suggesting damage to the ascending sensory signalling pathway owing to LKB1 deletion in 
the brain. Microtubule structures were also affected in the degenerated foci, with diminished 
neurofilament and tubulin expression. Deletion of both Prkaa genes, whose products 
AMPKα1 and AMPKα2 are also downstream targets of LKB1, with the same strategy, was 
without effect.  
Conclusion: We define LKB1 as an intrinsic suppressor of axon degeneration and a possible 
target for strategies that can reverse this process. 
 
 
 
 
 
 
 
Part of this work has been published in: Sun G, Reynolds R, Leclerc I, Rutter GA. Dis Model Mech. 
2011 Mar;4(2):193-202. 
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7.1. Introduction 
Neuronal polarization, involving the initiation of immature neurites, the specification and 
formation of axon and dendrites, and the formation of synaptic contacts, is essential for signal 
transmission in the central nervous system (CNS); (466;467). Proper microtubule 
organization is crucial for this process (468-470). Thus, disruption of microtubule structure, 
or of the formation of the myelin sheath that surrounds the axons, is associated with several 
pathologies, including axon degeneration (471;472) and rare myelin protein mutations (e.g. 
Pelizaeus-Merzbacher disease); (473;474). Axon degeneration is also found in various 
neurodegenerative disorders such as multiple sclerosis (MS), amyotrophic lateral sclerosis 
(ALS), Alzheimer‟s disease (AD), Parkinson‟s disease (PD) and others (471;472).  
LKB1 is implicated in the control of cell polarity (390) and AMPK has been proposed as a 
further probable mediator of the effects of LKB1 on cell polarity (475). In neurons, LKB1 is 
thought to control neuron polarity by affecting axon differentiation (306;308). The latter 
effects are thought to be mediated via the inactivation of a signal transduction cascade that 
would normally activate late-onset sporadic Alzheimer‟s disease (SAD)-A/B kinases, also 
called Brsk1/2 (306). In C. elegans, the homologue of the LKB1 binding partner STRADα, 
termed STRD-1, binds together with LKB1 to form a tightly associated functional complex 
with the C. elegans SAD-A/B kinase SAD-1 to organize synaptic proteins and establish 
neuron polarity (476). SAD-A/B kinase is thought to act by phosphorylating tau, a 
microtubule stabilization protein (477), at Ser262. Despite the above evidence, a direct 
demonstration that LKB1 is involved in these processes in vivo in adult mammals is lacking. 
Cre expression under rat Ins2 promoter (RIP2) has been found in mid and ventral brain and 
spinal cord (345;352). Using mice lacking LKB1 in these regions (352), we find here that 
LKB1 in certain brain areas is required for axon stability and normal hind-limb locomotor 
control. 
 
7.2. Methods 
7.2.1. Animals 
βLKB1KO and βAMPKdKO mice were generated as described in General Methods (Chapter 
2, page 61 and 62). 
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7.2.2. Body weight and foot print (paralysis) measurements 
To measure locomotion by following foot prints, both fore-paws were immersed in red ink 
and hind-paws were immersed in blue ink before mice were allowed to walk freely on white 
filter paper (Whatman). Fed mice were weighed one and two weeks after the first onset of 
paralysis. Weight increases after paralysis were calculated. 
7.2.3. RNA extraction and RT-PCR 
Total cellular RNA from the cervical, thoracic and lumbar regions of mouse spinal cord and 
hypothalamus was obtained using TRIzol reagent (Invitrogen, Paisley, UK) and RNA was 
further purified against DNA contamination with a DNA-free kit (Applied Biosystems, 
Warrington, UK). Total RNA (1.5-2 μg) was then reverse transcribed into cDNA with a high-
capacity reverse transcription kit (Applied Biosystems, Warrington, UK) according to the 
manufacturer‟s instructions. To detect deletion of exons of LKB1 and AMPK α1 and α2, the 
primers described in general methods were used. 
7.2.4. Western (immuno-) blotting analysis 
Mouse spinal cord was snap frozen in liquid nitrogen before lysis in ice-cold buffer [in mM: 
50 Tris-HCl (pH 7.4, 4°C), 150 NaCl, 1 NaF, 1 Na3VO4, 1 ethylenediaminetetraacetic acid, 
1 phenylmethylsulfonyl fluoride, 1% Nonidet P40, 0.25% sodium deoxycholate, and protease 
inhibitor cocktail (Roche, Burgess Hill, UK)]. Protein (50 μg) extracted from cervical, 
thoracic and lumbar regions of the spinal cord were loaded onto SDS-PAGE gels (10% Tris-
acrylamide gel) for analysis. 
 
7.3. Results 
7.3.1. Mice lacking LKB1 owing to the RIP2-Cre transgene develop hindlimb paralysis 
During characterization of the metabolic profiles of βLKB1KO mice (Chapter 4), we noticed 
that these mice developed simultaneous dysfunction of both hind limbs at approximately 7- 
and 8-weeks of age for females and males, respectively. This change was characterized by 
clumsy and autonomous twitching of both hind-limbs (Figure 7.1a, b). Such a phenotype was 
unexpected and was further analyzed in the present Chapter. At 1-2 weeks after the initial 
onset of an observable abnormality, both legs of βLKB1KO mice became paralyzed. 
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However, as assessed by toe-pinching, basal muscle reflexes in the hind-limbs of βLKB1KO 
mice still existed at this time point, indicative of unaffected muscle function. Moreover, both 
front-limbs of βLKB1KO mice maintained mobility (Figure 7.1b), and the mice were still 
able to gain access to food and water two weeks after the initial onset of symptoms. The latter 
findings suggested that the upper section (cervical) of the spinal cord was less affected than 
the lower section by LKB1 deletion. Furthermore, before paralysis onset, βLKB1KO mice 
showed similar mobility to wild type control mice. However, after the onset of hind-limb 
dysfunction, βLKB1KO mice displayed significantly reduced mobility as characterized by an 
unwillingness to move and by crouching, both of which are indications of possible trauma. In 
addition to the above changes, βLKB1KO mice displayed complete loss of control of their 
tails 1-2 weeks after the initial onset of the hind-limb dysfunction (Figure 7.1a). A large 
reduction in body weight increases was also observed up to two weeks after paralysis, after 
which point βLKB1KO mice displayed rapid weight loss and loss of urinary control (data not 
shown). In all cases, the animals died 4-5 weeks after the initial onset of paralysis (Figure 
7.1c). 
Recent studies on RIP2-Cre expression in adult mice by Wicksteed and colleagues (352) 
showed extensive expression of Cre in the mid and ventral brain. In the present study, Cre 
and LKB1 expression were also studied in the spinal cord. Analysis of LKB1 expression in 
the cervical, thoracic and lumbar regions of the spinal cord of βLKB1KO mice by reverse 
transcription PCR (RT-PCR) using primers flanking exon 3 and 6, and Western (immuno-) 
blotting analysis using anti-LKB1 antibody raised against the C-terminus of LKB1 
demonstrated that RIP2-Cre-mediated recombination occurred substantially in the thoracic 
area, and to a lesser extent in the cervical and lumber areas (Figure 7.2a, b). Correspondingly, 
immunohistochemical analysis of the spinal cord from βLKB1KO mice revealed lowered 
numbers of cells that were intensely stained for LKB1 in the grey matter of thoracic regions 
(Figure 7.2c) compared with wildtype controls. 
7.3.2. βLKB1KO mice develop axon degeneration in the white matter of the thoracic 
segment of the spinal cord 
To try to understand the molecular and cellular basis of the above changes, post-mortem 
analysis of different organs extracted from βLKB1KO mice was performed one or seven days 
after the initial onset of hind-limb dysfunction. The tissues analyzed included: whole brain 
(cerebral cortex, hypothalamus and cerebellum), heart, lung, liver, spleen, kidney, skeletal 
 189 
a
W
ild
 t
y
p
e
β
L
K
B
1
K
O
b
c
Wild type βLKB1KO
Onset of male
0.0 5.0 10.0 15.0 20.0
0
20
40
60
80
100
Week
P
e
rc
e
n
t 
o
n
s
e
t
Survival of male
0 5 10 15 20 25
0
20
40
60
80
100
Week
P
e
rc
e
n
t 
s
u
rv
iv
a
l
Survival of female
0 5 10 15 20 25
0
20
40
60
80
100
Week
P
e
rc
e
n
t 
s
u
rv
iv
a
l
Onset of female
0.0 5.0 10.0 15.0 20.0
0
20
40
60
80
100
Week
P
e
rc
e
n
t 
o
n
s
e
t
βLKB1KO
Wt
e
Wt
βLKB1KO
male female
forepaw hindpaw
1wk 2wk
0.0
0.2
0.4
0.6
0.8
W
e
ig
h
t 
in
c
re
a
s
e
 (
g
)
1 wk 2 wk
0.0
0.2
0.4
0.6
0.8
W
e
ig
h
t 
in
c
re
a
s
e
 (
g
)
βLKB1KO
Wt
*
*** *
d
 
Figure 7.1 LKB1KO mice develop hind-limb paralysis.  
(a) Representative image and (b) foot-print of a βLKB1KO mouse one week after the initial onset of 
hind-limb dysfunction, compared with a wild type control. Scale bar, 10 mm. (c) Hind-limb 
dysfunction onset curve and (d) survival curve for male and female βLKB1KO mice and their wild-
type controls. 100% indicates a completely healthy status, whereas 0% indicates onset of hind-limb 
dysfunction (clumsy and autonomous twitch of hind-limbs) and death. (e) Weight increases of 
βLKB1KO mice and wild type controls one and two weeks after the initial onset of hind-limb 
dysfunction. Data are expressed as means ± SEM; *p<0.05, ***p<0.001. n=10-12 mice per genotype. 
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Figure 7.2 Deletion of LKB1 in βLKB1KO mice spinal cord. 
(a) RT-PCR analysis of Cre expression and the effects on LKB1 transcript levels of deleting exons 3-
6 in different segments of spinal cords of βLKB1KO mice and their wild type (Wt) controls. The 
product sizes were 864 and 300bp for the flox‟d and null alleles respectively. (b) Western (immuno-) 
blotting analysis of LKB1 and neurofilament (165 kD) protein levels in different segments of spinal 
cord using rabbit anti-LKB1 antibody (1:500) and mouse anti-NF165kD antibody (1:1000). (c) 
Representative DAB staining for LKB1 of thoracic regions of spinal cords from βLKB1KO mice and 
their wild-type controls using anti-LKB1 antibody (1:100). W, white matter; G, grey matter. Scale 
bar, 50 µm. Cer, cervical; Thr, thoracic; Lum, lumbar segment of the spinal cord. Data are from mice 
aging from four to six weeks old and are before onset of hind-limb dysfunction.  
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muscle of hind-limb, pelvis, sciatic nerve and spinal cord. Haematoxylin and eosin (H&E) 
staining was used for general morphological analysis and luxol fast blue (LFB) was used to 
detect myelin. This analysis revealed several large foci of axon degeneration in the white 
matter of the thoracic region of βLKB1KO mouse spinal cord seven days after the initial 
onset of hind-limb disability (Figure 7.3bd‟, bi‟), whereas fewer and smaller foci only were 
found one day after initial onset (Figure 7.3bc‟, bh'). In the area where degeneration occurred, 
axon disintegration and demyelination were evident by using LFB staining, with a loss of 
dark blue myelin staining and the formation of large digestion chambers caused by myelin 
vacuolation (Figure 7.3bf‟, bh‟, bi‟, cb‟, cd‟, cf‟, ch‟). Notably, brightly eosinophilic acellular 
spheroids were present in some of the vacuolated chambers when the sections were stained 
with H&E (Figure 7.3bc‟, bd‟, arrows), suggesting possible necrosis or swollen axons (Figure 
7.3cd‟, ch‟); (478). At seven days after the onset of hind-limb dysfunction in βLKB1KO 
mice, a complete loss of myelin staining and the disappearance of axons was observed in the 
thoracic region of the spinal cord (Figure 7.3bd‟, bi‟, d, e). A striking increase in the overall 
number of cell nuclei was also evident at the foci of degeneration of βLKB1KO mice one day 
after the initial onset of hind-limb dysfunction, which is suggestive of inflammation and 
macrophage infiltration, and this increase continued as degeneration progressed (Figure 
7.3bc‟, bd‟, bh‟, bi‟ and Figure 7.6a). In addition to the large foci of axon degeneration, 
several smaller foci with fewer and smaller digestion chambers and vacuolated axons were 
found in the thoracic area of the spinal cord (Figure 7.3be‟, bj‟). In these areas, axons were 
not completely disintegrated, but still retained a partial myelin sheath, which was detached 
from the axons. 
7.3.3. βLKB1KO mice display impaired sensory signalling pathways in the thoracic 
segment of the spinal cord 
Transverse sections of degenerated area in the βLKB1KO mouse spinal cord one day after the 
initial onset of hind-limb dysfunction revealed degeneration foci mainly in the lateral and 
anterior funiculi, including in the spinothalamic and spinocerebellar tracts of the spinal cord. 
This finding indicated damage primarily to the ascending sensory signalling pathways 
(Figure 7.3ca‟, cc‟, ce‟, cg‟). By contrast, changes to the descending motor systems were less 
evident, suggesting that alterations in these pathways, which are likely to underlie the hind-
limb paralysis, might occur either in higher brain regions in which RIP2-Cre-mediated 
deletion is also likely to occur. Examination of βLKB1KO mice before paralysis also 
revealed several sites of mild demyelination in the thoracic region of the spinal cord (Figure  
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Figure 7.3 Histological changes in the white matter of the thoracic region of spinal cord from 
βLKB1KO mice.  
(a) Schematic illustration of a spinal cord tract indicating both the motor (descending, red) and 
sensory (ascending, blue) pathways. Image is obtained from Wikipedia “http://en.wikipedia.org/wiki 
/File:Spinal_cord_tracts_-_English.svg”. (b) Representative H&E staining of regions of the spinal 
cord from wild type mice (a‟, f‟) and βLKB1KO mice before (b‟, g‟), or one day (c‟, h‟) or seven days 
(d‟, i‟) after the initial onset of hind-limb dysfunction, or of the less-affected white matter of the 
thoracic region of the spinal cord from βLKB1KO mice one day after the initial onset of hind-limb 
dysfunction (e‟, j‟). Arrows indicate eosinophilic spheroid. Scale bar: 50 μm. (c) Representative H&E 
staining (a‟-d‟) and LFB staining (e‟-h‟) of transverse sections of the thoracic region of the spinal cord 
from wild type mice (a‟, b‟, e‟, f‟) and βLKB1KO mice one day after initial onset of hind-limb 
dysfunction (c‟, d‟, g‟, h‟). Arrows indicate eosinophilic spheroid. Scale bars: 100 μm (a‟, c‟, e‟, g‟); 
50 μm (b‟, d‟, f‟, h‟). (d, e) Quantification of degenerating (d) and demyelinated (e) axons in thoracic, 
cervical and lumbar regions of the white matter spinal cord from βLKB1KO mice before or after one 
day and seven days of initial onset of hind-limb dysfunction, and their wild type controls. Intensity of 
axon staining per μm2 area of white matter were measured based on NF165kD (d) and LFB staining 
(e) using ImageJ. *p<0.05, **p<0.01, ***p<0.001. n=4 mice per genotype.  
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7.3bb‟, bg‟, d, e), a phenotype similar to that seen in the cervical and lumbar areas of the 
spinal cord in βLKB1KO mice seven days after the onset of symptoms (Figure 7.3d, e; Figure 
7.4). A limited degree of LKB1 deletion was previously found in the hypothalamus of 
βLKB1KO mice (Chapter 4, Figure 4.1); (387), consistent with earlier studies using RIP2-
Cre deleter mice bred with a lacZ reporter strain (345;353). However, close examination of 
the hypothalamus and other parts of the brain, including the forebrain, cortex and cerebellum, 
did not reveal any evidence for the presence of degenerating axons in these regions of 
βLKB1KO mice before or after hind-limb paralysis (Figure 7.5). 
7.3.4. βLKB1KO mice display disintegration of neurofilaments and microtubules in the 
spinal cord 
To examine the effects of LKB1 deletion on the formation of microtubules and 
neurofilaments within spinal cord axons, the degenerated areas were stained with markers for 
neurofilaments [neuron filament 165kD (NF165kD; 2H3); Figure 7.6a], and tau which is a 
microtubule binding and stabilizing protein, and is highly expressed in the axons of central 
nervous system thus serving as an indicator for stabilized microtubules (Figure 7.6a). 
Affected sections of βLKB1KO mouse spinal cord displayed diminished NF165kD and tau 
staining in an age-dependent manner. Thus, disorganization, disintegration and partial loss of 
neurofilaments and microtubules in the foci of spinal cord were apparent in mice one day 
after the initial onset of hind-limb dysfunction, and almost total loss of signals was evident 
one week from the initial onset, indicating severe axon degeneration (Figure 7.6a). Several 
neurofilament-containing spheroids (arrows in Figure 7.6a) were also evident in the 
degenerated areas. These findings were confirmed by Western (immuno-) blotting analysis of 
protein extracts from thoracic regions of the spinal cord from βLKB1KO mice. Reduced 
NF165kD and tau immunoreactivity was also evident in the spinal cord sections from 
βLKB1KO mice one day after the initial onset of paralysis (Figure 7.6b). 
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Figure 7.4 Morphological changes of white matter cervical and lumbar regions of the spinal cord 
from βLKB1KO mice. 
Representative H&E staining (a-d) and LFB staining (e-h) of the white matter of cervical or lumbar 
regions of the spinal cord from Wt (a, c, e, g) and βLKB1KO mice one day after initial onset of hind-
limb dysfunction (b, d, f, h). Scale bar, 50 µm. 
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Figure 7.5 RIP2-Cre-mediated LKB1 deletion does not affect neuron morphology in the 
hypothalamus or other brain areas. 
Representative H&E staining of the third ventrical medial basal hypothalamus, forebrain cortex and 
cerebellum from βLKB1 KO mice and wild type controls (Wt). Scale bar, 50 µm. 
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Figure 7.6 Disorganization of microtubule structures in axons in the thoracic region of the spinal cord 
from βLKB1KO mice.  
(a) Representative immunofluorescence staining for NF165kD using mouse anti-NF165kD antibody 
(1:100; red), and mouse anti-tau antibody (1:50; green) of the thoracic region of wild type (Wt) and 
βLKB1KO mice spinal cord one day or seven days after the initial onset of hind-limb dysfunction. 
Arrows indicate neurofilament containing spheroid. W, white matter; G, grey matter. Scale bar, 25 
μm. (b) Western (immuno-) blot analysis of Tau and NF165kD levels in βLKB1KO mice spinal cord 
after one day of hind-limb dysfunction. GAPDH is used as a loading control. 
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7.3.5. βLKB1KO mice develop increased invasion of macrophage after the initial onset 
of hind-limb dysfunction 
Macrophage invasion is commonly observed during axon degeneration (479;480). Given the 
fact that the number of nuclei increased (Figure 7.7a), but number of axons decreased (Figure 
7.3d) in the spinal cord of βLKB1KO mice, we next explored the possibility that 
inflammatory macrophage infiltration might be involved in the present model. 
Consistent with this view, progressive macrophage invasion in areas of axon degeneration 
was revealed by periodic acid Schiff (PAS) staining for glycogen and other carbohydrate-
containing macromolecules in active macrophages (Figure 7.7b); (481). This was further 
confirmed by F4/80 immunofluorescence staining for these cells (482); (Figure 7.7c). 
However, neither the thoracic areas of the spinal cord of βLKB1KO mice before the onset of 
hind-limb dysfunction, nor the cervical or lumbar segments from these mice after paralysis, 
showed any positivity for PAS or F4/80 staining (data not shown).  
7.3.6. Deletion of AMPKα1 and AMPKα2 catalytic subunits does not affect spinal cord 
morphology or motor function 
Given the role of AMPK in mediating the effects of LKB1 in the control of cell polarity in 
other systems (475), we further investigated the role of this enzyme in mediating the spinal 
cord degeneration observed in βLKB1KO mice. In contrast to animals deleted for LKB1 in 
the spinal cord and other regions using the RIP2-Cre deleter strain, mice generated using the 
same transgene to delete both AMPK α subunits in the same cell types (βAMPKdKO mice); 
(Figure 7.8a); (381) did not display any locomotor abnormalities nor altered survival curves 
(not shown) compared with heterozygous or wild type animals. Moreover, close examination 
of the thoracic and other segments of the spinal cord from βAMPKdKO mice did not reveal 
any changes in axon or myelin formation (Figure 7.8b). Thus, LKB1 seems to control axon 
stability in the spinal cord independently of AMPK. 
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Figure 7.7 Macrophage infiltration in the thoracic region of the spinal cord from βLKB1KO mice. 
(a) Nuclei number counts per μm2 area of white matter thoracic region of βLKB1KO mouse spinal 
cord before or after one day and seven days of initial onset of hind-limb paralysis, and those of their 
wild type controls (Wt). ***p<0.001. n=4 mice per genotype. (b) Representative PAS staining of 
white matter of the thoracic region of the spinal cord of wild-type and βLKB1KO mice after one day 
or seven days of initial onset of hind-limb dysfunction. Note the deep-purple PAS-positive cells in the 
spinal cord of βLKB1KO mice. Scale bar, 50 μm. (c) Immunofluorescence staining for F4/80, using 
rabbit anti-F4/80 antibody (1:100; green), of white matter of the thoracic region of the spinal cord 
from wild type and βLKB1KO mice after seven days of hind-limb dysfunction. Scale bar, 25 μm. 
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Figure 7.8 βAMPKdKO mice do not develop hind-limb paralysis.  
(a) RT-PCR analysis of AMPKα1 transcript levels and the effects of Cre expression on AMPKα2 
transcript levels in different segments of the spinal cord from βLKB1KO mice and their wild-type 
controls. For AMPKα1, the product sizes were 588 and 408 bp for the wild type and null alleles, 
respectively. NS, non-specific band; Cer, cervical; Thr, thoracic; Lum, lumbar segment of the spinal 
cord. The corresponding values for AMPKα2 were 588 and 375 bp. (b) Representative H&E staining 
of the white matter of the thoracic region of spinal cord from βAMPKdKO mice and their 
heterozygous controls at the age of 12-weeks old. Scale bar, 50μm. 
 
 
 201 
7.4. Discussion 
In performing a metabolic characterization of mice deleted for LKB1 in the endocrine 
pancreas and a restricted set of CNS neurons using a RIP2-Cre transgene (βLKB1KO mice); 
(Chapter 4); (387), we noted that older animals became paralyzed. The principal aim of the 
present study was thus to dissect the pathology behind this change and, in doing so, to 
determine the role of LKB1 in regulating neuronal polarity and survival in the CNS in vivo.  
Although mice null for LKB1 throughout the body die before E11.5 (290;291), the use of an 
Emx1-Cre deleter strain to allow deletion in pyramidal neuron progenitors demonstrated that 
LKB1 is required for the polarization of cultured neurons from the neonatal hippocampus and 
cortex (306;308). We therefore reasoned that LKB1 might play a similar role in axon 
development and, importantly, in signal transmission along the spinal cord. Given the crucial 
role of the spinal cord for the normal control of motor function, we further reasoned that 
deletion of LKB1 in neurons that extend their axons along the spinal cord and in neurons in 
the spinal cord might allow us to study the importance of LKB1 function in neurons in the 
adult animal. In addition to near complete loss of LKB1 in pancreatic β cells, resulting in a 
substantial increase in pancreatic β cell mass and hyperinsulinism (Chapter 4); (387), this 
approach also led to the elimination of LKB1 from a subset of neurons within the CNS (see 
Results), including those in the hypothalamus (352) and spinal cord (this study). We would 
stress that it is unlikely that increased circulating insulin levels (Chapter 4); (387) drive the 
dramatic alterations that we observed in CNS neuron survival within the spinal cord. Thus, 
similar elevations in circulating insulin occur in a number of other transgenic mouse models 
as a result of β cell hyperplasia (395;483;484), with no reported effects on CNS function, 
motor control or mortality.  
The striking finding of this study is that RIP2-Cre-mediated LKB1 deletion in a restricted set 
of neurons leads to severe hind-limb dysfunction and paralysis in young adult mice and 
eventually to premature death. The white matter of the thoracic spinal cord from βLKB1KO 
mice displayed morphological changes, displaying some of the characteristics of axon 
degeneration: large foci of disrupted, vacuolized and demyelinated axons with disorganized 
microtubules. The above changes were accompanied by macrophage infiltration, a feature 
that is very similar to that found in humans (479;485) and rats (480;486) after spinal cord 
injury, and in P301L tau-expressing transgenic mice, in which the microtubules of spinal 
cords were also disrupted (487;488). To characterize what neurons in which LKB1 was 
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possibly deleted, transverse sections of thoracic spinal cord from βLKB1KO mice were 
closely assessed. The affected foci demonstrated widespread areas of axon degeneration in 
spinal tracts containing axons involved in predominantly ascending sensory pathways. 
Although deletion of LKB1 in βLKB1KO mice was also seen in the spinal cord, given that 
most of the neuron cell bodies of the degenerated axons in this location reside in the brain, we 
propose that deletion of LKB1 in these neurons in the brain leads to interruption of cell 
polarity and axon degeneration in the spinal cord, which eventually causes hind-limb 
paralysis. Notably, examination of neuron cell morphologies in the forebrain cortex, 
hypothalamus and cerebellum regions that have been shown by others to express Cre (352) 
and might also regulate locomotor behaviour, did not reveal any obvious axon degeneration 
phenotype. This observation might, however, reflect the expression of Cre in a limited 
population of neurons in these areas, such that axon degeneration, if it occurred at all, was 
difficult to observe.  
What molecular mechanisms underlie the effects of LKB1 deletion in neurons that form 
axons along the spinal cord? Deletion of LKB1 in pyramidal neurons from neonatal cortex 
results in disruption of axon formation, with decreased SAD-A/B phosphorylation and the 
phosphorylation of its downstream target tau (306). Although it is difficult to monitor 
phosphorylation levels of SAD-A/B or tau in RIP2-Cre neurons owing to the limited 
distribution of these neurons in the wide area of brain and low expression of Cre in these 
neurons, the work of Barnes and colleagues (306) suggests that an LKB1-SAD-tau 
(phosphorylated on Ser262) signalling pathway is important in controlling neuronal polarity 
in spinal cord. In addition, transgenic mice overexpressing human tau protein containing the 
FTDP-17 mutation (P301L) display behavioural abnormalities with symptoms of Wallerian 
degeneration in the spinal cord but with increased tau (S262) phosphorylation (487;488). 
Interestingly, others (489) have reported that hypophosphorylation of tau (S262), resulting 
from mutation of the KXGS domain, inhibited outgrowth of extensions in Sf9 cells. 
Conversely, hyperphosphorylation of tau at S262 destabilized microtubules and axons 
(489;490). Finally, Kishi and colleagues observed reduced tau (S262) phosphorylation and 
reduced axon extension in neurons from hippocampus and cortex of SAD-A/B null mice 
(477). Thus, the maintenance of an appropriate but limited degree of tau phosphorylation is 
likely to be essential for normal neuronal polarization and stability. Nonetheless, direct 
evidence for this contention would require the simultaneous inactivation of SAD-A/B in 
RIP2-Cre neurons, and thus lies outside the scope of the present study.  
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Might the decreased phosphorylation and activity of other targets for LKB1 be involved in 
neuronal degeneration? Importantly, deletion of both AMPK catalytic (α) subunits in the 
same cells as those affected by LKB1 deletion failed to lead to neuronal degeneration (this 
study). Recently, Williams et al. reported deletion of AMPK both α catalytic subunits in 
cortical neurons using the same strategy as deletion of LKB1 in these neurons did not alter 
early neuron development or neuronal polarity (491). Likewise, deletion of tuberous sclerosis 
complex 1 (TCS1), a downstream target of AMPK and involved in the control of the 
mammalian target of rapamycin (mTOR) and in regulating neuron polarity (492;493), using 
the RIP2-Cre transgene did not lead to hind-limb paralysis (395;407). These findings 
therefore argue against changes in mTOR signalling as being responsible for the axon 
degeneration observed here in βLKB1KO mice. Indeed, we would note that, by activating the 
mTOR pathway, LKB1 deletion might have been expected to mimic the effects of growth 
factors that act downstream of receptor tyrosine kinases, such as nerve growth factor (493), 
whereas we observed instead a degenerative phenotype, arguing strongly against the 
involvement of such survival pathways in this case. Finally, Par1 (also known as MARK2) 
controls neurite growth and cell polarity in other settings (494;495), and has been reported to 
lie downstream of LKB1 (496). However, although MARK2 knockout mice displayed 
dwarfism, no obvious behavioural deficiencies were reported (497). The latter observation 
argues against the involvement of an LKB1-MARK2-tau signalling pathway in controlling 
axon development in the spinal cord of βLKB1KO mice.  
 
7.5. Conclusion 
We demonstrate here that LKB1 is essential to maintain normal polarity and function of a 
crucial subset of neurons in the brain. Mice deleted for LKB1 in these cells might provide a 
useful animal model for studying axon degeneration and certain neurodegenerative disorders 
in humans. 
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Chapter 8 
Final discussion 
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8.1. Using tissue specific knockout or transgenic mice to study glucose homeostasis 
The main aim of this thesis has been to study the roles of two protein kinases, namely LKB1 
and a key downstream target, AMPK, in controlling the synthesis and secretion of two key 
glucose-regulating hormones, insulin and glucagon. The chief approach has been the 
generation and analysis of glucose metabolism using pancreatic β or α cell-specific knockout 
or transgenic mice. This appeared to be an important goal as neither of the two kinases have 
been studied in pancreatic endocrine cells in vivo, although both have been implicated in the 
regulation of insulin sensing in vivo and insulin secretion in pancreatic endocrine cells in 
vitro (260;376;498). Moreover, AMPK is thought to be the target of front line anti-diabetic 
drugs such as metformin and thiazolidinediones (249;251). Therefore, understanding the 
mechanisms of which AMPK and LKB1 regulate hormonal secretion from pancreatic 
endocrine cells was expected to shed light on how these cells are regulated both in health and 
in disease state. Furthermore, new knowledge of the role of these enzymes in the endocrine 
pancreas would seem to offer potential for the possible development of anti-diabetic drugs or 
improvement of existing anti-diabetic approaches.  
Tissue-specific knockout or transgenic mice have become invaluable tools to study functions 
of a protein in a particular cell type and most importantly to investigate such effects in 
regulating whole body animal physiology (499-501). Moreover, by mimicking human 
diseases by modifying a protein in the mice using this technique, people are able to develop 
and screen drugs to target these diseases (357).  This technique is extensively used in this 
study and forms the platform where most of the studies presented here are performed. 
However, it is important to point out two caveats when interpreting such studies: (1) the 
possibility exists that changing the expression of a gene might unmask a pathway whose role 
in normal physiology is, due to redundancy, usually minimal or zero. Therefore, the presence 
of apparent phenotypes after inactivation or activation of a gene might not occur in normal 
physiological conditions. Likewise, changing the expression of a gene might also mask a 
pathway whose role in normal physiology is important. To this ground, the absence (or 
mildness) of a phenotype after the inactivation of a particular gene cannot be taken as proof-
positive that the gene and gene product in question are unimportant; (2) that the considerable 
differences between the physiology of mice (mass ~ 25 g; lifespan < 3 years) versus man 
(mass ~ 50-90 kg; lifespan ~ 75 years) mean that extrapolation of results from the former to 
the latter must be made with caution; (3) that the promoter which is used to drive tissue-
specific deletion of certain genes might also express in other undesired tissues. Therefore, the 
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effects of deletion of target genes in undesired tissues on the general phenotypes of the mice 
need to be taken into consideration; (4) that deletion of target genes early in embryonic stages 
might pose different physiological impact on the mice compared to deletion of the same 
genes when the mice are mature, as compensation might occur when target genes are deleted 
in the former stages.   
Nonetheless, at least for the time being, tissue specific knockout mice do provide the most 
suitable in vivo system to analyse the role of enzymes such as LKB1 and AMPK and their 
roles they play in health and in disease settings.  
 
8.2. Significance of LKB1 and AMPK in pancreatic β cells 
AMPK, as a master energy sensor has been reported to regulate the function and survival of 
the principle glucose-regulating cell, pancreatic β cell ex vivo for almost 13 years 
(253;256;311;376). However, its role in regulating β cell physiology and whole body glucose 
metabolism has only been studied relatively recently by our group, using mice transplanted 
with islets overexpressing viruses carrying AMPK-CA or -DN (326) and by Benoit Viollet‟s 
group using whole body AMPK α1 or α2 knockout mice (360;362). Neither of these two 
models targeted AMPK specifically in pancreatic β cells.  
To achieve this goal, we chose to use the rat Ins2 promoter (RIP2) to generate mice lacking 
either one of these two protein kinases in pancreatic β cells and a subpopulations of neuronal 
cells (345;351;352). At the time when this study was initiated, only two β cell-expressing 
promoters (RIP2 and Pdx1) were available with RIP2 reported to be more β cell selective 
within the pancreas (344;345). However, we and others have noticed that RIP2 is expressed 
at extrapancreatic sites especially in medial basal hypothalamus where several glucose 
sensing neurons reside (Chapter 3, Figure 3.2). Therefore, cautions have been taken when we 
interpreted the results from knockout or transgenic mice generated using this promoter (see 
below).   
One of the most significant findings of this study is that both LKB1 and AMPK are important 
regulators of β cell function, morphology and survival albeit acting via at least partially in 
distinctive signalling pathways. Firstly, LKB1 inhibits β cell growth and proliferation, in line 
with its role as a tumour suppressor. Deletion of LKB1 in β cells thus enhanced these 
processes leading to increased total insulin content per pancreas via its inhibitory effects on 
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mTOR signalling pathways. On the other hand, LKB1 in pancreatic β cells affects insulin 
secretion. Thus, deletion of LKB1 in these cells led to mildly impaired glucose-stimulated 
insulin secretion, reduced electrical acitivity and intracellular Ca
2+
 levels which were 
associated with altered mitochondria morphology. Defects of both glucose uptake (reduction 
of GLUT2) and KATP channel activities (reduction of Kir6.2 gene expression) were suggested 
to contribute to above effects. Moreover, certain populations of β cells lacking LKB1 
underwent cell death, characterized by an increased number of both apoptotic and non-
apoptotic, autophagy related dead cells. As a result, the positive impact on insulin production, 
and β cell proliferation and growth after LKB1 deletion in β cells outweighed the negative 
effects of LKB1 on insulin secretion and β cell survival. Consequently, mice lacking this 
kinase in pancreatic β cells were more tolerant to glucose. Therefore, LKB1 might serve as a 
potential drug target for treating diabetes. Of course, it will require further studies to ascertain 
the possibility of developing anti-diabetic drugs to target LKB1 or more feasibly a 
downstream target with more selective enzymes in β cells. One foreseeable barrier for LKB1 
to be fully considered as a drug target is its potent role as a tumour suppressor (288). 
Unfortunately, we were not able to assess the possibility of formation of insulinoma in these 
mice due to early onset of paralysis and death. Generation of LKB1 deletion with more β cell 
specific promoter (mouse Ins1 promoter) will answer this question. 
By contrast, pancreatic β cells lacking AMPK both α catalytic subunits were smaller and 
glucose-stimulated insulin secretion was enhanced from these islets in vitro. This involved an 
increase in the numbers of readily releasable insulin granules beneath cell membrane. By 
contrast, overexpression of this kinase in these cells decreased insulin secretion. Although 
AMPK-null β cells also underwent cell death, it was not associated with autophagy. These 
data suggest that LKB1 affects pancreatic β cell function and morphology independently of 
AMPK. Indeed, there are 11 other AMPK-like protein kinases lying downstream of LKB1 
(294) and 8 of them were found to be expressed in pancreatic islets (see Table 1.1). It has 
been postulated that LKB1 might alter β cell morphology via MARK2 (Par1b), as islets null 
for MARK2 display similar changes of β cell polarity (296;297). However, it is not known 
whether the impaired glucose-stimulated insulin secretion from islets of βLKB1KO mice was 
also caused by inactivation of Mark2. The direct evidence of LKB1-MARK2 signalling 
pathways in controlling pancreatic β cell function and morphology will only come when 
similar experiment is conducted with Mark2 deleted in these cells selectively. Experiments to 
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examine whether the phenotype of βLKB1KO mice can be rescued by MARK2 will also be 
informative.  
 
8.3. Significance of LKB1 and AMPK in pancreatic α cells 
Glucagon secreted by pancreatic α cells is the body‟s chief defense against hypoglycaemia 
(158). Its importance in maintaining glucose homeostasis is reflected by two observations: 1) 
Loss of glucagon release in advanced type 1 or end-stage type 2 diabetes is the major risk of 
antidiabetic treatment with insulin or sulfonylurea (165-167); 2) A higher glucagon:insulin 
ratio is associated with type 2 diabetes (160;161). Despite its undisputed roles in controlling 
glucose metabolism, the mechanisms of glucagon release and pancreatic α cell physiology are 
less well established compared to that of insulin release from pancreatic β cells. 
This study and others have provided evidence that AMPK and LKB1 are regulators of 
pancreatic β cell function and morphology. Most importantly, mice lacking either kinase in 
this cell population develop altered glucose metabolism. However, the role of these two 
kinases in controlling pancreatic α cell function and morphology has never been studied.  By 
using mice expressing Cre recombinase under the preproglucagon promoter (PPG), we 
demonstrated here that LKB1-AMPK signalling pathway is involved in the control of 
pancreatic α cell function and whole body glucose responses to hypoglycaemia (Chapter 6). 
Thus, α cells with inactivation of LKB1 were defective in glucagon secretion in response to 3 
mmol/l glucose, likely resulting in the lower fasting plasma glucagon levels in these mice in 
vivo. Although the exact mechanism is not known, it is likely that LKB1 might exert these 
effects on glucagon secretion by virtue of factor(s) that are also regulated by L-arginine, 
because the glucagon release from αLKB1KO mice after injection of the mice with L-
arginine was reduced compared to the wild type mice. By imposing hypoglycaemia with two 
different approaches: fasting, and AICAR injections, we are able to show that mice deleted 
for LKB1 in pancreatic α cells are more sensitive to hypoglycaemia. We propose that this 
may be caused mainly by inhibition of glucagon release from pancreatic α cells, because α 
cell size or relative α cell mass were not altered in αLKB1KO mice. On the other hand, the 
latter observation reveals dramatic differences in the role of LKB1 in controlling cell 
morphology and growth between pancreatic α cell and β cells.  
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We have demonstrated in Chapters 3, 4 and 5 that LKB1 and AMPK are probably engaged in 
two distinctive signalling pathways in regulating β cell function, morphology and death. 
Much to our surprise, and in contrast to the situation in the β cell, the phenotypes of mice null 
for LKB1 in pancreatic α cells were mirrored by those of αAMPKα1KO mice. Thus, 
glucagon secretion in islets from mice lacking α1 catalytic subunits of AMPK in pancreatic α 
cells was also inhibited by 3 mmol/l glucose to the level similar to that in islets from 
αLKB1KO mice. Moreover, αAMPKα1 KO mice also displayed lower fasting blood glucose 
and an increase of AICAR sensitivity. Taken together, LKB1 might be required to maintain 
basal-glucose stimulated glucagon secretion in pancreatic α cells and counter-regulatory 
response to hypoglycaemia, and such effect is probably mediated via AMPK α1. 
As mentioned above, a higher glucagon:insulin ratio is often reported in type 2 diabetes 
(160;161). Moreover, mice deleted globally for glucagon receptors are resistant to 
hyperglycaemia by the β cell toxin, streptozotocin, suggesting a potential approach to treat 
diabetes by tuning down glucagon signalling. To explore the potential of targeting LKB1-
AMPK signalling in pancreatic α cells, it would be extremely useful to examine whether 
reduction of glucagon secretion elicited by deletion of LKB1 or AMPK α1 in pancreatic α 
cells would also attenuate the detrimental effects of STZ in mice containing these cells. Such 
experiments are presently on-going. 
 
8.4. Significance of LKB1 and AMPK in central nervous system 
RIP2 expression has recently been found in a distinctive region of the brain including the 
arcuate nucleus of the medial basal hypothalamus where the feeding control and glucose 
sensing neurons reside (352). Moreover, hypothalamic AMPK controls satiety and peripheral 
insulin sensitivity (332;336). Therefore, the roles of AMPK and LKB1 in these neuronal 
populations in central feeding control and peripheral insulin sensitivity were also examined in 
present study. We have demonstrated that LKB1 and AMPK are important regulators of 
central energy homeostasis albeit via different mechanisms. Thus, mice deleted for LKB1 in 
RIP2 neurons developed hypophagic phenotypes, whilst mice deleted for both AMPK α 
subunits in the same region had no overt changes of satiety. These results suggest that LKB1 
and AMPK are not coupled in RIP2 neurons to regulate feeding behaviour and LKB1 might 
do so via other signalling pathways, possibly the insulin signalling pathway, as mice with 
RIP2-Cre mediated PTEN deletion in the same neurons display similar hypophagic 
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phenotypes. By contrast, AMPK in RIP2 neurons regulated insulin sensitivity which was 
suggested by rapid decrease of glucose levels after insulin injection in βAMPKdKO mice, 
whilst the glucose levels were comparable in βLKB1KO mice after the same insulin 
injection. This result was consistent with the experiment conducted by Lam and colleagues 
(341) who observed reduced glucose output in rats with i.c.v injection of virus carrying 
AMPK-DN into medial basal hypothalamus. However, these observations also raise several 
unanswered questions of LKB1 and AMPK in controlling central energy homeostasis: 1) 
which neurons RIP2-Cre is expressed? It has been suggested by Hisadome et al., (404) that 
the majority of the POMC neurons do not overlap with RIP2 neurons. Indeed, deletion of 
LKB1 in POMC neurons showed altered insulin sensitivity, which was not observed in 
βLKB1KO mice (342). Therefore, it is possible that other hypothalamic neurons that control 
energy homeostasis are involved, such as cells expressing NPY along with the endogenous 
melanocortin antagonist, AgRP and cells containing α-MSH etc. (404).  2) What is/are the 
downstream protein kinase(s) of LKB1 in RIP2 neurons that ultimately regulate(s) food 
intake? It is not clear how many AMPK-like protein kinases are expressed in hypothalamus 
nor the distribution of these kinases in different hypothalamic sub-neuron types. It is also 
unclear as to which of the other AMPK-like protein kinases is involved in controlling satiety 
in the hypothalamus. 3) Would other upstream kinases such as CaMKKβ or TAK1 which has 
recently been found to be able to phosphorylate AMPK be involved in controlling AMPK-
mediated modulation of peripheral insulin sensitivity (502)?   
We also discovered in this study that LKB1 in RIP2 neurons is necessary to maintain the 
normal locomotor behaviour in adult mice. Loss of LKB1 from RIP2 neurons led to hind-
limb paralysis in adult mice largely by interrupting transmission of ascending sensory signals 
along the axons which project from these neurons into the spinal cord.  These effects were 
associated with disrupted and demylinated axons in the thoracic region of the spinal cord. By 
contrast, AMPK appeared to be redundant for this process, as mice deleted for both AMPKα 
subunits in the same neuron compartment did not develop any obvious locomotor defects. 
Our result also showed that neurons that express RIP2 are important to control not just energy 
homeostasis, but also locomotor behaviour. Thus, genes that affect neuron growth and 
polarity in these neurons might also exert detrimental effects on the latter. Since LKB1 
affects differentiation and polarity of pyramidial neurons from neonatal cortex via SAD 
kinases-mediated tau phosphorylation (306), it is likely that LKB1-SAD-tau signalling might 
also be involved in the control of growth and polarity of RIP2 neurons. Further studies using 
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mice deleted for SAD in RIP2 neurons are needed to confirm this hypothesis. Moreover, it is 
not known whether other AMPK-like kinase(s) might be involved in the control of neuron 
growth and polarity. Therefore, finding the likely AMPK-like protein kinases that might 
regulate neuronal polarity will shed light on how what downstream signalling of LKB1 in 
RIP2 neurons control locomotor behaviour.  
 
8.5. Final conclusion 
In conclusion, by creating tissue-specific knockout mouse models where LKB1 or AMPK is 
ablated in pancreatic β cells and a subpopulation of neurons in the central nervous system 
(RIP2-expressing area), and in the pancreatic α cells (PPG-expressing area) respectively, we 
demonstrate that both LKB1 and AMPK are required to control hormonal secretion in the 
endocrine pancreas and whole body glucose homeostasis, albeit through mechanisms that are 
distinctive in many ways.  Nonetheless, these findings further support the view that LKB1 
and AMPK or their downstream effectors might serve as potential drug targets in the 
endocrine pancreas to treat diabetes. 
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Appendix 1: PCR primers and Tm 
Gene Primer sequence Tm 
(
o
C) 
Ampkα1 wt (genotyping) Fwd: AGCCGACTTTGGTAAGGATG 57 
 Rev: CCCACTTTCCATTTTCTCCA  
Ampk α1 null (genotyping) Fwd: GGGCTGCAGGAATTCGATATCAAGC 57 
 Rev: CCTTCCTGAAATGACTTCTGGTGC  
Ampk α1 flox’d (genotyping) Fwd: TATTGCTGCCATTAGGCTAC 
Rev: GACCTGACAGAATAGGATATGCCCAACCTC 
58 
Ampkα2 flox’d (genotyping) Fwd: GCTTAGCACGTTACCCTGGATGG 
Rev: GTTATCAGCCCAACTAATTACAC 
69 
Lkb1 flox’d (genotyping) Fwd: GGGCTTCCACCTGGTGCCAGCCTGT 72 
 Rev: GAGATGGGTACCAGGAGTTGGGGCT  
RIP2 (genotyping) Fwd: TGCTAGCCTCAACCCTGACT 53 
CA (genotyping) Rev: TCTGGATCTCTCTGCGGATT  
DN (genotyping) Rev: ACTGCCACTTTATGGCCTGT  
Cre (genotyping and RT-PCR) Fwd: ATGTCCAATTTACTGACCG 
Rev: CGCCGCATAACCAGTGAAAC 
53 
β-actin (genotyping and RT-PCR) Fwd: TTGGCCTTAGGGTTCAGAGGGG 
Rev: CGTGGGCCGCCCTAGGCACCA 
53 
Ampkα1a (RT-PCR) Fwd: TGGAAGGTTGGACGAAAAGG 53 
 Rev: TCCACACCGGAAAGGATCTG  
Ampkα1b (RT-PCR) Fwd: TTCAGGCACCCTCACATC 59 
 Rev: TTATTGCGGCCCTCTTCA  
Ampkα2 (RT-PCR) Fwd: GCACCCTCCCTTTCGATGAT 53 
 Rev: CCCCCTCGGATCTTCTTGAA  
Myc (RT-PCR) Fwd: CAGAAGCTTATCTCCGAG 53 
CA_RT (RT-PCR) Rev: CAACTTTATGTCCAGTCAA  
DN_RT (PCR) Rev: CCATATGCCTGTGACAAT  
Lkb1 (RT-PCR) Fwd: AGGTGAAGGAGGTGCTGG 53 
 Rev: TCTGGGCTTGGTGGGATA  
Xbp-1 (RT-PCR) Fwd: ACACGCTTGGGAATGGACAC 53 
 Rev: CCATGGGAAGATGTTCTGGG  
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Appendix 2: Real-time PCR primers 
Gene Sequence 
Ampkα1 Fwd: TGGAAGGTTGGACGAAAAGG 
 Rev: TCCACACCGGAAAGGATCTG 
Ampkα2 Fwd: GCACCCTCCCTTTCGATGAT 
 Rev: CCCCCTCGGATCTTCTTGAA 
Lkb1 Fwd: GCCGGGCAACCTGCTACT 
 Rev: CAACACCGAGGTCGGAGATC 
Myc  Fwd: ATGGAGCAAAGCTTATCTCCGAG 
 Rev: ACTTTCCCGAAGGTGCCGA 
Pdx-1 Fwd: CGCGTCCAGCTCCCTTT 
 Rev: CCACGCGTGAGCTTTGGT 
Ki67 Fwd: CAAAAGGCGAAGTGGAGCTT 
 Rev: TGTTTCGCAACTTTCGTTTGTG 
Kir6.2 Fwd: GACCTCAAATGGCCACACACT 
 Rev: CAGCCAGCTGCACAGGAA 
Sur1 Fwd: TGCTGCAAAGGACGTTCCT 
 Rev: CCTCTCAGGTTAATCCCAGTTTCA 
Npy Fwd: CTCCGCTCTGCGACACTAC 
 Rev: AATCAGTGTCTCAGGGCT 
Glut2 Fwd: GGCACTGGCTGCCTTCAG 
 Rev: GGAAGCAGAGGGCGATGAC 
Ins1 Fwd: GAAGCGTGGCATTGTGGAT 
 Rev: TGGGCCTTAGTTGCAGTAGTTCT 
Ins2 Fwd: AGCCCTAAGTGATCCGCTACAA 
 Rev: CATGTTGAAACAATAACCTGGAAGA 
Gk Fwd: GCTTTTGAGACCCGTTTTGTG 
 Rev: GCCTTCGGTCCCCAGAGT 
Gcg Fwd: CATTCACCAGCGACTACAGCAA 
 Rev: TCATCAACCACTGCACAAAATCT 
Chop Fwd: AGGAGCCAGGGCCAACA 
 Rev: TCTGGAGAGCGAGGGCTTT 
Grp78 Fwd: GGCCGCGTGGAGATCATA 
 Rev: CACATACGACGGCGTGATG 
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Appendix 3: List of antibodies 
Antibody Host Dilution 
(WB) 
Dilution 
(IHC/ICC) 
Antigen 
retrieval 
Company  (Catalogue 
No.) 
Anti-LKB1 Rb 1:1000   Millipore (07-694) 
Anti-LKB1 Rb  1:100 Citrate Nabeel Bardeesy 
(Harvard Medical School) 
Anti-phospho-AMPK 
(Thr172) 
Rb 1:500   NEB (2535) 
Anti-phopho-ACC (Ser79) Rb 1:500   Millipore (07-303) 
Anti-Insulin Gp  1:200 Citrate Dako (A0564) 
Anti-Glucagon Ms  1:2000 Citrate Sigma (G2654) 
Anti-E-cadherin Rb  1:100 TE NEB (4065) 
Anti-phopho-S6 ribosomal 
protein (Ser235/236) 
Rb 1:500 1:75 TE NEB (4857) 
Anti-Actin (C2) Ms  1:100 TE Santa Cruz (sc-8432) 
Anti-GLUT2 Rb  1:100 TE Bernard Thorens 
(university of Lausanne) 
Anti-Ki67 Rb  1:200 TE Epitomics (4203-1) 
Anti-ZO1 Rat  1:100 TE Paolo Meda (University 
of Geneva) 
Anti-α-tubulin Ms 1:1000   Sigma (T5168) 
Anti-β-tubulin Ms  1:100 TE Abcam (ab7751) 
Anti-VEGF receptor2 Rb  1:100 TE NEB (2479) 
Anti-POMC Ck 1:500   Abcam (ab14064) 
Anti-Neuron filament (2H3) 
(165kDa) 
Ms 1:1000 1:100 TE Developmental studies 
hybridoma bank 
Anti-Tau Ms 1:500 1:50 TE Millipore (MAB3420) 
Anti-F4/80 Rat  1:100 TE AbD (MCA497RT) 
Anti-GAPDH Ms 1:300   Millipore (MAB374) 
Anti-LC3 Rb 1:500 1:200 Citrate Abcam (ab48394) 
Anti-p62 Ms 1:1000   Vania Braga (Imperial 
College London) 
Anti-phospho-ULK1 (S555) Rb 1:1000   NEB (5869) 
Anti-COX IV Rb 1:1000   NEB (4844) 
Rb, rabbit; Ms, mouse; Ck, chicken; Gp, guinea pig; WB, Western blotting; IHC, 
immunohistochemistry; ICC, immunocytochemistry. Citrate, 10 mmol/l Sodium Citrate (pH 
6.0); TE, Tris (10 mmol/l)·EDTA (1 mmol/l) with Tween (pH 9.0) 
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Appendix 4: List of plasmid maps 
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